"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,ZA,B,ZA 918047 B,194-764-740-736-394,1992-07-29,1992,ZA 918047 A,1991-10-08,ZA 918047 A,1991-10-08,COMPOSITE LIVING SKIN EQUIVALENTS,,EISENBERG MARK,EISENBERG MARK;;MARK EISENBERG,,https://lens.org/194-764-740-736-394,Granted Patent,no,0,0,1,1,0,A61L27/60,A61F/,,0,0,,,,EXPIRED
2,DK,T3,DK 0526550 T3,100-348-299-910-271,1998-08-31,1998,DK 91908747 T,1991-04-24,AU PJ981990 A;;AU PK430291 A;;AU 1960/091001 W,1990-04-24,Kompositækvivalent til levende hud,"PCT No. PCT/AU91/00160 Sec. 371 Date Nov. 27, 1991 Sec. 102(e) Date Nov. 27, 1991 PCT Filed Apr. 24, 1991 PCT Pub. No. WO91/16010 PCT Pub. Date Oct. 31, 1991A composite living skin equivalent is described comprising an epidermal layer of cultured keratinocyte cells, a layer of non-porous collagen, and a dermal layer of cultured fibroblast cells in a porous cross-linked collagen sponge matrix. Preferably the non-porous collagen is Type 1, Type 3 or mixtures of Types 1 and 3 bovine collagen, which has been pepsin treated. A process for preparing the skin equivalent is described, as well as a test kit for in vitro testing of the skin equivalent. The skin equivalent has use for skin grafting as well as in vitro testing of the effects of various substances on skin. +RR The questions raised in reexamination request No. 90/003,418, filed Apr. 25, 1994, have been considered and the results thereof are reflected in this reissue patent which constitutes the reexamination certificate required by 35 U.S.C. 307 as provided in 37 CFR 1.570(e).",ORTEC INTERNATIONAL INC,EISENBERG MARK,,https://lens.org/100-348-299-910-271,Granted Patent,no,0,0,26,51,0,A61F2/105;;A61K35/12;;A61L27/24;;A61L27/3804;;A61L27/3813;;A61L27/3891;;A61L27/56;;A61L27/60;;C12N5/0698;;C12N2502/094;;C12N2502/1323;;C12N2503/06;;C12N2533/54;;G01N33/5005;;G01N33/5014;;Y10S128/08;;A61L27/3804;;C12N2502/094;;A61K35/12;;C12N2533/54;;A61L27/60;;A61F2/105;;C12N5/0698;;A61L27/56;;C12N2502/1323;;A61L27/3891;;C12N2503/06;;G01N33/5005;;A61L27/3813;;A61L27/24;;G01N33/5014;;Y10S128/08,A61K35/36;;A61B10/00;;A61F2/10;;A61K35/12;;A61L27/00;;A61L27/38;;A61L27/60;;C12N5/071;;G01N33/50,,0,0,,,,EXPIRED
3,NO,D0,NO 924034 D0,089-788-726-302-661,1992-10-19,1992,NO 924034 A,1992-10-19,AU PJ891990 A;;AU PK430291 A;;AU 1960/091001 W,1990-03-02,KOMPOSITTMATERIALE EKVIVALENT TIL LEVENDE HUD,,EISENBERG MARK,EISENBERG MARK,,https://lens.org/089-788-726-302-661,Patent Application,no,0,0,2,51,0,,A61F/;;A61F2/10;;C12N5/071,,0,0,,,,PENDING
4,AT,T1,AT E161408 T1,073-480-933-713-138,1998-01-15,1998,AT 91908747 T,1991-04-24,AU PJ981990 A;;AU PK430291 A,1990-04-24,ZUSAMMENGESETZTES ÄQUIVALENT DER LEBENDEN HAUT,"PCT No. PCT/AU91/00160 Sec. 371 Date Nov. 27, 1991 Sec. 102(e) Date Nov. 27, 1991 PCT Filed Apr. 24, 1991 PCT Pub. No. WO91/16010 PCT Pub. Date Oct. 31, 1991A composite living skin equivalent is described comprising an epidermal layer of cultured keratinocyte cells, a layer of non-porous collagen, and a dermal layer of cultured fibroblast cells in a porous cross-linked collagen sponge matrix. Preferably the non-porous collagen is Type 1, Type 3 or mixtures of Types 1 and 3 bovine collagen, which has been pepsin treated. A process for preparing the skin equivalent is described, as well as a test kit for in vitro testing of the skin equivalent. The skin equivalent has use for skin grafting as well as in vitro testing of the effects of various substances on skin. +RR The questions raised in reexamination request No. 90/003,418, filed Apr. 25, 1994, have been considered and the results thereof are reflected in this reissue patent which constitutes the reexamination certificate required by 35 U.S.C. 307 as provided in 37 CFR 1.570(e).",EISENBERG MARK,EISENBERG MARK,,https://lens.org/073-480-933-713-138,Granted Patent,no,0,0,26,51,0,A61F2/105;;A61K35/12;;A61L27/24;;A61L27/3804;;A61L27/3813;;A61L27/3891;;A61L27/56;;A61L27/60;;C12N5/0698;;C12N2502/094;;C12N2502/1323;;C12N2503/06;;C12N2533/54;;G01N33/5005;;G01N33/5014;;Y10S128/08;;A61L27/3804;;C12N2502/094;;A61K35/12;;C12N2533/54;;A61L27/60;;A61F2/105;;C12N5/0698;;A61L27/56;;C12N2502/1323;;A61L27/3891;;C12N2503/06;;G01N33/5005;;A61L27/3813;;A61L27/24;;G01N33/5014;;Y10S128/08,A61K35/36;;A61B10/00;;A61F2/10;;A61K35/12;;A61L27/00;;A61L27/38;;A61L27/60;;C12N5/071;;G01N33/50,,0,0,,,,DISCONTINUED
5,US,A,US 6039760 A,181-787-357-873-222,2000-03-21,2000,US 60227196 A,1996-02-16,US 60227196 A;;AU PJ981990 A;;AU PK430291 A;;US 12386093 A;;US 77741991 A,1990-04-24,Composite living skin equivalent,"Skin equivalents and processes for preparing them are described. The living skin equivalent comprises a layer of cultured keratinocyte cells, a layer of high purity, non-porous collagen and a dermal layer of cultured fibroblast cells in a porous, cross-linked collagen sponge. Processes are described for producing the skin equivalent with descriptions on how to obtain and treat skin precursor materials to yield suitable fibroblasts and keratinocytes. The collagen layers, the physical forms thereof, and treatments thereof are also described. Preferably, the non-porous, highly-purified collagen is selected from Type 1, Type 3, or mixtures of Type 1 and Type 3 collagen. The collagen is purified ideally by treatment with pepsin, to remove antigenic substances. The collagen sponge used can be any suitable form of collagen sponge which will support fibroblast growth. The keratinocytes used in the invention are preferably prepared by the ""drop"" method spotted evenly on culture media and incubated to coalescence.",ORTEC INTERNATIONAL INC,EISENBERG MARK,ORTEC INTERNATIONAL INC (1998-04-14);;ORCEL LLC (2001-08-29),https://lens.org/181-787-357-873-222,Granted Patent,yes,6,133,26,51,0,A61F2/105;;A61K35/12;;A61L27/24;;A61L27/3804;;A61L27/3813;;A61L27/3891;;A61L27/56;;A61L27/60;;C12N5/0698;;C12N2502/094;;C12N2502/1323;;C12N2503/06;;C12N2533/54;;G01N33/5005;;G01N33/5014;;Y10S128/08;;A61L27/3804;;C12N2502/094;;A61K35/12;;C12N2533/54;;A61L27/60;;A61F2/105;;C12N5/0698;;A61L27/56;;C12N2502/1323;;A61L27/3891;;C12N2503/06;;G01N33/5005;;A61L27/3813;;A61L27/24;;G01N33/5014;;Y10S128/08,A61B10/00;;A61K35/36;;A61F2/10;;A61K35/12;;A61L27/00;;A61L27/38;;A61L27/60;;C12N5/071;;G01N33/50,623/15;;435/240;;424/424,2,2,018-282-392-449-669;;018-282-392-449-669,2451303;;2451303,"Boyce, et al, Biologic Attachment, Growth, and Differentiation of Cultured Human Epidermal Keratinocytes on a Graftable Collagen and Chondroitin 6 Sulfate Substrate, Surgery, Apr. 1988, pp. 421 430.;;Boyce, et al. Biological Attachment, Growth & Differentiation of Cultured Human Epidermal Keratinocytes on Graftable Collagen and Chondroitin 6 Sulfate Substrate; Surgery Apr. 1988, pp. 421 431.",EXPIRED
6,US,A,US 5282859 A,042-806-747-277-494,1994-02-01,1994,US 77741991 A,1991-11-27,AU PJ981990 A;;AU PK430291 A,1990-04-24,Composite living skin equivalents,"A composite living skin equivalent is described comprising an epidermal layer of cultured keratinocyte cells, a layer of non-porous collagen, and a dermal layer of cultured fibroblast cells in a porous cross-linked collagen sponge matrix. Preferably the non-porous collagen is Type 1, Type 3 or mixtures of Types 1 and 3 bovine collagen, which has been pepsin treated. A process for preparing the skin equivalent is described, as well as a test kit for in vitro testing of the skin equivalent. The skin equivalent has use for skin grafting as well as in vitro testing of the effects of various substances on skin.",EISENBERG MARK,EISENBERG MARK,ORTEC INTERNATIONAL INC (1998-04-14),https://lens.org/042-806-747-277-494,Granted Patent,yes,61,56,26,51,0,A61F2/105;;A61K35/12;;A61L27/24;;A61L27/3804;;A61L27/3813;;A61L27/3891;;A61L27/56;;A61L27/60;;C12N5/0698;;C12N2502/094;;C12N2502/1323;;C12N2503/06;;C12N2533/54;;G01N33/5005;;G01N33/5014;;Y10S128/08;;A61L27/3804;;C12N2502/094;;A61K35/12;;C12N2533/54;;A61L27/60;;A61F2/105;;C12N5/0698;;A61L27/56;;C12N2502/1323;;A61L27/3891;;C12N2503/06;;G01N33/5005;;A61L27/3813;;A61L27/24;;G01N33/5014;;Y10S128/08,A61B10/00;;A61F2/10;;A61K35/12;;A61L27/00;;A61L27/38;;A61K35/36;;A61L27/60;;C12N5/071;;G01N33/50,623/11;;623/15;;623/66;;X128DIG 8;;435/240.241;;424/424;;602/42,29,28,052-809-158-205-341;;126-639-862-761-943;;032-884-919-896-349;;007-165-105-741-21X;;035-771-913-313-139;;049-125-617-651-709;;012-188-791-271-467;;038-342-927-715-896;;112-163-631-356-431;;014-244-070-093-281;;055-394-624-767-307;;066-111-093-397-170;;010-333-152-236-505;;022-856-919-104-603;;075-595-490-036-758;;015-618-103-219-38X;;057-801-129-618-628;;053-003-805-659-715;;082-311-998-917-640;;018-282-392-449-669;;059-273-878-622-970;;014-629-095-545-317;;034-741-010-256-416;;095-978-901-452-398;;033-401-172-067-434;;085-268-677-008-241;;101-613-661-266-468;;045-400-114-557-567,4296199;;10.1111/1523-1747.ep12260838;;4933759;;pmc2200288;;10.1083/jcb.54.3.626;;4339818;;10.1093/jnci/53.4.1061;;4610165;;10.1016/s0076-6879(79)58142-7;;423766;;293669;;pmc411710;;10.1073/pnas.76.11.5665;;286310;;10.1073/pnas.76.3.1274;;pmc383233;;6987234;;10.1002/jbm.820140108;;pmc348657;;10.1073/pnas.77.4.2088;;6929540;;7358747;;10.1002/jbm.820140203;;10.1097/00006534-198103000-00024;;7232576;;10.1126/science.7008197;;7008197;;10.1016/0047-6374(81)90077-4;;7311621;;10.1126/science.7031899;;7031899;;6306115;;10.1111/1523-1747.ep12539993;;6505616;;10.1056/nejm198408163110706;;6379456;;3114337;;10.1016/s0190-9622(87)70199-6;;2461880;;10.1038/eye.1988.31;;2451303;;2568523;;2474667;;10.1097/00005373-198908000-00016;;10.1001/jama.1989.03430150093032;;2677425;;10.1001/jama.262.15.2125;;2795787;;10.1001/jama.1989.03430150108036;;10.1001/jama.262.15.2140;;10.1016/0142-9612(90)90152-g;;2350555;;10.1016/0022-4804(90)90225-q;;2113969;;2254975;;10.1097/00005373-199012001-00030;;10.1111/j.1365-2133.1986.tb02783.x;;2417615,"Cancer Research, vol. 28, Feb. 1968, pp. 286 291 Patterns of Three dimensional Growth in vitro in Collagen Coated Cellulose Sponge: Carcinomas and Embryonic Tissues J. Leighton, R. Mark, and G. Justh.;;Journal of Investigative Dermatology, vol. 56, No. 3, 1971, pp. 205 210, Growth of Postembryonic Skin Epithelial Cells on Collagen Gels, M. A. Karasek and M. E. Charlton.;;Journal of Cell Biology, vol. 54, 1972, pp. 626 637 Collagen Substrata For Studies on Cell Behavior T. Ellsdale and J. Bard.;;Zoon 2, 1974, pp. 99 104 Scanning Electron Microscopy of Chick Embryo Nerve Fibres and Heart Fibroblasts on collagen Substrata in Vitro, T. Ebendal.;;Journal of the National Cancer Institute, vol. 53, No. 45, Oct. 1974, pp. 1061 1064, P. Worst, E. Valentine, & N. Fusenig. Formation of Epidermis After Reimplantation of Pure Primary Epidermal Cell Cultures from Perinatal Mouse Skin.;;Methods in Enzymology, vol. 58, 1979, pp. 263 278 New Techniques for Culturing Differentiated Cells: Reconstituted Basement Membrane Rafts, L. Reid adn M. Rojkind.;;Proc. Nat l Acad. Science, USA, 76, 1979, pp. 5665 5668 Green , et al. Growth of Human Epidermal Cells Into Multiple Epithelial Suitable for Grafting.;;Proc. Nat l. Acad. Science, USA, vol. 76, No. 3, Mar. 1979, pp. 1274 1278; E. Bell, B. Ivarsson, and C. Merrill Production of a tissue like structure by contraction of collagen lattices by human fibroblasts of different proliferative potential.;;Journal of Biomedical Materials Research, vol. 14, 1980, pp. 65 81; I. V. Yannas and J. F. Burke Design of an Artificial Skin. I. Basic Design Principles.;;Proc. Natl. Acad. Sci., USA, vol. 77, No. 4, Apr. 1980; pp. 2088 2092; J. Yang, J. Richards R. Guzman, W. Inagawa, & S. Nandi Sustained growth in primary culture of normal mammary epithelial cells embedded in collagen gels.;;Jour. of Biomedical Materials Res., vol. 14, 1980, pp. 107 131. Design of an artificial skin. II. Control of Chemical Composition. I. V. Yannas, J. F. Burke, P. L. Gordon, C. Huang, and R. Rubenstein.;;Plastic and Reconstructive Surgery, Mar. 1981, pp. 386 392, vol. 67, No. 3; E. Bell, H. P. Ehrlich, S. Sher, C. Merrill, B. Hull, R. Sarber, T. Nakatsuji, D. Church and D. J. Buttle Development and Use of a Living Skin Equivalent.;;Science, vol. 211, Mar. 6, 1981, pp. 1051 1054 E. Bell, H. P. Ehrlich, D. J. Buttle, T. Nakatsuji Living Tissue Formed in vitro and Accepted as Skin Equivalent Tissue of Full Thickness.;;Mechanisms of Ageing and Development, 17, 1981, pp. 107 117 Regulation of proliferation of fibroblasts of low and high population doubling levels grown in collagen lattices. R. Sarber, B. Hull, C. Merrill, T. Soranno, and E. Bell.;;Science, vol. 215, Jan. 8, 1982, pp. 174 176 I. V. Yannas, J. F. Burke, D. P. Orgill, and E. M. Skrabut Wound Tissue Can Utilize a Polymeric Template to Synthesize a Functional Extension of Skin.;;Journal of Investigative Dermatology, 81; Jul. 1983, pp. 2 10 The Reconstitution of Living Skin. E. Bell, S. Sher. B. Hull, C. Merrill, S. Rosen, A. Chamson, D. Asselineau, L. Dubertret, B. Coulomb, C. Lapiere, B. Nusgens, and Y. Neveux.;;Scanning Electron Microscopy, III, 1984, pp. 1313 1320 C. Doillon, C. Whyne, R. Berg, R. Olson, and F. Silver Fibroblast collagen Sponge Interactions and the Spatial Deposition of Newly synthesized Collagen Fibers in vitro and in vivo.;;The New England Journal of Medicine, vol. 311, No. 7, Aug. 1984, pp. 448, 450 451. G. G. Gallico, III, N. O Connor, C. Compton, Ol Kehinde, and H. Green. Permanent Coverage of Large Burn Wounds with Autologous Cultured Human Epithelium.;;Journ. Amer. Acad. Dermatology, vol. 17, No. 2, Aug. 1987 pp. 246 250. D. M. Carter, A. N. Lin, M. Varghese, D. Caldwell, L. Pratt., and M. Eisinger; Treatment of junctional epidermolysis bullosa with epidermal autografts.;;Eye; 2, 1988, pp. 172 177; R. J. Pye Cultured Keratinocytes as Biological Wound Dressings.;;Surgery, vol. 103, No. 4, Apr. 1988, pp. 421 431; S. Boyce and J. F. Hansbrough; Biologic attachment, growth, and differentiation of cultured human epidermal keratinocytes on a graftable collagen and chondroitin 6 sulfate substrate.;;The Lancet, Jul. 22, 1989, pp. 191, 193 J. Nanchahal, R. Dover, W. Otto, and S. Dhital Cultured Composite Skin Grafts: Biological Skin Equivalents Permitting Massive Expansion.;;Journal of Trauma, vol. 29, No. 8, Aug. 1989, pp. 1165 1167 H. Morykwas, T. Stevenson, C. Marcelo, J. Thornton, D. Smith, Jr. In Vitro and In Vivo Testing of a Collagen Sheet to Support Keratinocyte Growth For Use As a Burn Wound Covering.;;Journal of Med. Assoc., vol. 262, No. 15, Oct. 20, 1989 pp. 2125 2130. J. Hansbrough, S. Boyce, M. Cooper, T. Foreman Burn Wound Closure With cultured Autologous Keratinocytes and Fibroblasts Attached to a Collagen Glycosaminoglycan Substrate.;;Jour. Amer. Med. Assoc., vol. 262, No. 15, pp. 2140 2141. Oct. 20, 1989, D. Woodley Covering Wounds with Cultured Keratinocytes.;;Biomaterials, vol. 11, Apr. 1990, pp. 181 185 P. Rowling, M. Raxworth, E. Wood, J. Kearney Fabrication and Reorganization of Dermal Equivalents suitable for Skin Grafting After Major Cutaneous Injury.;;Jour. Surg. Research; 48; Jun. 1990, pp. 528 533 M. Cooper, J. Hansbrough, T. Foreman In Vitro Effects of Matrix Peptides on a Cultured Dermal Epidermal Skin Substitute.;;Journal of Trauma, vol. 30, No. 12 Supplement, Dec. 1990 pp. 155 160, J. F. Hansbrough Current Status of Skin Replacements For Coverage of Extensive Burn Wounds.;;Brit. Journ of Derm.; 114, pp. 91 101, Coulomb et al. A New Method For Studying Epidermalization In Vitro.",EXPIRED
7,CA,C,CA 2080693 C,075-801-593-989-96X,2001-11-27,2001,CA 2080693 A,1991-04-24,AU PJ981990 A;;AU PK430291 A;;AU 1960/091001 W,1990-04-24,COMPOSITE LIVING SKIN EQUIVALENTS,"A composite living skin equivalent is described comprising an epidermal laye r of cultured keratinocyte cells, a layer of non-porous collagen, and a dermal layer of cultured fibroblast cells in a porous cross-linked collagen sponge matrix. Preferably the non-porous collagen is Type 1, Type 3 or mixtures of Types 1 and 3 bovin e collagen, which has been pepsin treated. A process for preparing the skin equivalent is described, as well as a test kit for in vitro testing of the skin equivalent. The skin equivalent has use for skin grafting as well as in vitro testing of the effects of various substances on skin.",EISENBERG MARK,EISENBERG MARK,,https://lens.org/075-801-593-989-96X,Granted Patent,no,0,0,26,51,0,A61F2/105;;A61K35/12;;A61L27/24;;A61L27/3804;;A61L27/3813;;A61L27/3891;;A61L27/56;;A61L27/60;;C12N5/0698;;C12N2502/094;;C12N2502/1323;;C12N2503/06;;C12N2533/54;;G01N33/5005;;G01N33/5014;;Y10S128/08;;A61L27/3804;;C12N2502/094;;A61K35/12;;C12N2533/54;;A61L27/60;;A61F2/105;;C12N5/0698;;A61L27/56;;C12N2502/1323;;A61L27/3891;;C12N2503/06;;G01N33/5005;;A61L27/3813;;A61L27/24;;G01N33/5014;;Y10S128/08,A61K35/36;;A61B10/00;;A61F2/10;;A61K35/12;;A61L27/00;;A61L27/38;;A61L27/60;;C12N5/071;;G01N33/50,,0,0,,,,EXPIRED
8,CA,A1,CA 2080693 A1,034-774-685-004-904,1991-10-25,1991,CA 2080693 A,1991-04-24,AU PJ981990 A;;AU PK430291 A;;AU 1960/091001 W,1990-04-24,COMPOSITE LIVING SKIN EQUIVALENTS,"2080693 9116010 PCTABS00007 A composite living skin equivalent is described comprising an epidermal layer of cultured keratinocyte cells, a layer of non-porous collagen, and a dermal layer of cultured fibroblast cells in a porous cross-linked collagen sponge matrix. Preferably the non-porous collagen is Type 1, Type 3 or mixtures of Types 1 and 3 bovine collagen, which has been pepsin treated. A process for preparing the skin equivalent is described, as well as a test kit for in vitro testing of the skin equivalent. The skin equivalent has use for skin grafting as well as in vitro testing of the effects of various substances on skin.",EISENBERG MARK,EISENBERG MARK,,https://lens.org/034-774-685-004-904,Patent Application,no,0,0,26,51,0,A61F2/105;;A61K35/12;;A61L27/24;;A61L27/3804;;A61L27/3813;;A61L27/3891;;A61L27/56;;A61L27/60;;C12N5/0698;;C12N2502/094;;C12N2502/1323;;C12N2503/06;;C12N2533/54;;G01N33/5005;;G01N33/5014;;Y10S128/08;;A61L27/3804;;C12N2502/094;;A61K35/12;;C12N2533/54;;A61L27/60;;A61F2/105;;C12N5/0698;;A61L27/56;;C12N2502/1323;;A61L27/3891;;C12N2503/06;;G01N33/5005;;A61L27/3813;;A61L27/24;;G01N33/5014;;Y10S128/08,A61K35/36;;A61B10/00;;A61F2/10;;A61K35/12;;A61L27/00;;A61L27/38;;A61L27/60;;C12N5/071;;G01N33/50,,0,0,,,,EXPIRED
9,EP,B1,EP 0526550 B1,185-108-371-622-516,1997-12-29,1997,EP 91908747 A,1991-04-24,AU 1960/091001 W;;AU PJ981990 A;;AU PK430291 A,1990-04-24,COMPOSITE LIVING SKIN EQUIVALENTS,"PCT No. PCT/AU91/00160 Sec. 371 Date Nov. 27, 1991 Sec. 102(e) Date Nov. 27, 1991 PCT Filed Apr. 24, 1991 PCT Pub. No. WO91/16010 PCT Pub. Date Oct. 31, 1991A composite living skin equivalent is described comprising an epidermal layer of cultured keratinocyte cells, a layer of non-porous collagen, and a dermal layer of cultured fibroblast cells in a porous cross-linked collagen sponge matrix. Preferably the non-porous collagen is Type 1, Type 3 or mixtures of Types 1 and 3 bovine collagen, which has been pepsin treated. A process for preparing the skin equivalent is described, as well as a test kit for in vitro testing of the skin equivalent. The skin equivalent has use for skin grafting as well as in vitro testing of the effects of various substances on skin. +RR The questions raised in reexamination request No. 90/003,418, filed Apr. 25, 1994, have been considered and the results thereof are reflected in this reissue patent which constitutes the reexamination certificate required by 35 U.S.C. 307 as provided in 37 CFR 1.570(e).",EISENBERG MARK,EISENBERG MARK,"EISENBERG, MARK TRANSFER- ORTEC INTERNATIONAL, INC (1999-02-26);;CESSIONE EPO REG. 20;ORTEC INTERNATIONAL INC. (1998-09-15);;ORTEC INTERNATIONAL, INC. (1999-02-01)",https://lens.org/185-108-371-622-516,Granted Patent,yes,6,0,26,51,0,A61F2/105;;A61K35/12;;A61L27/24;;A61L27/3804;;A61L27/3813;;A61L27/3891;;A61L27/56;;A61L27/60;;C12N5/0698;;C12N2502/094;;C12N2502/1323;;C12N2503/06;;C12N2533/54;;G01N33/5005;;G01N33/5014;;Y10S128/08;;A61L27/3804;;C12N2502/094;;A61K35/12;;C12N2533/54;;A61L27/60;;A61F2/105;;C12N5/0698;;A61L27/56;;C12N2502/1323;;A61L27/3891;;C12N2503/06;;G01N33/5005;;A61L27/3813;;A61L27/24;;G01N33/5014;;Y10S128/08,A61K35/36;;A61B10/00;;A61F2/10;;A61K35/12;;A61L27/00;;A61L27/38;;A61L27/60;;C12N5/071;;G01N33/50,,3,0,,,"BELL. E. et al. (1983): ""The Reconstruction of Living Skin, The Journal of Investigative Dermatology"", Volume 81, No. 1, Supplement pages 2-10. (see pages 1 and 5 in particular);;DYKES, P.J. et al. (1991): ""In Vitro Reconstruction of Human Skin: The Use of Skin Equivalents as Potential Indicators of Cutaneous Toxicity, Toxicology In Vitro"", Volume 5, No. 1, pages 1-8 (see introduction and discussion in particular);;ROWLING, P.J.E. et al. (1990): ""Fabrication and Reorganization of Dermal Equivalents Suitable for Skin Grafting after Major Cutaneous Injury, Biomaterials"", Volume 11, pages 181-185; published April 1990",EXPIRED
10,NZ,A,NZ 240126 A,197-850-440-292-314,1992-08-26,1992,NZ 24012691 A,1991-10-07,NZ 24012691 A,1991-10-07,COMPOSITE LIVING SKIN EQUIVALENT,,EISENBERG MARK,EISENBERG MARK,,https://lens.org/197-850-440-292-314,Patent Application,no,0,0,1,1,0,,A61F2/10;;C12N5/06;;G01N33/48,,0,0,,,,DISCONTINUED
11,HU,A,HU T63319 A,014-613-555-529-988,1993-08-30,1993,HU 333892 A,1991-04-24,AU PJ981990 A;;AU PK430291 A;;AU 1960/091001 W,1990-04-24,METHOD FOR PRODUCING COMPOSITION EQUIVALENT WITH LIVING SKIN,"PCT No. PCT/AU91/00160 Sec. 371 Date Nov. 27, 1991 Sec. 102(e) Date Nov. 27, 1991 PCT Filed Apr. 24, 1991 PCT Pub. No. WO91/16010 PCT Pub. Date Oct. 31, 1991A composite living skin equivalent is described comprising an epidermal layer of cultured keratinocyte cells, a layer of non-porous collagen, and a dermal layer of cultured fibroblast cells in a porous cross-linked collagen sponge matrix. Preferably the non-porous collagen is Type 1, Type 3 or mixtures of Types 1 and 3 bovine collagen, which has been pepsin treated. A process for preparing the skin equivalent is described, as well as a test kit for in vitro testing of the skin equivalent. The skin equivalent has use for skin grafting as well as in vitro testing of the effects of various substances on skin. +RR The questions raised in reexamination request No. 90/003,418, filed Apr. 25, 1994, have been considered and the results thereof are reflected in this reissue patent which constitutes the reexamination certificate required by 35 U.S.C. 307 as provided in 37 CFR 1.570(e).",EISENBERG MARK,EISENBERG MARK,,https://lens.org/014-613-555-529-988,Unknown,no,0,0,26,51,0,A61F2/105;;A61K35/12;;A61L27/24;;A61L27/3804;;A61L27/3813;;A61L27/3891;;A61L27/56;;A61L27/60;;C12N5/0698;;C12N2502/094;;C12N2502/1323;;C12N2503/06;;C12N2533/54;;G01N33/5005;;G01N33/5014;;Y10S128/08;;A61L27/3804;;C12N2502/094;;A61K35/12;;C12N2533/54;;A61L27/60;;A61F2/105;;C12N5/0698;;A61L27/56;;C12N2502/1323;;A61L27/3891;;C12N2503/06;;G01N33/5005;;A61L27/3813;;A61L27/24;;G01N33/5014;;Y10S128/08,A61B10/00;;A61F2/10;;A61K35/12;;A61K35/36;;A61L27/00;;A61L27/38;;A61L27/60;;C12N5/071;;G01N33/50,,0,0,,,,DISCONTINUED
12,HU,D0,HU 9203338 D0,053-356-659-767-008,1993-01-28,1993,HU 333892 A,1991-04-24,AU PJ981990 A;;AU PK430291 A;;AU 1960/091001 W,1990-04-24,PREPARATIVES EQUIVALENT WITH SKIN,"PCT No. PCT/AU91/00160 Sec. 371 Date Nov. 27, 1991 Sec. 102(e) Date Nov. 27, 1991 PCT Filed Apr. 24, 1991 PCT Pub. No. WO91/16010 PCT Pub. Date Oct. 31, 1991A composite living skin equivalent is described comprising an epidermal layer of cultured keratinocyte cells, a layer of non-porous collagen, and a dermal layer of cultured fibroblast cells in a porous cross-linked collagen sponge matrix. Preferably the non-porous collagen is Type 1, Type 3 or mixtures of Types 1 and 3 bovine collagen, which has been pepsin treated. A process for preparing the skin equivalent is described, as well as a test kit for in vitro testing of the skin equivalent. The skin equivalent has use for skin grafting as well as in vitro testing of the effects of various substances on skin. +RR The questions raised in reexamination request No. 90/003,418, filed Apr. 25, 1994, have been considered and the results thereof are reflected in this reissue patent which constitutes the reexamination certificate required by 35 U.S.C. 307 as provided in 37 CFR 1.570(e).",EISENBERG MARK,EISENBERG MARK,,https://lens.org/053-356-659-767-008,Patent Application,no,0,0,26,51,0,A61F2/105;;A61K35/12;;A61L27/24;;A61L27/3804;;A61L27/3813;;A61L27/3891;;A61L27/56;;A61L27/60;;C12N5/0698;;C12N2502/094;;C12N2502/1323;;C12N2503/06;;C12N2533/54;;G01N33/5005;;G01N33/5014;;Y10S128/08;;A61L27/3804;;C12N2502/094;;A61K35/12;;C12N2533/54;;A61L27/60;;A61F2/105;;C12N5/0698;;A61L27/56;;C12N2502/1323;;A61L27/3891;;C12N2503/06;;G01N33/5005;;A61L27/3813;;A61L27/24;;G01N33/5014;;Y10S128/08,A61K35/36;;A61B10/00;;A61F2/10;;A61K35/12;;A61L27/00;;A61L27/38;;A61L27/60;;C12N5/071;;G01N33/50,,0,0,,,,DISCONTINUED
13,CN,A,CN 1071568 A,093-123-587-961-146,1993-05-05,1993,CN 91109937 A,1991-10-18,CN 91109937 A;;AU PJ981990 A,1990-04-24,COMPOSITE LIVING SKIN EQUIVALENTS,"A composite living skin equivalent is described comprising an epidermal layer of cultured keratinocyte cells, a layer of non-porous collagen, and a dermal layer of cultured fibroblast cells in a porous cross-linked collagen sponge matrix. Preferably the non-porous collagen is Type 1, Type 3 or mixtures of Types 1 and 3 bovine collagen, which has been pepsin treated. A process for preparing the skin equivalent is described, as well as a test kit for in vitro testing of the skin equivalent. The skin equivalent has use for skin grafting as well as in vitro testing of the effects of various substances on skin.",EISENBERG MARK,EISENBERG MARK,,https://lens.org/093-123-587-961-146,Patent Application,no,0,2,2,51,0,,A61B10/00;;A61F2/10;;A61L27/00;;C12N5/08,,0,0,,,,EXPIRED
14,BR,A,BR 9106354 A,070-831-384-301-175,1993-04-27,1993,BR 9106354 A,1991-04-24,AU PJ981990 A;;AU PK430291 A;;AU 1960/091001 W,1990-04-24,"EQUIVALENTE DE PELE VIVA COMPOSTA,SEU PROCESSO DE PREPARACAO; KIT DE TESTE,SEU PROCESSO DE PREPARACAO,E PROCESSO DE TESTAR EFEITO DE SUBSTANCIA SOBRE A PELE","PCT No. PCT/AU91/00160 Sec. 371 Date Nov. 27, 1991 Sec. 102(e) Date Nov. 27, 1991 PCT Filed Apr. 24, 1991 PCT Pub. No. WO91/16010 PCT Pub. Date Oct. 31, 1991A composite living skin equivalent is described comprising an epidermal layer of cultured keratinocyte cells, a layer of non-porous collagen, and a dermal layer of cultured fibroblast cells in a porous cross-linked collagen sponge matrix. Preferably the non-porous collagen is Type 1, Type 3 or mixtures of Types 1 and 3 bovine collagen, which has been pepsin treated. A process for preparing the skin equivalent is described, as well as a test kit for in vitro testing of the skin equivalent. The skin equivalent has use for skin grafting as well as in vitro testing of the effects of various substances on skin. +RR The questions raised in reexamination request No. 90/003,418, filed Apr. 25, 1994, have been considered and the results thereof are reflected in this reissue patent which constitutes the reexamination certificate required by 35 U.S.C. 307 as provided in 37 CFR 1.570(e).",EISENBERG MARK,EISENBERG MARK,,https://lens.org/070-831-384-301-175,Patent Application,no,0,0,26,51,0,A61F2/105;;A61K35/12;;A61L27/24;;A61L27/3804;;A61L27/3813;;A61L27/3891;;A61L27/56;;A61L27/60;;C12N5/0698;;C12N2502/094;;C12N2502/1323;;C12N2503/06;;C12N2533/54;;G01N33/5005;;G01N33/5014;;Y10S128/08;;A61L27/3804;;C12N2502/094;;A61K35/12;;C12N2533/54;;A61L27/60;;A61F2/105;;C12N5/0698;;A61L27/56;;C12N2502/1323;;A61L27/3891;;C12N2503/06;;G01N33/5005;;A61L27/3813;;A61L27/24;;G01N33/5014;;Y10S128/08,A61K35/36;;A61B10/00;;A61F2/10;;A61K35/12;;A61L27/00;;A61L27/38;;A61L27/60;;C12N5/071;;G01N33/50,,0,0,,,,DISCONTINUED
15,US,E,US RE035399 E,080-126-373-649-36X,1996-12-10,1996,US 34652594 A,1994-11-29,US 34652594 A;;AU PJ981990 A;;AU PK430291 A;;AU 1960/091001 W;;US 77741991 A,1990-04-24,Composite living skin equivalents,"A composite living skin equivalent is described comprising an epidermal layer of cultured keratinocyte cells, a layer of non-porous collagen, and a dermal layer of cultured fibroblast cells in a porous cross-linked collagen sponge matrix. Preferably the non-porous collagen is Type 1, Type 3 or mixtures of Types 1 and 3 bovine collagen, which has been pepsin treated. A process for preparing the skin equivalent is described, as well as a test kit for in vitro testing of the skin equivalent. The skin equivalent has use for skin grafting as well as in vitro testing of the effects of various substances on skin. The questions raised in reexamination request No. 90/003,418, filed Apr. 25, 1994, have been considered and the results thereof are reflected in this reissue patent which constitutes the reexamination certificate required by 35 U.S.C. 307 as provided in 37 CFR 1.570(e).",EISENBERG; MARK,EISENBERG MARK,,https://lens.org/080-126-373-649-36X,Amended Patent,yes,70,62,26,51,0,A61F2/105;;A61K35/12;;A61L27/24;;A61L27/3804;;A61L27/3813;;A61L27/3891;;A61L27/56;;A61L27/60;;C12N5/0698;;C12N2502/094;;C12N2502/1323;;C12N2503/06;;C12N2533/54;;G01N33/5005;;G01N33/5014;;Y10S128/08;;A61L27/3804;;C12N2502/094;;A61K35/12;;C12N2533/54;;A61L27/60;;A61F2/105;;C12N5/0698;;A61L27/56;;C12N2502/1323;;A61L27/3891;;C12N2503/06;;G01N33/5005;;A61L27/3813;;A61L27/24;;G01N33/5014;;Y10S128/08,A61B10/00;;A61F2/10;;A61K35/12;;A61L27/00;;A61K35/36;;A61L27/38;;A61L27/60;;C12N5/071;;G01N33/50,623/11;;623/15;;623/66;;X128DIG  8;;435/240.24;;424/424;;602/42,32,30,052-809-158-205-341;;126-639-862-761-943;;032-884-919-896-349;;007-165-105-741-21X;;035-771-913-313-139;;049-125-617-651-709;;012-188-791-271-467;;038-342-927-715-896;;112-163-631-356-431;;014-244-070-093-281;;055-394-624-767-307;;066-111-093-397-170;;010-333-152-236-505;;022-856-919-104-603;;075-595-490-036-758;;015-618-103-219-38X;;057-801-129-618-628;;053-003-805-659-715;;082-311-998-917-640;;018-282-392-449-669;;059-273-878-622-970;;014-629-095-545-317;;034-741-010-256-416;;095-978-901-452-398;;033-401-172-067-434;;085-268-677-008-241;;101-613-661-266-468;;045-400-114-557-567;;026-712-678-590-809;;054-216-676-722-735,4296199;;10.1111/1523-1747.ep12260838;;4933759;;pmc2200288;;10.1083/jcb.54.3.626;;4339818;;10.1093/jnci/53.4.1061;;4610165;;10.1016/s0076-6879(79)58142-7;;423766;;293669;;pmc411710;;10.1073/pnas.76.11.5665;;286310;;10.1073/pnas.76.3.1274;;pmc383233;;6987234;;10.1002/jbm.820140108;;pmc348657;;10.1073/pnas.77.4.2088;;6929540;;7358747;;10.1002/jbm.820140203;;10.1097/00006534-198103000-00024;;7232576;;10.1126/science.7008197;;7008197;;10.1016/0047-6374(81)90077-4;;7311621;;10.1126/science.7031899;;7031899;;6306115;;10.1111/1523-1747.ep12539993;;6505616;;10.1056/nejm198408163110706;;6379456;;3114337;;10.1016/s0190-9622(87)70199-6;;2461880;;10.1038/eye.1988.31;;2451303;;2568523;;2474667;;10.1097/00005373-198908000-00016;;10.1001/jama.1989.03430150093032;;2677425;;10.1001/jama.262.15.2125;;2795787;;10.1001/jama.1989.03430150108036;;10.1001/jama.262.15.2140;;10.1016/0142-9612(90)90152-g;;2350555;;10.1016/0022-4804(90)90225-q;;2113969;;2254975;;10.1097/00005373-199012001-00030;;10.1111/j.1365-2133.1986.tb02783.x;;2417615;;10.1007/bf00494336;;6196325;;10.1016/0887-2333(91)90042-c;;20731992,"Cancer Research, vol. 28, Feb. 1968, pp. 286 291 Patterns of Three dimensional Growth in vitro in Collagen coated Cellulose Sponge:Carcinomas and Embryonic Tissues J. Leighton, R. Mark, and G. Justh.;;Journal of Investigative Dermatology, vol. 56, No. 3, 1971, pp. 205 210, Growth of Postembryonic Skin Epithelial Cells on Collagen Gels, M. A. Karasek and M. E. Charlton.;;Journal of Cell Biology, vol. 54, 1972, pp. 626 637 Collagen Substrate For Studies on Cell Behavior T. Ellsdale and J. Bard.;;Zoon 2, 1974, pp. 99 104 Scanning Electron Microscopy of Chick Embryo Nerve Fibres and Heart Fibroblasts on collagen Substrata in Vitro, T. Ebendal.;;Journal of the National Cancer Institute, vol. 53, No. 4, Oct. 1974, pp. 1061 1064, P. Worst, E. Valentine, & N. Fusenig. Formation of Epidermis After Reimplantation of Pure Primary Epidermal Cell Cultures from Perinatal Mouse Skin.;;Methods in Enzymology, vol. 58, 1979, pp. 263 278 New Techniques for Culturing Differentiated Cells: Reconstituted Basement Membrane Rafts, L. Reid adn M. Rojkind.;;Proc. Nat l Acad. Science, USA, 76, 1979, pp. 5665 5668 Green, et al. Growth of Human Epidermal Cells Into Multiple Epithelial Suitable for Grafting.;;Proc. Nat l. Acad. Science, USA, vol. 76, No. 3, Mar. 1979, pp. 1274 1278; E. Bell, B. Ivarsson, and C. Merrill Production of a tissue like structure by contraction of collagen lattices by human fibroblasts of different proliferative potential.;;Journal of Biomedical Materials Research, vol. 14, 1980, pp. 65 81; I. V. Yannas and J. F. Burke Design of an Artificial Skin. I. Basic design principles.;;Proc. Natl. Acad. Sci., USA, vol. 77, No. 4, Apr. 1980; pp. 2088 2092; J. Yang, J. Richards, R. Guzman, W. Imagawa, & S. Nandi Sustained growth in primary culture of normal mammary epithelial cells embedded in collagen gels.;;Jour. of Biomedical Materials Res., vol. 14, 1980, pp. 107 131. Design of an artificial skin. II. Control of Chemical Composition I. V. Yannas, J. F. Burke, P. L. Gordon, C. Huang, and R. Rubenstein.;;Plastic and Reconstructive Surgery, Mar. 1981, pp. 386 392, vol. 67, No. 3; E. Bell, H. P. Ehrlich, S. Sher, C. Merrill, B. Hull, R. Sarber, T. Nakatsuji, D. Church, and D. J. Buttle Development and Use of a Living Skin Equivalent.;;Science, vol. 211, Mar. 6, 1981, pp. 1051 1054 E. Bell, H. P. Ehrlich, D. J. Buttle, T. Nakatsuji Living Tissue Formed in vitro and Accepted as Skin Equivalent Tissue of Full Thickness.;;Mechanisms of Ageing and Development, 17, 1981, pp. 107 117 Regulation of proliferation of fibroblasts of low and high population doubling levels grown in collagen lattices. R. Sarber, B. Hull, C. Merrill, T. Soranno, and E. Bell.;;Science, vol. 215, Jan. 8, 1982, pp. 174 176 I. V. Yannas, J. F. Burke, D. P. Orgill, and E. M. Skrabut Wound Tissue Can Utilize a Polymeric Template to Synthesize a Functional Extension of Skin.;;Journal of Investigative Dermatology, 81; Jul. 1983, pp. 2 10 The Reconstitution of Living Skin. E. Bell, S. Sher, B. Hull, C. Merrill, S. Rosen, A. Chamson, D. Asselineau, L. Dubertret, B. Coulomb, C. Lapiere, B. Nusgens, and Y. Neveux.;;Scanning Electron Microscopy, III, 1984, pp. 1313 1320 C. Doillon, C. Whyne, R. Berg, R. Olson, and F. Silver Fibroblast collagen Sponge Interactions and the Spatial Deposition of Newly synthesized Collagen Fibers In Vitro and In Vivo.;;The New England Journal of Medicine, vol. 311, No. 7, Aug. 1984, pp. 448, 450 451. G. G. Gallico, III, N. O Connor, C. Compton, O1 Kehinde, and H. Green. Permanent Coverage of Large Burn Wounds with Autologous Cultured Human Epithelium.;;Journ. Amer. Acad. Dermatology, vol. 17, No. 2, Aug. 1987 pp. 246 250. D. M. Carter, A. N. Lin, M. Varghese, D. Caldwell, L. Pratt., and M. Eisinger; Treatment of junctional epidermolysis bullosa with epidermal autografts.;;Eye; 2, 1988, pp. 172 177; R. J. Pye Cultured Keratinocytes as Biological Wound Dressings.;;Surgery, vol. 103, No. 4, Apr. 1988, pp. 421 431; S. Boyce and J. F. Hansbrough; Biologic attachment, growth, and differentiation of cultured human epidermal keratinocytes on a graftable collagen and chondroitin 6 sulfate substrate.;;The Lancet, Jul. 22, 1989, pp. 191, 193 J. Nanchahal, R. Dover, W. Otto, and S. Dhital Cultured Composite Skin Grafts: Biological Skin Equivalents Permitting Massive Expansion.;;Journal of Trauma, vol. 29, No. 8, Aug. 1989, pp. 1165 1167 U. Horykwas, T. Stevenson, C. Marcelo, J. Thornton, D. Smith, Jr. In Vitro and In Vivo Testing of a Collagen Sheet to Support Keratinocyte Growth For Use As a Burn Wound Covering.;;Journ. Amer. Med. Assoc., vol. 262, No. 15, Oct. 20, 1989 pp. 2125 2130. J. Hansbrough, S. Boyce, M. Cooper, T. Foreman Burn Wound Closure With cultured Autologous Keratinocytes and Fibroblasts Attached to a Collagen Glycosaminoglycan Substrate.;;Jour. Amer. Med. Assoc., vol. 262, No. 15, pp. 2140 2141. Oct. 20, 1989, D. Woodley Covering Wounds with Cultured Keratinocytes.;;Biomaterials, vol. 11, Apr. 1990, pp. 181 185 P. Rowling, M. Raxworth, E. Wood, J. Kearney Fabrication and Reorganization of Dermal Equivalents suitable for Skin Grafting After Major Cutaneous Injury.;;Jour. Surg. Research; 48; Jun. 1990, pp. 528 533 M. Cooper, J. Hansbrough, T. Foreman In Vitro Effects of Matrix Peptides on a Cultured Dermal Epidermal Skin Substitute.;;Journal of Trauma, vol. 30, No. 12 Supplement, Dec. 1990 pp. 155 160. J. F. Hansbrough Current Status of Skin Replacements For Coverage of Extensive Burn Wounds.;;Brit. Journ of Derm.; 114, pp. 91 101, Coulomb et al. A New Method For Studying Epidermalization In Vitro.;;Histochemistry; 79: pp. 1 7, 1983. Y. Ookusa, K. Takata, M. Nagashima, H. Hirano Distribution of Glycoconjugates in Normal Human Skin Using Biotinyl Lectins and Avidin Horseradish Peroxidase.;;Organogenesis; 1987 Annual Report E. Bell, H. M. Stein.;;Toxicity In Vitro, vol. 5, No. 1, pp. 1 8; 1991. P. J. Dykes, M. J. Edwards, M. R. O Donovan, V. Merrett, H. E. Morgan, R. Marks. In Vitro Reconstruction of Human Skin: The Use of Skin Equivalents As Potential Indicators of Cutaneous Toxicity.",PENDING
16,NO,L,NO 924034 L,017-014-452-893-159,1992-10-22,1992,NO 924034 A,1992-10-19,AU PJ891990 A;;AU PK430291 A;;AU 1960/091001 W,1990-03-02,KOMPOSITTMATERIALE EKVIVALENT TIL LEVENDE HUD,"En kompositt ekvivalent til levende hud beskrives og omfatter et epidermalt lag dyrkede keratinocyttcelier, et lag ikke-porøst kollagen og et dermalt lag dyrkede fibroblast-celler i en porøs tverrbundet kollagentampong-matrise. Det ikke-porzse kollagen er fcrzrinnsvis type l-, type 3- eller blandinger av type l- og type 3-bovinkollagen, som er pepsin-behandlet. Det beskrives en fremgangsmåte til fremstilling av hudekvivalenten, så vel som en tesrutrustning for in vitro testing av hudekvivalenten. Hudekvivalenten har anvendelse ved hudtransplantasjon, så vel som in viere testing av forskjellige stoffers effekter på hud.",EISENBERG MARK,EISENBERG MARK,,https://lens.org/017-014-452-893-159,Abstract,no,0,0,2,51,0,,A61F/;;A61F2/10;;C12N5/071,,0,0,,,,PENDING
17,AU,B2,AU 632693 B2,109-209-796-198-18X,1993-01-07,1993,AU 1991/077569 A,1991-04-24,AU PJ981990 A;;AU PK430291 A,1990-04-24,COMPOSITE LIVING SKIN EQUIVALENTS,"PCT No. PCT/AU91/00160 Sec. 371 Date Nov. 27, 1991 Sec. 102(e) Date Nov. 27, 1991 PCT Filed Apr. 24, 1991 PCT Pub. No. WO91/16010 PCT Pub. Date Oct. 31, 1991A composite living skin equivalent is described comprising an epidermal layer of cultured keratinocyte cells, a layer of non-porous collagen, and a dermal layer of cultured fibroblast cells in a porous cross-linked collagen sponge matrix. Preferably the non-porous collagen is Type 1, Type 3 or mixtures of Types 1 and 3 bovine collagen, which has been pepsin treated. A process for preparing the skin equivalent is described, as well as a test kit for in vitro testing of the skin equivalent. The skin equivalent has use for skin grafting as well as in vitro testing of the effects of various substances on skin. +RR The questions raised in reexamination request No. 90/003,418, filed Apr. 25, 1994, have been considered and the results thereof are reflected in this reissue patent which constitutes the reexamination certificate required by 35 U.S.C. 307 as provided in 37 CFR 1.570(e).",MARK EISENBERG,MARK EISENBERG,,https://lens.org/109-209-796-198-18X,Granted Patent,no,1,0,26,51,0,A61F2/105;;A61K35/12;;A61L27/24;;A61L27/3804;;A61L27/3813;;A61L27/3891;;A61L27/56;;A61L27/60;;C12N5/0698;;C12N2502/094;;C12N2502/1323;;C12N2503/06;;C12N2533/54;;G01N33/5005;;G01N33/5014;;Y10S128/08;;A61L27/3804;;C12N2502/094;;A61K35/12;;C12N2533/54;;A61L27/60;;A61F2/105;;C12N5/0698;;A61L27/56;;C12N2502/1323;;A61L27/3891;;C12N2503/06;;G01N33/5005;;A61L27/3813;;A61L27/24;;G01N33/5014;;Y10S128/08,A61K35/36;;A61B10/00;;A61F2/10;;A61K35/12;;A61L27/00;;A61L27/38;;A61L27/60;;C12N5/071;;G01N33/50,,0,0,,,,EXPIRED
18,GR,T3,GR 3026463 T3,122-652-329-330-951,1998-06-30,1998,GR 980400647 T,1998-03-27,AU PJ981990 A;;AU PK430291 A;;AU 1960/091001 W,1990-04-24,COMPOSITE LIVING SKIN EQUIVALENTS,"PCT No. PCT/AU91/00160 Sec. 371 Date Nov. 27, 1991 Sec. 102(e) Date Nov. 27, 1991 PCT Filed Apr. 24, 1991 PCT Pub. No. WO91/16010 PCT Pub. Date Oct. 31, 1991A composite living skin equivalent is described comprising an epidermal layer of cultured keratinocyte cells, a layer of non-porous collagen, and a dermal layer of cultured fibroblast cells in a porous cross-linked collagen sponge matrix. Preferably the non-porous collagen is Type 1, Type 3 or mixtures of Types 1 and 3 bovine collagen, which has been pepsin treated. A process for preparing the skin equivalent is described, as well as a test kit for in vitro testing of the skin equivalent. The skin equivalent has use for skin grafting as well as in vitro testing of the effects of various substances on skin. +RR The questions raised in reexamination request No. 90/003,418, filed Apr. 25, 1994, have been considered and the results thereof are reflected in this reissue patent which constitutes the reexamination certificate required by 35 U.S.C. 307 as provided in 37 CFR 1.570(e).",EISENBERG MARK,EISENBERG MARK,,https://lens.org/122-652-329-330-951,Granted Patent,no,0,0,26,51,0,A61F2/105;;A61K35/12;;A61L27/24;;A61L27/3804;;A61L27/3813;;A61L27/3891;;A61L27/56;;A61L27/60;;C12N5/0698;;C12N2502/094;;C12N2502/1323;;C12N2503/06;;C12N2533/54;;G01N33/5005;;G01N33/5014;;Y10S128/08;;A61L27/3804;;C12N2502/094;;A61K35/12;;C12N2533/54;;A61L27/60;;A61F2/105;;C12N5/0698;;A61L27/56;;C12N2502/1323;;A61L27/3891;;C12N2503/06;;G01N33/5005;;A61L27/3813;;A61L27/24;;G01N33/5014;;Y10S128/08,A61K35/36;;A61B10/00;;A61F2/10;;A61K35/12;;A61L27/00;;A61L27/38;;A61L27/60;;C12N5/071;;G01N33/50,,0,0,,,,EXPIRED
19,AU,A,AU 1991/077569 A,035-358-963-698-015,1991-11-11,1991,AU 1991/077569 A,1991-04-24,AU PJ981990 A;;AU PK430291 A,1990-04-24,COMPOSITE LIVING SKIN EQUIVALENTS,"PCT No. PCT/AU91/00160 Sec. 371 Date Nov. 27, 1991 Sec. 102(e) Date Nov. 27, 1991 PCT Filed Apr. 24, 1991 PCT Pub. No. WO91/16010 PCT Pub. Date Oct. 31, 1991A composite living skin equivalent is described comprising an epidermal layer of cultured keratinocyte cells, a layer of non-porous collagen, and a dermal layer of cultured fibroblast cells in a porous cross-linked collagen sponge matrix. Preferably the non-porous collagen is Type 1, Type 3 or mixtures of Types 1 and 3 bovine collagen, which has been pepsin treated. A process for preparing the skin equivalent is described, as well as a test kit for in vitro testing of the skin equivalent. The skin equivalent has use for skin grafting as well as in vitro testing of the effects of various substances on skin. +RR The questions raised in reexamination request No. 90/003,418, filed Apr. 25, 1994, have been considered and the results thereof are reflected in this reissue patent which constitutes the reexamination certificate required by 35 U.S.C. 307 as provided in 37 CFR 1.570(e).",ORTEC INTERNATIONAL INC,EISENBERG MARK,,https://lens.org/035-358-963-698-015,Patent Application,no,0,0,26,51,0,A61F2/105;;A61K35/12;;A61L27/24;;A61L27/3804;;A61L27/3813;;A61L27/3891;;A61L27/56;;A61L27/60;;C12N5/0698;;C12N2502/094;;C12N2502/1323;;C12N2503/06;;C12N2533/54;;G01N33/5005;;G01N33/5014;;Y10S128/08;;A61L27/3804;;C12N2502/094;;A61K35/12;;C12N2533/54;;A61L27/60;;A61F2/105;;C12N5/0698;;A61L27/56;;C12N2502/1323;;A61L27/3891;;C12N2503/06;;G01N33/5005;;A61L27/3813;;A61L27/24;;G01N33/5014;;Y10S128/08,A61K35/36;;A61B10/00;;A61F2/10;;A61K35/12;;A61L27/00;;A61L27/38;;A61L27/60;;C12N5/071;;G01N33/50,,0,0,,,,EXPIRED
20,MX,A,MX 9101682 A,119-325-703-553-420,1994-06-30,1994,MX 9101682 A,1991-10-21,MX 9101682 A,1991-10-21,COMPUESTOS EQUIVALENTES A LA PIEL VIVA.,"se describe un compuesto equivalente a la piel viva que comprende una capa epidérmica de células cultivadas queratinociticas, una capa de colágeno no poroso, y una capa dérmica de células fibroblasticas cultivadas en una matriz de esponga de colágeno de enlace cruzado porosa. Preferentemente el colágeno no poroso es colágeno bovino del tipo 1, tipo 3 o mezcla de los tipos 1 y 3, el cual ha sido tratado con pepsina. Se describe un proceso para preparar el equivalente de piel, así como un equipo de prueba para la prueba in vitro del equivalente de la piel. El equivalente de piel tiene aplicación para injertos de piel así como para las pruebas in vitro de los efectos de varias substancias en la piel.",EISENBERG MARK,EISENBERG MARK,,https://lens.org/119-325-703-553-420,Patent Application,no,0,0,1,1,0,,A61F2/10,,0,0,,,,PENDING
21,EP,A4,EP 0526550 A4,094-529-370-709-624,1993-06-30,1993,EP 91908747 A,1991-04-24,AU 1960/091001 W;;AU PJ981990 A;;AU PK430291 A,1990-04-24,COMPOSITE LIVING SKIN EQUIVALENTS,"PCT No. PCT/AU91/00160 Sec. 371 Date Nov. 27, 1991 Sec. 102(e) Date Nov. 27, 1991 PCT Filed Apr. 24, 1991 PCT Pub. No. WO91/16010 PCT Pub. Date Oct. 31, 1991A composite living skin equivalent is described comprising an epidermal layer of cultured keratinocyte cells, a layer of non-porous collagen, and a dermal layer of cultured fibroblast cells in a porous cross-linked collagen sponge matrix. Preferably the non-porous collagen is Type 1, Type 3 or mixtures of Types 1 and 3 bovine collagen, which has been pepsin treated. A process for preparing the skin equivalent is described, as well as a test kit for in vitro testing of the skin equivalent. The skin equivalent has use for skin grafting as well as in vitro testing of the effects of various substances on skin. +RR The questions raised in reexamination request No. 90/003,418, filed Apr. 25, 1994, have been considered and the results thereof are reflected in this reissue patent which constitutes the reexamination certificate required by 35 U.S.C. 307 as provided in 37 CFR 1.570(e).","EISENBERG, MARK","EISENBERG, MARK","EISENBERG, MARK TRANSFER- ORTEC INTERNATIONAL, INC (1999-02-26);;CESSIONE EPO REG. 20;ORTEC INTERNATIONAL INC. (1998-09-15);;ORTEC INTERNATIONAL, INC. (1999-02-01)",https://lens.org/094-529-370-709-624,Search Report,no,1,0,26,51,0,A61F2/105;;A61K35/12;;A61L27/24;;A61L27/3804;;A61L27/3813;;A61L27/3891;;A61L27/56;;A61L27/60;;C12N5/0698;;C12N2502/094;;C12N2502/1323;;C12N2503/06;;C12N2533/54;;G01N33/5005;;G01N33/5014;;Y10S128/08;;A61L27/3804;;C12N2502/094;;A61K35/12;;C12N2533/54;;A61L27/60;;A61F2/105;;C12N5/0698;;A61L27/56;;C12N2502/1323;;A61L27/3891;;C12N2503/06;;G01N33/5005;;A61L27/3813;;A61L27/24;;G01N33/5014;;Y10S128/08,A61K35/36;;A61B10/00;;A61F2/10;;A61K35/12;;A61L27/00;;A61L27/38;;A61L27/60;;C12N5/071;;G01N33/50,,0,0,,,,EXPIRED
22,WO,A1,WO 1991/016010 A1,103-653-149-470-792,1991-10-31,1991,AU 1960/091001 W,1991-04-24,AU PJ981990 A;;AU PK430291 A,1990-04-24,COMPOSITE LIVING SKIN EQUIVALENTS,"A composite living skin equivalent is described comprising an epidermal layer of cultured keratinocyte cells, a layer of non-porous collagen, and a dermal layer of cultured fibroblast cells in a porous cross-linked collagen sponge matrix. Preferably the non-porous collagen is Type 1, Type 3 or mixtures of Types 1 and 3 bovine collagen, which has been pepsin treated. A process for preparing the skin equivalent is described, as well as a test kit for in vitro testing of the skin equivalent. The skin equivalent has use for skin grafting as well as in vitro testing of the effects of various substances on skin.",EISENBERG MARK,EISENBERG MARK,,https://lens.org/103-653-149-470-792,Patent Application,yes,5,48,26,51,0,A61F2/105;;A61K35/12;;A61L27/24;;A61L27/3804;;A61L27/3813;;A61L27/3891;;A61L27/56;;A61L27/60;;C12N5/0698;;C12N2502/094;;C12N2502/1323;;C12N2503/06;;C12N2533/54;;G01N33/5005;;G01N33/5014;;Y10S128/08;;A61L27/3804;;C12N2502/094;;A61K35/12;;C12N2533/54;;A61L27/60;;A61F2/105;;C12N5/0698;;A61L27/56;;C12N2502/1323;;A61L27/3891;;C12N2503/06;;G01N33/5005;;A61L27/3813;;A61L27/24;;G01N33/5014;;Y10S128/08,A61B10/00;;A61F2/10;;A61K35/12;;A61L27/00;;A61K35/36;;A61L27/38;;A61L27/60;;C12N5/071;;G01N33/50,,3,2,054-216-676-722-735;;033-401-172-067-434,10.1016/0887-2333(91)90042-c;;20731992;;10.1016/0142-9612(90)90152-g;;2350555,"BELL. E. et al. (1983) ""The Reconstruction of Living Skin, The Journal of Investigative Dermatology"", Volume 81, No. 1, Supplement pages 2-10. (see pages 1 and 5 in particular).;;DYKES, P.J. et al. (1991) ""In Vitro Reconstruction of Human Skin: The Use of Skin Equivalents as Potential Indicators of Cutaneous Toxicity, Toxicology In Vitro"", Volume 5, No. 1, pages 1-8 (see introduction and discussion in particular).;;ROWLING, P.J.E. et al. (1990) ""Fabrication and Reorganization of Dermal Equivalents Suitable for Skin Grafting after Major Cutaneous Injury, Biomaterials"", Volume 11, pages 181-185; published April 1990.",PATENTED
23,FI,A,FI 924773 A,155-597-398-127-306,1992-10-21,1992,FI 924773 A,1992-10-21,AU PJ981990 A;;AU PK430291 A;;AU 1960/091001 W,1990-04-24,KOMPOSITIONSSUBSTITUTER AV LEVANDE HUD,"PCT No. PCT/AU91/00160 Sec. 371 Date Nov. 27, 1991 Sec. 102(e) Date Nov. 27, 1991 PCT Filed Apr. 24, 1991 PCT Pub. No. WO91/16010 PCT Pub. Date Oct. 31, 1991A composite living skin equivalent is described comprising an epidermal layer of cultured keratinocyte cells, a layer of non-porous collagen, and a dermal layer of cultured fibroblast cells in a porous cross-linked collagen sponge matrix. Preferably the non-porous collagen is Type 1, Type 3 or mixtures of Types 1 and 3 bovine collagen, which has been pepsin treated. A process for preparing the skin equivalent is described, as well as a test kit for in vitro testing of the skin equivalent. The skin equivalent has use for skin grafting as well as in vitro testing of the effects of various substances on skin. +RR The questions raised in reexamination request No. 90/003,418, filed Apr. 25, 1994, have been considered and the results thereof are reflected in this reissue patent which constitutes the reexamination certificate required by 35 U.S.C. 307 as provided in 37 CFR 1.570(e).",EISENBERG MARK,EISENBERG MARK,,https://lens.org/155-597-398-127-306,Patent Application,no,0,0,26,51,0,A61F2/105;;A61K35/12;;A61L27/24;;A61L27/3804;;A61L27/3813;;A61L27/3891;;A61L27/56;;A61L27/60;;C12N5/0698;;C12N2502/094;;C12N2502/1323;;C12N2503/06;;C12N2533/54;;G01N33/5005;;G01N33/5014;;Y10S128/08;;A61L27/3804;;C12N2502/094;;A61K35/12;;C12N2533/54;;A61L27/60;;A61F2/105;;C12N5/0698;;A61L27/56;;C12N2502/1323;;A61L27/3891;;C12N2503/06;;G01N33/5005;;A61L27/3813;;A61L27/24;;G01N33/5014;;Y10S128/08,A61K35/36;;A61B10/00;;A61F2/10;;A61K35/12;;A61L27/00;;A61L27/38;;A61L27/60;;C12N5/071;;G01N33/50,,0,0,,,,DISCONTINUED
24,CN,C,CN 1062441 C,012-008-053-548-451,2001-02-28,2001,CN 91109937 A,1991-10-18,CN 91109937 A;;AU PJ981990 A,1990-04-24,Composite living skin equivalents and preparation process thereof,,AORTECH INTERNAT PTY LTD,EISENBERG MARK,,https://lens.org/012-008-053-548-451,Granted Patent,no,0,0,2,51,0,,A61B10/00;;A61F2/10;;A61L27/00;;C12N5/08,,0,0,,,,EXPIRED
25,DE,T2,DE 69128530 T2,125-806-812-895-299,1998-08-20,1998,DE 69128530 T,1991-04-24,AU PJ981990 A;;AU PK430291 A;;AU 1960/091001 W,1990-04-24,ZUSAMMENGESETZTES ÄQUIVALENT DER LEBENDEN HAUT,"PCT No. PCT/AU91/00160 Sec. 371 Date Nov. 27, 1991 Sec. 102(e) Date Nov. 27, 1991 PCT Filed Apr. 24, 1991 PCT Pub. No. WO91/16010 PCT Pub. Date Oct. 31, 1991A composite living skin equivalent is described comprising an epidermal layer of cultured keratinocyte cells, a layer of non-porous collagen, and a dermal layer of cultured fibroblast cells in a porous cross-linked collagen sponge matrix. Preferably the non-porous collagen is Type 1, Type 3 or mixtures of Types 1 and 3 bovine collagen, which has been pepsin treated. A process for preparing the skin equivalent is described, as well as a test kit for in vitro testing of the skin equivalent. The skin equivalent has use for skin grafting as well as in vitro testing of the effects of various substances on skin. +RR The questions raised in reexamination request No. 90/003,418, filed Apr. 25, 1994, have been considered and the results thereof are reflected in this reissue patent which constitutes the reexamination certificate required by 35 U.S.C. 307 as provided in 37 CFR 1.570(e).",EISENBERG MARK,EISENBERG MARK,,https://lens.org/125-806-812-895-299,Granted Patent,no,0,3,26,51,0,A61F2/105;;A61K35/12;;A61L27/24;;A61L27/3804;;A61L27/3813;;A61L27/3891;;A61L27/56;;A61L27/60;;C12N5/0698;;C12N2502/094;;C12N2502/1323;;C12N2503/06;;C12N2533/54;;G01N33/5005;;G01N33/5014;;Y10S128/08;;A61L27/3804;;C12N2502/094;;A61K35/12;;C12N2533/54;;A61L27/60;;A61F2/105;;C12N5/0698;;A61L27/56;;C12N2502/1323;;A61L27/3891;;C12N2503/06;;G01N33/5005;;A61L27/3813;;A61L27/24;;G01N33/5014;;Y10S128/08,A61K35/36;;A61B10/00;;A61F2/10;;A61K35/12;;A61L27/00;;A61L27/38;;A61L27/60;;C12N5/071;;G01N33/50,,0,0,,,,EXPIRED
26,FI,A0,FI 924773 A0,193-309-795-415-378,1992-10-21,1992,FI 924773 A,1992-10-21,AU PJ981990 A;;AU PK430291 A;;AU 1960/091001 W,1990-04-24,KOMPOSITIONSSUBSTITUTER AV LEVANDE HUD,"PCT No. PCT/AU91/00160 Sec. 371 Date Nov. 27, 1991 Sec. 102(e) Date Nov. 27, 1991 PCT Filed Apr. 24, 1991 PCT Pub. No. WO91/16010 PCT Pub. Date Oct. 31, 1991A composite living skin equivalent is described comprising an epidermal layer of cultured keratinocyte cells, a layer of non-porous collagen, and a dermal layer of cultured fibroblast cells in a porous cross-linked collagen sponge matrix. Preferably the non-porous collagen is Type 1, Type 3 or mixtures of Types 1 and 3 bovine collagen, which has been pepsin treated. A process for preparing the skin equivalent is described, as well as a test kit for in vitro testing of the skin equivalent. The skin equivalent has use for skin grafting as well as in vitro testing of the effects of various substances on skin. +RR The questions raised in reexamination request No. 90/003,418, filed Apr. 25, 1994, have been considered and the results thereof are reflected in this reissue patent which constitutes the reexamination certificate required by 35 U.S.C. 307 as provided in 37 CFR 1.570(e).",EISENBERG MARK,EISENBERG MARK,,https://lens.org/193-309-795-415-378,Patent Application,no,0,0,26,51,0,A61F2/105;;A61K35/12;;A61L27/24;;A61L27/3804;;A61L27/3813;;A61L27/3891;;A61L27/56;;A61L27/60;;C12N5/0698;;C12N2502/094;;C12N2502/1323;;C12N2503/06;;C12N2533/54;;G01N33/5005;;G01N33/5014;;Y10S128/08;;A61L27/3804;;C12N2502/094;;A61K35/12;;C12N2533/54;;A61L27/60;;A61F2/105;;C12N5/0698;;A61L27/56;;C12N2502/1323;;A61L27/3891;;C12N2503/06;;G01N33/5005;;A61L27/3813;;A61L27/24;;G01N33/5014;;Y10S128/08,A61K35/36;;A61B10/00;;A61F2/10;;A61K35/12;;A61L27/00;;A61L27/38;;A61L27/60;;C12N5/071;;G01N33/50,,0,0,,,,DISCONTINUED
27,DE,D1,DE 69128530 D1,182-815-291-526-026,1998-02-05,1998,DE 69128530 T,1991-04-24,AU PJ981990 A;;AU PK430291 A;;AU 1960/091001 W,1990-04-24,ZUSAMMENGESETZTES ÄQUIVALENT DER LEBENDEN HAUT,"PCT No. PCT/AU91/00160 Sec. 371 Date Nov. 27, 1991 Sec. 102(e) Date Nov. 27, 1991 PCT Filed Apr. 24, 1991 PCT Pub. No. WO91/16010 PCT Pub. Date Oct. 31, 1991A composite living skin equivalent is described comprising an epidermal layer of cultured keratinocyte cells, a layer of non-porous collagen, and a dermal layer of cultured fibroblast cells in a porous cross-linked collagen sponge matrix. Preferably the non-porous collagen is Type 1, Type 3 or mixtures of Types 1 and 3 bovine collagen, which has been pepsin treated. A process for preparing the skin equivalent is described, as well as a test kit for in vitro testing of the skin equivalent. The skin equivalent has use for skin grafting as well as in vitro testing of the effects of various substances on skin. +RR The questions raised in reexamination request No. 90/003,418, filed Apr. 25, 1994, have been considered and the results thereof are reflected in this reissue patent which constitutes the reexamination certificate required by 35 U.S.C. 307 as provided in 37 CFR 1.570(e).",EISENBERG MARK,EISENBERG MARK,,https://lens.org/182-815-291-526-026,Granted Patent,no,0,0,26,51,0,A61F2/105;;A61K35/12;;A61L27/24;;A61L27/3804;;A61L27/3813;;A61L27/3891;;A61L27/56;;A61L27/60;;C12N5/0698;;C12N2502/094;;C12N2502/1323;;C12N2503/06;;C12N2533/54;;G01N33/5005;;G01N33/5014;;Y10S128/08;;A61L27/3804;;C12N2502/094;;A61K35/12;;C12N2533/54;;A61L27/60;;A61F2/105;;C12N5/0698;;A61L27/56;;C12N2502/1323;;A61L27/3891;;C12N2503/06;;G01N33/5005;;A61L27/3813;;A61L27/24;;G01N33/5014;;Y10S128/08,A61K35/36;;A61B10/00;;A61F2/10;;A61K35/12;;A61L27/00;;A61L27/38;;A61L27/60;;C12N5/071;;G01N33/50,,0,0,,,,EXPIRED
28,ES,T3,ES 2111566 T3,086-042-163-343-186,1998-03-16,1998,ES 91908747 T,1991-04-24,AU PJ981990 A;;AU PK430291 A,1990-04-24,EQUIVALENTES COMPUESTOS DE PIEL VIVA.,"PCT No. PCT/AU91/00160 Sec. 371 Date Nov. 27, 1991 Sec. 102(e) Date Nov. 27, 1991 PCT Filed Apr. 24, 1991 PCT Pub. No. WO91/16010 PCT Pub. Date Oct. 31, 1991A composite living skin equivalent is described comprising an epidermal layer of cultured keratinocyte cells, a layer of non-porous collagen, and a dermal layer of cultured fibroblast cells in a porous cross-linked collagen sponge matrix. Preferably the non-porous collagen is Type 1, Type 3 or mixtures of Types 1 and 3 bovine collagen, which has been pepsin treated. A process for preparing the skin equivalent is described, as well as a test kit for in vitro testing of the skin equivalent. The skin equivalent has use for skin grafting as well as in vitro testing of the effects of various substances on skin. +RR The questions raised in reexamination request No. 90/003,418, filed Apr. 25, 1994, have been considered and the results thereof are reflected in this reissue patent which constitutes the reexamination certificate required by 35 U.S.C. 307 as provided in 37 CFR 1.570(e).",EISENBERG MARK,EISENBERG MARK,,https://lens.org/086-042-163-343-186,Granted Patent,no,0,0,26,51,0,A61F2/105;;A61K35/12;;A61L27/24;;A61L27/3804;;A61L27/3813;;A61L27/3891;;A61L27/56;;A61L27/60;;C12N5/0698;;C12N2502/094;;C12N2502/1323;;C12N2503/06;;C12N2533/54;;G01N33/5005;;G01N33/5014;;Y10S128/08;;A61L27/3804;;C12N2502/094;;A61K35/12;;C12N2533/54;;A61L27/60;;A61F2/105;;C12N5/0698;;A61L27/56;;C12N2502/1323;;A61L27/3891;;C12N2503/06;;G01N33/5005;;A61L27/3813;;A61L27/24;;G01N33/5014;;Y10S128/08,A61K35/36;;A61B10/00;;A61F2/10;;A61K35/12;;A61L27/00;;A61L27/38;;A61L27/60;;C12N5/071;;G01N33/50,,0,0,,,,EXPIRED
29,EP,A1,EP 0526550 A1,015-209-284-365-943,1993-02-10,1993,EP 91908747 A,1991-04-24,AU 1960/091001 W;;AU PJ981990 A;;AU PK430291 A,1990-04-24,COMPOSITE LIVING SKIN EQUIVALENTS.,"PCT No. PCT/AU91/00160 Sec. 371 Date Nov. 27, 1991 Sec. 102(e) Date Nov. 27, 1991 PCT Filed Apr. 24, 1991 PCT Pub. No. WO91/16010 PCT Pub. Date Oct. 31, 1991A composite living skin equivalent is described comprising an epidermal layer of cultured keratinocyte cells, a layer of non-porous collagen, and a dermal layer of cultured fibroblast cells in a porous cross-linked collagen sponge matrix. Preferably the non-porous collagen is Type 1, Type 3 or mixtures of Types 1 and 3 bovine collagen, which has been pepsin treated. A process for preparing the skin equivalent is described, as well as a test kit for in vitro testing of the skin equivalent. The skin equivalent has use for skin grafting as well as in vitro testing of the effects of various substances on skin. +RR The questions raised in reexamination request No. 90/003,418, filed Apr. 25, 1994, have been considered and the results thereof are reflected in this reissue patent which constitutes the reexamination certificate required by 35 U.S.C. 307 as provided in 37 CFR 1.570(e).",EISENBERG MARK,EISENBERG MARK,"EISENBERG, MARK TRANSFER- ORTEC INTERNATIONAL, INC (1999-02-26);;CESSIONE EPO REG. 20;ORTEC INTERNATIONAL INC. (1998-09-15);;ORTEC INTERNATIONAL, INC. (1999-02-01)",https://lens.org/015-209-284-365-943,Patent Application,yes,0,1,26,51,0,A61F2/105;;A61K35/12;;A61L27/24;;A61L27/3804;;A61L27/3813;;A61L27/3891;;A61L27/56;;A61L27/60;;C12N5/0698;;C12N2502/094;;C12N2502/1323;;C12N2503/06;;C12N2533/54;;G01N33/5005;;G01N33/5014;;Y10S128/08;;A61L27/3804;;C12N2502/094;;A61K35/12;;C12N2533/54;;A61L27/60;;A61F2/105;;C12N5/0698;;A61L27/56;;C12N2502/1323;;A61L27/3891;;C12N2503/06;;G01N33/5005;;A61L27/3813;;A61L27/24;;G01N33/5014;;Y10S128/08,A61K35/36;;A61B10/00;;A61F2/10;;A61K35/12;;A61L27/00;;A61L27/38;;A61L27/60;;C12N5/071;;G01N33/50,,0,0,,,,EXPIRED
30,IN,B,IN 174100 B,176-520-519-243-028,1994-09-10,1994,IN 786CA1991 A,1991-10-21,IN 786CA1991 A,1991-10-21,Process for the preparation of a composite living skin equivalent,,EISENBERG MARK DR,EISENBERG MARK DR,,https://lens.org/176-520-519-243-028,Granted Patent,no,0,0,2,2,0,,A61B17/00;;C12N11/00,,0,0,,,,EXPIRED
31,US,A,US 3486124 A,100-619-291-133-57X,1969-12-23,1969,US 3486124D A,1968-06-04,US 73429268 A,1968-06-04,POWER SUPPLY AMPLIFIER HAVING MEANS FOR PROTECTING THE OUTPUT TRANSISTORS,,HEWLETT PACKARD CO,EISENBERG MARK F,,https://lens.org/100-619-291-133-57X,Granted Patent,no,2,10,1,1,0,H03F3/3071;;H03F3/3071;;H03F1/52;;H03F1/52,H03F1/52;;H03F3/30,330/13,0,0,,,,EXPIRED
32,US,A,US 3622899 A,085-983-777-050-482,1971-11-23,1971,US 3622899D A,1969-05-08,US 82303469 A,1969-05-08,HIGH-VOLTAGE POWER AMPLIFIER CIRCUIT,,HEWLETT PACKARD CO,EISENBERG MARK F,,https://lens.org/085-983-777-050-482,Granted Patent,no,5,46,1,1,0,H03F1/0244;;H03F1/0244;;H03F3/42;;H03F3/42,H03F1/02;;H03F3/42,330/22,0,0,,,,EXPIRED
33,IE,B1,IE 80689 B1,032-108-367-545-847,1998-12-02,1998,IE 351291 A,1991-10-08,IE 351291 A,1991-10-08,Composite living skin equivalents,,EISENBERG MARK DR,EISENBERG MARK DR,,https://lens.org/032-108-367-545-847,Granted Patent,no,0,0,2,2,0,A61L27/60,A61F2/10;;A61L27/00;;C12N5/08,,0,0,,,,EXPIRED
34,US,A,US 3508162 A,137-689-593-029-467,1970-04-21,1970,US 3508162D A,1968-06-05,US 73468068 A,1968-06-05,MEANS FOR LIMITING CURRENT IN A POWER SUPPLY AMPLIFIER,,HEWLETT PACKARD CO,EISENBERG MARK F,,https://lens.org/137-689-593-029-467,Granted Patent,no,2,5,2,2,0,H02H3/087;;H03F1/52;;H03F1/52;;H02H3/087,H02H3/087;;H03F1/42;;H03F1/52;;H03F3/20;;H03F3/30,330/11,0,0,,,,EXPIRED
35,IN,B,IN 177080 B,017-415-340-864-49X,1996-11-02,1996,IN 597CA1993 A,1993-10-11,IN 597CA1993 A;;IN 786CA1991 A,1991-10-21,Process for preparing a composite living skin equivalent,,EISENBERG MARK DR,EISENBERG MARK DR,,https://lens.org/017-415-340-864-49X,Granted Patent,no,0,0,2,2,0,,A61B17/00;;C12N11/00,,0,0,,,,EXPIRED
36,MY,A,MY 131052 A,127-660-365-927-087,2007-07-31,2007,MY PI9101945 A,1991-10-22,MY PI9101945 A,1991-10-22,COMPOSITE LIVING SKIN EQUIVALENTS,"A COMPOSITE LIVING SKIN EQUIVALENT IS DESCRIBED COMPRISING AN EPIDERMAL LAYER OF CULTURED KERATINOCYTE CELLS, A LAYER OF NON-POROUS COLLAGEN, AND DERMAL LAYER OF CULTURED FIBROBLAST CELLS IN A POROUS CROSS-LINKED COLLAGEN SPONGE MATRIX. PREFERABLY THE NON-POROUS COLLAGEN IS TYPE 1, TYPE 3 OR MIXTURES OF TYPES 1 AND 3 BOVINE COLLAGEN, WHICH HAS BEEN PEPSIN TREATED. A PROCESS FOR PREPARING THE SKIN EQUIVALENT IS DESCRIBED, AS WELL AS A TEST KIT FOR IN VITRO TESTING OF THE SKIN EQUIVALENT. THE SKIN EQUIVALENT HAS USE FOR SKIN GRAFTING AS WELL AS IN VITRO TESTING OF THE EFFECTS OF VARIOUS SUBSTANCES ON SKIN.(FIG 1)",EISENBERG MARK DR,EISENBERG MARK DR,,https://lens.org/127-660-365-927-087,Granted Patent,no,0,0,1,1,0,,A61F2/10;;A61L27/00,,0,0,,,,EXPIRED
37,IE,A1,IE 913512 A1,154-347-376-499-901,1993-04-21,1993,IE 351291 A,1991-10-08,IE 351291 A,1991-10-08,COMPOSITE LIVING SKIN EQUIVALENTS,,MARK EISENBERG DR,EISENBERG DR MARK,,https://lens.org/154-347-376-499-901,Patent Application,no,0,0,2,2,0,A61L27/60,A61F2/10;;A61L27/00;;C12N5/08,A5R RAM           RAM,0,0,,,,EXPIRED
38,US,A,US 3673461 A,138-194-758-947-752,1972-06-27,1972,US 3673461D A,1970-06-08,US 4443470 A,1970-06-08,CIRCUIT FOR DRIVING THE CATHODES OF A DISPLAY DEVICE,"A multiphase circuit for driving the cathodes of a gas cell display device utilizing transistor drivers for sequentially driving each phase and switching circuitry cooperating with the drivers for de-energizing the previously ""on"" cathodes and rapidly shutting off the previously operating driver. The cells energized by an ""on"" cathode are caused to glow when there is a concurrent signal on the proper anode. The output of each driver is coupled to a switching transistor which, when caused to conduct, feeds a standoff voltage to a preceding phase and the collector of the driver associated with that phase, rapidly restoring the phase to a voltage level below the ionization point of the gas cells. A resistor across the emitter and base of the switching transistor maintains a proper bias and a diode across its collector and emitter protects the switching transistor from surges at shutdown.",BURROUGHS CORP,EISENBERG MARK F,,https://lens.org/138-194-758-947-752,Granted Patent,no,2,5,1,1,0,G09G3/285;;G09G3/285;;H04N3/125;;H04N3/125;;H01J17/494;;H01J17/494,G09G3/29;;H01J17/49;;H04N3/12,315169   TV;;315169   R,0,0,,,,EXPIRED
39,US,A1,US 2018/0148247 A1,034-691-936-922-707,2018-05-31,2018,US 201715673136 A,2017-08-09,US 201715673136 A;;US 201662428121 P,2016-11-30,Candy Dispenser,"A candy dispenser include a dispenser housing having a dispenser housing opening, a candy reservoir within the dispenser housing having a candy reservoir chute aligned with the dispenser housing opening, and a dispenser shield disposed within the dispenser housing and movable so that a dispenser shield opening can align with the dispenser housing opening and the candy reservoir chute at a dispensing position to dispense a candy piece. An indeterminate outcome actuation mechanism with an actuation mechanism input device causes the dispenser shield to move between the dispensing position and at least one non-dispensing position when the actuation mechanism input device is displaced such that the dispenser shield may be disposed in any one of the dispensing position and the non-dispensing positions when the actuation mechanism input device is displaced so that a candy piece may or may not be dispensed each time.",MY FAVORITE COMPANY INC,WRIGHT NEIL;;EISENBERG MARK,MY FAVORITE COMPANY INC (2017-10-04),https://lens.org/034-691-936-922-707,Patent Application,yes,0,1,8,8,0,A23G3/50;;B65D81/365;;B65D83/0418;;B65D85/60;;B65D81/365;;B65D83/04;;B65D83/0409;;B65D83/0409;;B65D85/60;;B65D85/60;;B65D2583/0472;;B65D2583/0477;;B65D2583/0486;;B65D2583/0486;;G07F11/22;;G07F11/22;;G07F11/44;;G07F11/44,B65D83/04;;A23G3/50;;G07F11/22,,0,0,,,,ACTIVE
40,US,B2,US 10730686 B2,167-133-150-877-744,2020-08-04,2020,US 201916565010 A,2019-09-09,US 201916565010 A;;US 201715673136 A;;US 201662428121 P,2016-11-30,Candy dispenser,"A confectionary item dispenser include a dispenser housing having a dispenser housing opening, a reservoir within the dispenser housing having a reservoir chute aligned with the dispenser housing opening, and a dispenser shield disposed within the dispenser housing and movable so that a dispenser shield opening can align with the dispenser housing opening and the reservoir chute at a dispensing position to dispense a confectionary item. An indeterminate outcome actuation mechanism with an actuation mechanism input device causes the dispenser shield to move between the dispensing position and a non-dispensing position when the actuation mechanism input device is displaced such that the dispenser shield may be disposed in one of the dispensing position and the non-dispensing position when the actuation mechanism input device is displaced so that a confectionary item may or may not be dispensed each time.",MY FAVORITE COMPANY INC,WRIGHT NEIL;;EISENBERG MARK,MY FAVORITE COMPANY INC (2017-10-04),https://lens.org/167-133-150-877-744,Granted Patent,yes,60,0,8,8,0,A23G3/50;;B65D81/365;;B65D83/0418;;B65D85/60;;B65D81/365;;B65D83/04;;B65D83/0409;;B65D83/0409;;B65D85/60;;B65D85/60;;B65D2583/0472;;B65D2583/0477;;B65D2583/0486;;B65D2583/0486;;G07F11/22;;G07F11/22;;G07F11/44;;G07F11/44,G07F11/22;;A23G3/50;;B65D81/36;;B65D83/04;;B65D85/60;;G07F11/44,,3,0,,,"Handmade Wooden push button Candy Dispenser by WildWoodCarver http://www.pinterest.com/74802043786115084/ 2 pages.;;Motion Activated Candy Machine, http://www.gadgetreview.com/motioin-activated-candy-machine 9 pages.;;Personalized Executive Candy Dispenser, http://www.personalizationmall.com/Personalized-Candy-Dispenser-for-Executived-p13159.prod?sdest=Search&sdestid=62503591 3 Pages.",ACTIVE
41,CN,A,CN 110844358 A,138-393-584-496-075,2020-02-28,2020,CN 201910983503 A,2017-11-29,US 201662428121 P;;US 201715673136 A;;CN 201711229625 A,2016-11-30,Candy dispenser,"The invention provides a candy dispenser and an actuating mechanism for indeterminate outcome of the candy dispenser. The candy dispenser include a dispenser housing having a dispenser housing opening; a candy reservoir, which is used for maintaining candy pieces and has a candy reservoir chute aligned with the dispenser housing opening; and a dispenser shield disposed within the dispenser housingand movable so that a dispenser shield opening can align with the dispenser housing opening and the candy reservoir chute at a dispensing position to dispense a candy piece. An indeterminate outcomeactuation mechanism with an actuation mechanism input device causes the dispenser shield to move between a dispensing position and a non-dispensing position when the actuation mechanism input device is displaced such that the dispenser shield may be disposed in any one of the dispensing position and the non-dispensing position when the actuation mechanism input device is displaced so that a candypiece may or may not be dispensed each time.",MY FAVORITE COMPANY INC,NEIL WRIGHT;;MARK EISENBERG,,https://lens.org/138-393-584-496-075,Patent Application,no,18,0,8,8,0,A23G3/50;;B65D81/365;;B65D83/0418;;B65D85/60;;B65D81/365;;B65D83/04;;B65D83/0409;;B65D83/0409;;B65D85/60;;B65D85/60;;B65D2583/0472;;B65D2583/0477;;B65D2583/0486;;B65D2583/0486;;G07F11/22;;G07F11/22;;G07F11/44;;G07F11/44,B65D85/60;;B65D83/04,,0,0,,,,ACTIVE
42,CN,A,CN 108116786 A,054-992-223-018-843,2018-06-05,2018,CN 201711229625 A,2017-11-29,US 201662428121 P;;US 201715673136 A,2016-11-30,Candy Dispenser,"A candy dispenser (10) includes a dispenser housing (12) having a dispenser housing opening (14), a candy reservoir (22) within the dispenser housing (12) and having a candy reservoir chute (24) aligned with the dispenser housing opening (14), and a dispenser shield (16) disposed within the dispenser housing (12) and movable so that a dispenser shield opening (20) can align with the dispenser housing opening (14) and the candy reservoir chute (24) at a dispensing position to dispense a candy piece (26). An indeterminate outcome actuation mechanism (160) with an actuation mechanism input device(28) causes the dispenser shield (16) to move between the dispensing position and at least one non-dispensing position when the actuation mechanism input device (28) is displaced such that the dispenser shield (16) may be disposed in any one of the dispensing position and the non-dispensing positions when the actuation mechanism input device (28) is displaced so that the candy piece (26) may or may not be dispensed each time.",MY FAVORITE COMPANY INC,NEIL WRIGHT;;MARK EISENBERG,,https://lens.org/054-992-223-018-843,Patent Application,no,6,0,8,8,0,A23G3/50;;B65D81/365;;B65D83/0418;;B65D85/60;;B65D81/365;;B65D83/04;;B65D83/0409;;B65D83/0409;;B65D85/60;;B65D85/60;;B65D2583/0472;;B65D2583/0477;;B65D2583/0486;;B65D2583/0486;;G07F11/22;;G07F11/22;;G07F11/44;;G07F11/44,B65D85/60;;B65D83/04,,0,0,,,,ACTIVE
43,US,A1,US 2019/0389647 A1,066-344-546-489-973,2019-12-26,2019,US 201916565010 A,2019-09-09,US 201916565010 A;;US 201715673136 A;;US 201662428121 P,2016-11-30,Candy Dispenser,"A confectionary item dispenser include a dispenser housing having a dispenser housing opening, a reservoir within the dispenser housing having a reservoir chute aligned with the dispenser housing opening, and a dispenser shield disposed within the dispenser housing and movable so that a dispenser shield opening can align with the dispenser housing opening and the reservoir chute at a dispensing position to dispense a confectionary item. An indeterminate outcome actuation mechanism with an actuation mechanism input device causes the dispenser shield to move between the dispensing position and a non-dispensing position when the actuation mechanism input device is displaced such that the dispenser shield may be disposed in one of the dispensing position and the non-dispensing position when the actuation mechanism input device is displaced so that a confectionary item may or may not be dispensed each time.",MY FAVORITE COMPANY INC,WRIGHT NEIL;;EISENBERG MARK,MY FAVORITE COMPANY INC (2017-10-04),https://lens.org/066-344-546-489-973,Patent Application,yes,37,0,8,8,0,A23G3/50;;B65D81/365;;B65D83/0418;;B65D85/60;;B65D81/365;;B65D83/04;;B65D83/0409;;B65D83/0409;;B65D85/60;;B65D85/60;;B65D2583/0472;;B65D2583/0477;;B65D2583/0486;;B65D2583/0486;;G07F11/22;;G07F11/22;;G07F11/44;;G07F11/44,B65D83/04;;A23G3/50;;B65D81/36;;B65D85/60;;G07F11/22;;G07F11/44,,0,0,,,,ACTIVE
44,US,B2,US 10407235 B2,076-483-255-273-673,2019-09-10,2019,US 201715673136 A,2017-08-09,US 201715673136 A;;US 201662428121 P,2016-11-30,Candy dispenser,"A candy dispenser include a dispenser housing having a dispenser housing opening, a candy reservoir within the dispenser housing having a candy reservoir chute aligned with the dispenser housing opening, and a dispenser shield disposed within the dispenser housing and movable so that a dispenser shield opening can align with the dispenser housing opening and the candy reservoir chute at a dispensing position to dispense a candy piece. An indeterminate outcome actuation mechanism with an actuation mechanism input device causes the dispenser shield to move between the dispensing position and at least one non-dispensing position when the actuation mechanism input device is displaced such that the dispenser shield may be disposed in any one of the dispensing position and the non-dispensing positions when the actuation mechanism input device is displaced so that a candy piece may or may not be dispensed each time.",MY FAVORITE COMPANY INC,WRIGHT NEIL;;EISENBERG MARK,MY FAVORITE COMPANY INC (2017-10-04),https://lens.org/076-483-255-273-673,Granted Patent,yes,59,3,8,8,0,A23G3/50;;B65D81/365;;B65D83/0418;;B65D85/60;;B65D81/365;;B65D83/04;;B65D83/0409;;B65D83/0409;;B65D85/60;;B65D85/60;;B65D2583/0472;;B65D2583/0477;;B65D2583/0486;;B65D2583/0486;;G07F11/22;;G07F11/22;;G07F11/44;;G07F11/44,B65D83/04;;A23G3/50;;B65D81/36;;B65D85/60;;G07F11/22;;G07F11/44,,4,0,,,"Motion Activated Candy Machine, http://www.gadgetreview.com/motioin-activated-candy-machine 9 pages.;;Personalized Executive Candy Dispenser, http://www.personalizationmall.com/Personalized-Candy-Dispenser-for-Executived-p13159.prod?sdest=Search&sdestid=62503591 3 Pages.;;Handmade Wooden push button Candy Dispenser by WildWoodCarver http://www.pinterest.com/74802043786115084/ 2 pages.;;Chinese Search Report for application No. 2017112296255 dated Nov. 29, 2017.",ACTIVE
45,DE,T2,DE 3856116 T2,053-986-817-886-050,1998-08-20,1998,DE 3856116 T,1988-07-25,US 7694987 A,1987-07-23,Mund-zu-Mund-Wiederbelebungsgerät,,PLASCO INC,EISENBERG MELVIN I;;WESTFALL MARK,"MICROTEK MEDICAL, INC., COLUMBUS, MISS., US (2004-09-23)",https://lens.org/053-986-817-886-050,Granted Patent,no,0,0,15,15,0,A61M16/00;;A61M16/0048;;A61M16/0048,A61M16/00;;A61M16/06,,0,0,,,,EXPIRED
46,US,A,US 4819628 A,112-406-535-953-213,1989-04-11,1989,US 7694987 A,1987-07-23,US 7694987 A,1987-07-23,Mouth-to-mouth resuscitator device,"A resuscitator device for providing a physical shield between the rescuer and a victim requiring mouth-to-mouth resuscitation. The device comprises a flexible sheet having an opening centrally formed therein and a rigid tube secured to the sheet around the periphery of the opening for inserting into the mouth of the victim. A self closing one-way valve is contained in the tube and extends downward from the sheet opening and includes a flexible sleeve normally held closed at the outer end thereof by the action of a spring formed from a strip of rigid and flexible material secured to the outer end of the sleeve. The rescuer exhales a deep breath into the input of the valve via said opening in the sheet, to overcome the resilient force of the spring for discharging forced air into the mouth of the victim. After the rescuer has fully exhaled, the spring strip resiliently closes the valve to prevent any back flow of air, mist or liquid from the victim to the rescuer. Grooves are formed in the victim's side of the sheet to provide air pathways to the outside for air exhaled by the victim. A patch of an irregular non-smooth surface is also formed on the victim's side of the sheet to prevent the sheet from clinging to the nose, for allowing air flow out from the victim's nose.",PLASCO INC,EISENBERG MELVIN I;;WESTFALL MARK,MICROTEK MEDICAL INC (2003-11-21);;PLASCO INCORPORATED 3849 SWANSON CT. GURNEE LINOIS 60031 A IL CORP (1987-07-14),https://lens.org/112-406-535-953-213,Granted Patent,yes,6,30,15,15,0,A61M16/00;;A61M16/0048;;A61M16/0048,A61M16/00;;A61M16/06,128/203.11;;128/202.28,0,0,,,,EXPIRED
47,EP,A2,EP 0303367 A2,148-866-321-201-52X,1989-02-15,1989,EP 88306825 A,1988-07-25,US 7694987 A,1987-07-23,Mouth-to-mouth resuscitator device.,"A resuscitator device (10) for providing a physical shield between the rescuer and a victim requiring mouth-to-mouth resuscitation, and comprising a flexible sheet (12) to conform to the contour of the face of the victim in the area around the mouth and nose. A mouth opening (18) is centrally formed in said sheet. A hollow rigid tube (20) surrounds and is secured to the periphery of said mouth opening (18) and depends downward therefrom for inserting into the mouth of the victim. A self closing, one way valve (30) is contained in the tube (20), and includes a flexible, sleeve (32) having an air inlet open end in communication with the mouth opening (18) and an air outlet end (38) which is held normally closed by the action of a spring strip (34) secured to the sleeve (32) adjacent the outlet end (38).  ",PLASCO INC,EISENBERG MELVIN I;;WESTFALL MARK,,https://lens.org/148-866-321-201-52X,Patent Application,yes,0,4,15,15,0,A61M16/00;;A61M16/0048;;A61M16/0048,A61M16/00;;A61M16/06,,0,0,,,,EXPIRED
48,US,A1,US 2003/0081869 A1,188-560-295-811-031,2003-05-01,2003,US 31314502 A,2002-12-06,US 31314502 A;;US 50666900 A,2000-02-17,Axle bolt,"
   An axle bolt has a shaft with a pair of opposed ends. An axle passage extends within the shaft and a transverse passage extends radially outwardly from the axial passage. A head attached to one end of the shaft has an outer face. A recess extends in from the outer face and the bottom of the recess is in communication with the axial passage. A lubrication fitting in the recess has one end in communication with the bottom of the recess and another end designed to be connected to a lubrication device. The recess in the bolt head is sufficiently deep that the second end of the lubrication fitting is within the recess and does not extend beyond the outer face. 
",EISENBERG MARK H.;;POTOCZNY WALTER,EISENBERG MARK H;;POTOCZNY WALTER,CTS INC (2002-12-06),https://lens.org/188-560-295-811-031,Patent Application,yes,35,0,3,3,0,F16C33/6622;;Y10T29/49405;;Y10T29/49423;;Y10T29/49405;;Y10T29/49423;;F16C33/6622,F16C33/66,384/396,0,0,,,,EXPIRED
49,DE,D1,DE 3856116 D1,091-188-911-361-877,1998-02-19,1998,DE 3856116 T,1988-07-25,US 7694987 A,1987-07-23,Mund-zu-Mund-Wiederbelebungsgerät,,PLASCO INC,EISENBERG MELVIN I;;WESTFALL MARK,"MICROTEK MEDICAL, INC., COLUMBUS, MISS., US (2004-09-23)",https://lens.org/091-188-911-361-877,Granted Patent,no,0,0,15,15,0,A61M16/00;;A61M16/0048;;A61M16/0048,A61M16/00;;A61M16/06,,0,0,,,,EXPIRED
50,US,B2,US 10909324 B2,069-170-399-844-999,2021-02-02,2021,US 201916260389 A,2019-01-29,US 201916260389 A;;US 201862728380 P,2018-09-07,Features for classification of stories,Methods and devices for story detection in text are provided. A device can include an input device for receiving text data a processor configured to: tokenize each paragraph in the text data and split each tokenized paragraph into sentences; parse each sentence from the tokenized paragraphs; label each predicate in each sentence with its respective semantic role; and assign a verb class to each predicate; and determine whether respective arguments of each predicate contains a character. The device can further include a support vector machine configured to determine whether a story is present within each paragraph based upon whether each predicate contains a character.,EISENBERG JOSHUA DANIEL;;FINLAYSON MARK;;THE FLORIDA INTERNATIONAL UNIV BOARD OF TRUSTEES,EISENBERG JOSHUA DANIEL;;FINLAYSON MARK,THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (2019-02-04),https://lens.org/069-170-399-844-999,Granted Patent,yes,24,1,2,2,0,G06F40/30;;G06F40/205;;G06F40/284;;G06F16/35;;G06N20/10;;G06V30/40;;G06F18/2411;;G06N20/10;;G06F16/353;;G06F40/30;;G06F40/205;;G06F40/284;;G06V30/40,G06F40/30;;G06F16/35;;G06F40/205;;G06F40/284;;G06N20/10;;G06V30/40,,1,0,,,"Karin Kipper Schuler, VerbNet: A Broad-Coverage, Comprehensive Verb Lexicon, Ph.D. thesis in Computer and Information Science, University of Pennsylvania, 2005.",ACTIVE
51,US,B2,US 6742932 B2,008-200-795-321-788,2004-06-01,2004,US 31314502 A,2002-12-06,US 31314502 A;;US 50666900 A,2000-02-17,Axle bolt,"
    An axle bolt has a shaft with a pair of opposed ends. An axle passage extends within the shaft and a transverse passage extends radially outwardly from the axial passage. A head attached to one end of the shaft has an outer face. A recess extends in from the outer face and the bottom of the recess is in communication with the axial passage. A lubrication fitting in the recess has one end in communication with the bottom of the recess and another end designed to be connected to a lubrication device. The recess in the bolt head is sufficiently deep that the second end of the lubrication fitting is within the recess and does not extend beyond the outer face. 
",CTS INC,EISENBERG MARK H;;POTOCZNY WALTER,CTS INC (2002-12-06),https://lens.org/008-200-795-321-788,Granted Patent,yes,37,9,3,3,0,F16C33/6622;;Y10T29/49405;;Y10T29/49423;;Y10T29/49405;;Y10T29/49423;;F16C33/6622,F16C33/66,384/396;;384/462;;411/395;;184/5.1;;29/890.12;;29/890.13,0,0,,,,EXPIRED
52,DE,T2,DE 3853501 T2,026-634-177-703-43X,1996-01-04,1996,DE 3853501 T,1988-07-25,US 7694987 A,1987-07-23,Mund-zu-Mund-Wiederbelebungsgerät.,,PLASCO INC,EISENBERG MELVIN I;;WESTFALL MARK,"MICROTEK MEDICAL, INC. (N.D.GES.D. STAATES DELAWAR (2004-12-30)",https://lens.org/026-634-177-703-43X,Granted Patent,no,0,0,15,15,0,A61M16/00;;A61M16/0048;;A61M16/0048,A61M16/00;;A61M16/06,,0,0,,,,EXPIRED
53,EP,B1,EP 0629414 B1,023-698-421-921-281,1998-01-14,1998,EP 94200657 A,1988-07-25,EP 88306825 A;;US 7694987 A,1987-07-23,Mouth-to-mouth resuscitator device,,PLASCO INC,EISENBERG MELVIN I;;WESTFALL MARK,,https://lens.org/023-698-421-921-281,Granted Patent,yes,3,0,15,15,0,A61M16/00;;A61M16/0048;;A61M16/0048,A61M16/00;;A61M16/06,,0,0,,,,EXPIRED
54,US,A1,US 2020/0081980 A1,035-527-093-471-283,2020-03-12,2020,US 201916260389 A,2019-01-29,US 201916260389 A;;US 201862728380 P,2018-09-07,FEATURES FOR CLASSIFICATION OF STORIES,Methods and devices for story detection in text are provided. A device can include an input device for receiving text data a processor configured to: tokenize each paragraph in the text data and split each tokenized paragraph into sentences; parse each sentence from the tokenized paragraphs; label each predicate in each sentence with its respective semantic role; and assign a verb class to each predicate; and determine whether respective arguments of each predicate contains a character. The device can further include a support vector machine configured to determine whether a story is present within each paragraph based upon whether each predicate contains a character.,EISENBERG JOSHUA DANIEL;;FINLAYSON MARK;;THE FLORIDA INTERNATIONAL UNIV BOARD OF TRUSTEES,EISENBERG JOSHUA DANIEL;;FINLAYSON MARK,THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (2019-02-04),https://lens.org/035-527-093-471-283,Patent Application,yes,17,10,2,2,0,G06F40/30;;G06F40/205;;G06F40/284;;G06F16/35;;G06N20/10;;G06V30/40;;G06F18/2411;;G06N20/10;;G06F16/353;;G06F40/30;;G06F40/205;;G06F40/284;;G06V30/40,G06F16/35;;G06N20/10;;G06V30/40,,0,0,,,,ACTIVE
55,US,B1,US 10191975 B1,091-179-642-157-119,2019-01-29,2019,US 201715804589 A,2017-11-16,US 201715804589 A,2017-11-16,Features for automatic classification of narrative point of view and diegesis,"Methods for classifying a point of view and diegesis are provided. A method can include providing a processor in operable communication with a computer-readable medium, receiving a narrative text, extracting a set of features from the narrative text, transmitting the features into a feature vector, transmitting a plurality of feature vectors to a support vector machine, predicting a point of view and diegesis for the narrative text associate with a particular feature vector, and annotating the narrative text.",EISENBERG JOSHUA DANIEL;;FINLAYSON MARK;;THE FLORIDA INTERNATIONAL UNIV BOARD OF TRUSTEES,EISENBERG JOSHUA DANIEL;;FINLAYSON MARK,THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (2017-11-14),https://lens.org/091-179-642-157-119,Granted Patent,yes,20,6,1,1,0,G06F16/35;;G06F40/268;;G06F40/253;;G06F40/205;;G06F40/284;;G06F40/30;;G06F16/353;;G06F16/35;;G06F40/30;;G06F40/117;;G06F40/166;;G06F40/205;;G06F40/253;;G06F40/268;;G06F40/284,G06F17/21;;G06F17/27;;G06F17/24,,14,7,055-166-700-907-099;;026-543-117-146-244;;023-928-444-110-407;;079-096-954-600-943;;031-056-855-501-837;;090-283-612-169-104;;008-612-342-871-841,10.3115/1073336.1073361;;10.18653/v1/w16-5705;;10.1145/1961189.1961199;;10.1086/268763;;843571;;10.2307/2529310;;10.3115/v1/p14-5010;;10.3115/1621474.1621488,"Kudo et al., Chunking with Support Vector Machines, 2001, NAACL, ACL, pp. 1-8.;;Eisenberg et al., Automatic Identification of Narrative Diegesis and Point of View, Nov. 5, 2016, ACL, pp. 36-46.;;Aufderheide, “Public intimacy: the development of first-person documentary,” Afterimage: The Journal of Media Arts and Cultural Criticism, Jul. 1997, pp. 1-13.;;Ceran et al., “A hybrid model and memory based story classifier,” The Third Workshop on Computational Models of Narrative, May 2012, pp. 58-62.;;Chang et al., “LIBSVM: a library for support vector machines,” ACM Transactions on Intelligent Systems and Technology, Apr. 2011, pp. 1-39.;;Davison, “The third-person effect in communication,” The Public Opinion Quarterly, Jan. 1983, pp. 1-15, vol. 47, No. 1.;;Finlayson, “Collecting semantics in the wild: the story workbench,” Proceedings of the AAAI Fall Symposium on Naturally Inspired Artificial Intelligence, Nov. 2008, pp. 1-8.;;Finlayson, “The story workbench: an extensible semi-automatic text annotation tool,” Proceedings of the Fourth Workshop on Intelligent Narrative Technologies, Oct. 2011, pp. 21-24.;;Gordon et al., “Identifying personal stories in millions of weblog entries,” Proceedings of the Third International Conference on Weblogs and Social Media, May 2009, pp. 1-8.;;Landis et al., “The measurement of observer agreement for categorical data,” Biometrics, Mar. 1977, pp. 159-174, vol. 33, No. 1.;;Manning et al., “The stanford coreNLP natural language processing toolkit,” Proceedings of the 52nd Annual Meeting of the Association for Computational Linguistics, Jun. 2014, pp. 1-6.;;Sagae et al., “A data-driven approach for classification of subjectivity in personal narratives,” Proceedings of the 2013 International Workshop on Computational Models of Narrative, Aug. 2013, pp. 198-213.;;Verhagen et al., “SemEval-2007 Task 15: TempEval temporal relation identification,” Proceedings of the 4th International Workshop on Semantic Evaluations, Jun. 2007, pp. 75-80.;;Wiebe, “Tracking point of view in narrative,” Computational Linguistics, Jun. 1994, pp. 233-287, vol. 20, No. 2.",ACTIVE
56,CA,A1,CA 2337778 A1,133-284-843-751-532,2001-08-17,2001,CA 2337778 A,2001-02-15,US 50666900 A,2000-02-17,AXLE BOLT,An axle bolt has a shaft with a pair of opposed ends. An axle passage exten ds within tile shaft and a transverse passage extends radially outwardly from t he axial passage. A head attached to one end of the shaft has an outer face. A recess extends in from the outer face and the bottom of the recess is in communication with th e axial passage. A lubrication fitting in the recess has one end in communication wi th the bottom of the recess and another end designed to be connected to a lubricati on device. The recess in the bolt head is sufficiently deep that the second end of the lubrication fitting is within the recess and does not extend beyond the outer face.</SDO AB>,CTS INC,EISENBERG MARK H;;POTOCZNY WALTER,,https://lens.org/133-284-843-751-532,Patent Application,no,0,0,3,3,0,F16C33/6622;;Y10T29/49405;;Y10T29/49423;;Y10T29/49405;;Y10T29/49423;;F16C33/6622,F16C33/66,,0,0,,,,DISCONTINUED
57,KR,B1,KR 970002589 B1,032-719-248-251-70X,1997-03-06,1997,KR 880009293 A,1988-07-23,US 7694987 A,1987-07-23,MOUTH-TO-MOUTH RESUSCITATOR DEVICE,,PLASCO INC,WESTFALL MARK;;EISENBERG MELVIN I,,https://lens.org/032-719-248-251-70X,Granted Patent,no,0,0,15,15,0,A61M16/00;;A61M16/0048;;A61M16/0048,A61M16/00;;A61M16/06,,0,0,,,,EXPIRED
58,EP,A3,EP 0303367 A3,045-012-324-272-952,1990-12-19,1990,EP 88306825 A,1988-07-25,US 7694987 A,1987-07-23,MOUTH-TO-MOUTH RESUSCITATOR DEVICE,"A resuscitator device (10) for providing a physical shield between the rescuer and a victim requiring mouth-to-mouth resuscitation, and comprising a flexible sheet (12) to conform to the contour of the face of the victim in the area around the mouth and nose. A mouth opening (18) is centrally formed in said sheet. A hollow rigid tube (20) surrounds and is secured to the periphery of said mouth opening (18) and depends downward therefrom for inserting into the mouth of the victim. A self closing, one way valve (30) is contained in the tube (20), and includes a flexible, sleeve (32) having an air inlet open end in communication with the mouth opening (18) and an air outlet end (38) which is held normally closed by the action of a spring strip (34) secured to the sleeve (32) adjacent the outlet end (38).  ","PLASCO, INCORPORATED","EISENBERG, MELVIN I.;;WESTFALL, MARK",,https://lens.org/045-012-324-272-952,Search Report,yes,4,0,15,15,0,A61M16/00;;A61M16/0048;;A61M16/0048,A61M16/00;;A61M16/06,,0,0,,,,EXPIRED
59,DE,D1,DE 3853501 D1,182-258-799-170-092,1995-05-11,1995,DE 3853501 T,1988-07-25,US 7694987 A,1987-07-23,Mund-zu-Mund-Wiederbelebungsgerät.,,PLASCO INC,EISENBERG MELVIN I;;WESTFALL MARK,"MICROTEK MEDICAL, INC. (N.D.GES.D. STAATES DELAWAR (2004-12-30)",https://lens.org/182-258-799-170-092,Granted Patent,no,0,0,15,15,0,A61M16/00;;A61M16/0048;;A61M16/0048,A61M16/00;;A61M16/06,,0,0,,,,EXPIRED
60,EP,A1,EP 0629414 A1,091-314-004-618-776,1994-12-21,1994,EP 94200657 A,1988-07-25,EP 88306825 A;;US 7694987 A,1987-07-23,Mouth-to-mouth resuscitator device.,"A resuscitator device (10) for providing a physical shield between the rescuer and a victim requiring mouth-to-mouth resuscitation, and comprising a flexible sheet (12) to conform to the contour of the face of the victim in the area around the mouth and nose. A mouth opening (18) is centrally formed in said sheet. A hollow rigid tube (20) surrounds and is secured to the periphery of said mouth opening (18) and depends downward therefrom for inserting into the mouth of the victim. A self closing, one-way valve (30) is contained in the tube (20), and includes a flexible, sleeve (32) having an air inlet open end in communication with the mouth opening (18) and an air outlet end (38) which is held normally closed by the action of a spring strip (34) secured to the sleeve (32) adjacent the outlet end (38).",PLASCO INC,EISENBERG MELVIN I;;WESTFALL MARK,,https://lens.org/091-314-004-618-776,Patent Application,yes,3,1,15,15,0,A61M16/00;;A61M16/0048;;A61M16/0048,A61M16/00;;A61M16/06,,0,0,,,,EXPIRED
61,EP,B1,EP 0303367 B1,103-107-078-658-174,1995-04-05,1995,EP 88306825 A,1988-07-25,US 7694987 A,1987-07-23,Mouth-to-mouth resuscitator device.,,PLASCO INC,EISENBERG MELVIN I;;WESTFALL MARK,,https://lens.org/103-107-078-658-174,Granted Patent,yes,4,0,15,15,0,A61M16/00;;A61M16/0048;;A61M16/0048,A61M16/00;;A61M16/06,,0,0,,,,EXPIRED
62,CA,C,CA 1300450 C,095-046-414-541-174,1992-05-12,1992,CA 571887 A,1988-07-13,US 7694987 A,1987-07-23,MOUTH-TO-MOUTH RESUSCITATOR DEVICE,"A resuscitator device for providing a physical shield between the rescuer and a victim requiring mouth-to-mouth resuscitation, and comprising a flexible sheet to conform to the contour of the face of the victim in the area around the mouth and nose. A mouth opening is centrally formed in said sheet. A hollow rigid tube surrounds and is secured to the periphery of said mouth opening and depends downward therefrom to an outer end, for inserting into the mouth of the victim. A self closing, one way valve is contained in the tube, and includes a flexible, sleeve having an air inlet open end in communication with the mouth opening and an air outlet end adjacent the outer end of the tube which is normally closed from the action of a spring strip secured to the sleeve adjacent the outlet end. An air tight seal is made with the lips of the rescuer and victim separated by the sheet functioning as a shield, when the rescuer exhales a deep breath under presssure into the inlet of the valve. The forced air overcomes the resilient force of the spring strip and opens the sir outlet, for discharging the air inside the victim's mouth. When the breath is fully exhaled, the spring strip resiliently closes the air outlet to prevent any back flow of air, mist or liquid from the victim to the rescuer. The rescuer then moves his lips away from the sheet to take another deep breath and thereby breaks the seal to permit exhaling from the victim. Grooves formed in the victim's side of the sheet provide air pathways to the outside and prevent blockage of air from the mouth of the victim. An irregular non-smooth surface is formed on an area of the sheet to prevent clinging of the sheet to the nose, which could inhibit air flow out from the victim's nose.",PLASCO INC,EISENBERG MELVIN I;;WESTFALL MARK,,https://lens.org/095-046-414-541-174,Granted Patent,no,0,0,15,15,0,A61M16/00;;A61M16/0048;;A61M16/0048,A61M16/00;;A61M16/06,D41280008    M,0,0,,,,EXPIRED
63,TW,A,TW 200903343 A,066-697-552-510-824,2009-01-16,2009,TW 97108212 A,2008-03-07,US 793307 P,2007-03-08,Specimen tracking and management,"Techniques are described for using radio-frequency identification (RFID) tags to track patient specimens throughout the collection and analysis of patient specimens. A series of RFID tags may be used to track the specimens starting with the collection of a patient's tissue specimen at a surgery or examination room, through the process of preparing the specimens at a laboratory, to a specialist's office where the specimens are analyzed, and eventually into storage where the left-over specimen materials may be archived. A database may be used to capture unique identifiers for the RFID tags and other information throughout the process.",3M INNOVATIVE PROPERTIES CO,EISENBERG PETER MARK;;GRUNES MITCHELL BENJAMIN,,https://lens.org/066-697-552-510-824,Patent of Addition,no,0,0,4,4,0,G06Q10/08;;G16H10/40;;G16H10/60;;G06Q10/08;;G16H10/40;;G16H10/60,G06K7/10;;G06K19/077;;G16H10/40;;G16H10/60,,0,0,,,,PENDING
64,TW,A,TW 200901075 A,101-530-647-016-450,2009-01-01,2009,TW 97108220 A,2008-03-07,US 12480907 P,2007-03-08,Rule-driven specimen tracking and management,"Techniques are described for using radio-frequency identification (RFID) tags to track patient specimens throughout the collection and analysis of patient specimens. A series of RFID tags may be used to track the specimens starting with the collection of a patient's tissue specimen at a surgery or examination room, through the process of preparing the specimens at a laboratory, to a specialist's office where the specimens are analyzed, and eventually into storage where the left-over specimen materials may be archived. A database may be used to capture unique identifiers for the RFID tags and other information throughout the process.",3M INNOVATIVE PROPERTIES CO,EISENBERG PETER MARK;;GRUNES MITCHELL BENJAMIN,,https://lens.org/101-530-647-016-450,Patent of Addition,no,0,0,5,5,0,A61B10/0096;;G06Q10/0832;;G06Q10/0833;;A61B90/98;;G16H10/40;;G16H70/60;;A61B10/0096;;G06Q10/0833;;G06Q10/0832;;A61B90/98;;G16H10/40;;G16H70/60,G06Q50/00;;A61B16/00,,0,0,,,,PENDING
65,CA,A,CA 952213 A,044-646-014-682-938,1974-07-30,1974,CA 144224 A,1972-06-08,US 15472971 A,1971-06-21,LOW POWER DISPLAY DRIVER HAVING BRIGHTNESS CONTROL,,BURROUGHS CORP,EISENBERG MARK F;;HOLZ GEORGE E,,https://lens.org/044-646-014-682-938,Granted Patent,no,0,0,13,13,0,G09G3/285;;G09G3/285;;H04N3/125;;H04N3/125;;H01J17/494;;H01J17/494,G06F3/147;;G09G3/282;;G09G3/29;;H01J17/49;;H04N3/12,340-174,0,0,,,,EXPIRED
66,TW,A,TW 200921519 A,151-777-643-043-556,2009-05-16,2009,TW 97108199 A,2008-03-07,US 6612007 P,2007-03-08,Print device for specimen tracking and management,"Techniques are described for using radio-frequency identification (RFID) tags to track patient specimens throughout the collection and analysis of patient specimens. A series of RFID tags may be used to track the specimens starting with the collection of a patient's tissue specimen at a surgery or examination room, through the process of preparing the specimens at a laboratory, to a specialist's office where the specimens are analyzed, and eventually into storage where the left-over specimen materials may be archived. A database may be used to capture unique identifiers for the RFID tags and other information throughout the process.",3M INNOVATIVE PROPERTIES CO,EISENBERG PETER MARK;;GRUNES MITCHELL BENJAMIN,,https://lens.org/151-777-643-043-556,Patent of Addition,no,0,0,4,4,0,G06Q10/087;;G16H10/40;;G06Q10/087;;G16H10/40,G06K1/20;;G06K19/07,,0,0,,,,PENDING
67,AU,A,AU 1982/081195 A,137-783-781-390-509,1982-10-21,1982,AU 1982/081195 A,1982-03-09,US 25432081 A,1981-04-15,HYDROPONIC SYSTEM,,WHITTAKER CORP,HANCOCK MARK W;;EISENBERG STEVEN K,,https://lens.org/137-783-781-390-509,Patent Application,no,0,0,3,3,0,A01G31/02;;Y02P60/21,A01G31/00;;A01G31/02,,0,0,,,,DISCONTINUED
68,EP,A1,EP 0062966 A1,127-313-704-039-601,1982-10-20,1982,EP 82301074 A,1982-03-03,US 25432081 A,1981-04-15,Improved system and method for hydroponically growing plants.,"A system for hydroponically growing plants includes a pressure vessel (18) containing equipment such as a splash plate (20) for substantially increasing the surface area of liquid to be introduced into the pressure vessel. The system also includes a gas transfer conduit (22) for passing selected plant growth promoting gas such as oxygen, air, ammonia and/or carbon dioxide, from a gas source into the vessel and a conduit (14) for passing hydroponic plant growing liquid into the vessel and for directing it against the splash plate or the like and thus facilitate rapid dissolving therein of the gas introduced into the pressure vessel. Conduits (36, 42, 44) are also provided for passing the gas-enriched liquid to a plurality of plants and may also be provided for returning the same to the pressure vessel for replenishment of the gas depleted therefrom. The system may include gas vents, a holding vessel (12) for the liquid and a gas level sensor (54) connected to the return conduit (50) and to a valve (24) in the gas supply line for regulating the concentration of gas in the pressure vessel in response to the concentration of gas in the depleted liquid. The method preferably employs the system on a substantially continuous basis. The pressure vessel is usually operated at superatmospheric pressure to assure a maximum concentration of dissolved gas in the liquid.",WHITTAKER CORP,HANCOCK MARK W;;EISENBERG STEVEN K,,https://lens.org/127-313-704-039-601,Patent Application,yes,4,8,3,3,0,A01G31/02;;Y02P60/21,A01G31/00;;A01G31/02,,0,0,,,,DISCONTINUED
69,CH,A,CH 538744 A,093-575-719-146-168,1973-06-30,1973,CH 329071 A,1971-03-05,US 2175670 A;;US 4765070 A,1970-03-23,Anzeigevorrichtung,,BURROUGHS CORP,MARK FREDERICK EISENBERG;;WILLIAM JOSEPH HARMON,,https://lens.org/093-575-719-146-168,Granted Patent,no,0,1,13,14,0,G09G3/29;;G09G3/285,G09G3/29,,0,0,,,,EXPIRED
70,US,A,US 4379375 A,072-114-041-183-286,1983-04-12,1983,US 24555781 A,1981-03-19,US 24555781 A,1981-03-19,Hydroponic growing system and method,"An improved hydroponic growing system comprises, in combination, an elongated preferably rectangular hollow trough having substantially closed sidewalls and bottom and an open top defining a central space. The trough defines a pair of spaced tracks extending the length thereof in the space and an elongated flexible strip is slideably disposed in the tracks. The strip contains a plurality of spaced apertures extending vertically therethrough along the length thereof and in each aperture is disposed a plant growing cup having a hollow body defining a central space, an open top, a porous bottom and substantially closed or perforated sidewalls. The sidewalls bear outwardly extending peripheral supports so that the body of the cup extends down into the trough space and the cup is releasably held in position by the support bearing on the upper face of the strip. The porous cup bottom may include a metal or plastic grid or may be formed integrally with the sidewalls and contain a plurality of holes sufficiently large to permit plant roots and hydroponic fluid to pass through but small enough to prevent plant seeds from falling down therethrough. Preferably, the cup is conical or cylindrical and the strip is a single continuous strip. Alternatively, the strip can comprise a plurality of substrips linked lengthwise together. The trough may include an internal conduit with spaced openings to supply hydroponic makeup fluid to the trough space. The trough includes spaced hydroponic fluid exits for removal of hydroponic fluid.",WHITTAKER CORP,EISENBERG STEVEN K;;HANCOCK MARK W,WHITTAKER CORPORATION A CORP. OF CA (1981-03-13);;GROWING INDUSTRIES INC. A CORP. OF (1985-10-31),https://lens.org/072-114-041-183-286,Granted Patent,yes,14,47,7,7,0,A01G31/02;;A01G31/02;;Y02P60/21;;Y02P60/21,A01G31/00;;A01G31/02;;A01G31/04,47/65,1,0,,,"Anon., ""Danes Try Conveyor Belt Cropping"", The Grower, Aug. 31, 1978, pp. 395, 396 (only).",EXPIRED
71,CA,A,CA 1208909 A,070-050-711-847-57X,1986-08-05,1986,CA 421192 A,1983-02-09,CA 421192 A,1983-02-09,HYDROPONIC GROWING SYSTEM AND METHOD,"An improved hydroponic growing system comprises, in combination, an elongated preferably rectangular hollow trough having substantially closed sidewalls and bottom and an open top defining a central space. The trough defines a pair of spaced tracks extending the length thereof in the space and an elongated flexible strip is slideably disposed in the tracks. The strip contains a plurality of spaced apertures extending vertically therethrough along the length thereof and in each aperture is disposed a plant growing cup having a hollow body defining a central space, an open top, a porous bottom and substantially closed or perforated sidewalls. The sidewalls bear outwardly extending peripheral supports so that the body of the cup extends down into the trough space and the cup is releasably held in position by the support bearing on the upper face of the strip. The porous cup bottom may include a metal or plastic grid or may be formed integrally with the sidewalls and contain a plurality of holes sufficiently large to permit plant roots and hydroponic fluid to pass through but small enough to prevent plant seeds from falling down therethrough. Preferably, the cup is conical or cylindrical and the strip is a single continuous strip.",WHITTAKER CORP,EISENBERG STEVEN K;;HANCOCK MARK W,,https://lens.org/070-050-711-847-57X,Granted Patent,no,0,1,1,1,0,Y02P60/21,A01G31/02,47-1,0,0,,,,EXPIRED
72,TW,A,TW 200911194 A,167-788-164-426-271,2009-03-16,2009,TW 97108211 A,2008-03-07,US 793207 P,2007-03-08,Specimen tracking and management verification,"Techniques are described for using radio-frequency identification (RFID) tags to track patient specimens throughout the collection and analysis of patient specimens. A series of RFID tags may be used to track the specimens starting with the collection of a patient's tissue specimen at a surgery or examination room, through the process of preparing the specimens at a laboratory, to a specialist's office where the specimens are analyzed, and eventually into storage where the left-over specimen materials may be archived. A database may be used to capture unique identifiers for the RFID tags and other information throughout the process.",3M INNOVATIVE PROPERTIES CO,EISENBERG PETER MARK;;GRUNES MITCHELL BENJAMIN,,https://lens.org/167-788-164-426-271,Patent of Addition,no,0,1,5,5,0,A61B10/00;;A61B10/0096;;G01N1/31;;G01N35/00732;;G01N2035/00782;;B65G41/002;;A61B90/98;;G16H10/40;;A61B10/0096;;G01N1/31;;G01N2035/00782;;A61B10/00;;G01N35/00732;;B65G41/002;;A61B90/98;;G16H10/40,A61B10/00;;G01N35/00;;G16H10/40,,0,0,,,,PENDING
73,AU,A,AU 1982/081196 A,035-341-976-353-939,1982-09-23,1982,AU 1982/081196 A,1982-03-09,US 24555781 A,1981-03-19,HYDROPONIC TROUGH,,WHITTAKER CORP,EISENBERG STEVEN K;;HANCOCK MARK W,,https://lens.org/035-341-976-353-939,Patent Application,no,0,3,7,7,0,A01G31/02;;A01G31/02;;Y02P60/21;;Y02P60/21,A01G31/00;;A01G31/02;;A01G31/04,,0,0,,,,DISCONTINUED
74,EP,A1,EP 0061244 A1,071-469-695-192-727,1982-09-29,1982,EP 82301076 A,1982-03-03,US 24555781 A,1981-03-19,Improved hydroponic growing system and method.,"A hydroponic growing system (20) comprises an elongated preferably rectangular hollow trough (22) having substantially closed sidewalls and bottom and an open top defining a central space. The trough defines a pair of spaced tracks extending the length thereof in the space and an elongated flexible strip (46) is slideably disposed in the tracks. The strip contains a plurality of spaced apertures extending vertically therethrough along the length thereof and in each aperture is disposed a plant growing cup (50) having a hollow body defining a central space, an open top, a porous bottom and substantially closed or perforated sidewalls. The sidewalls bear outwardly extending peripheral supports so that the body of the cup extends down into the trough space and the cup is releasably held in position by the support bearing on the upper face of the strip. The trough may include an internal conduit with spaced openings (78) to supply hydroponic makeup fluid (68) to the trough space. The trough includes spaced hydroponic fluid exits (80) for removal of hydroponic fluid. The system is used by growing plants from seeds to seedlings in the cups, then inserting the cups through the strips into the trough and continuing hydroponic growing therein with periodic harvesting of the grown plants (72) at the downstream end of the trough together with periodic addition of seedling plans in cups to the upstream end of the trough.",WHITTAKER CORP,EISENBERG STEVEN K;;HANCOCK MARK W,,https://lens.org/071-469-695-192-727,Patent Application,yes,4,17,7,7,0,A01G31/02;;A01G31/02;;Y02P60/21;;Y02P60/21,A01G31/00;;A01G31/02;;A01G31/04,,0,0,,,,DISCONTINUED
75,DE,A1,DE 2110805 A1,019-673-217-779-913,1971-10-14,1971,DE 2110805 A,1971-03-06,US 2175670 A;;US 4765070 A,1970-03-23,"Schaltung zur zeitlich-sequentiellen Steuerung mehrerer,einer Anordnung von Anzeigeelementen zugeordneter Steuerelektroden",,BURROUGHS CORP,FREDERICK EISENBERG MARK;;JOSEPH HARMON JUN WILLIAM,,https://lens.org/019-673-217-779-913,Patent Application,no,0,0,13,14,0,G09G3/29;;G09G3/285,G09G3/29,,0,0,,,,EXPIRED
76,CA,A,CA 944042 A,091-643-063-301-08X,1974-03-19,1974,CA 107720 A,1971-03-15,US 2175670 A;;US 4765070 A,1970-03-23,DISPLAY PANEL RESET AND SAFETY TIMING CIRCUIT,,BURROUGHS CORP,EISENBERG MARK F;;HARMON WILLIAM J JR,,https://lens.org/091-643-063-301-08X,Granted Patent,no,0,0,13,14,0,G09G3/29;;G09G3/285,G09G3/29,340-174,0,0,,,,EXPIRED
77,DE,A1,DE 2229053 A1,114-732-309-566-588,1973-01-11,1973,DE 2229053 A,1972-06-14,US 15473171 A,1971-06-21,ABTAST-STEUERSCHALTUNG FUER ANZEIGEVORRICHTUNGEN,,BURROUGHS CORP,EISENBERG MARK FREDERICK;;HARMON JUN WILLIAM JOSEPH,,https://lens.org/114-732-309-566-588,Patent Application,no,1,0,10,10,0,H01J17/494;;H04N3/125;;G09G3/285;;H04N3/125;;H01J17/494;;G09G3/285,G09G3/29;;H01J17/49;;H04N3/12,,0,0,,,,EXPIRED
78,CA,A,CA 957748 A,128-784-880-082-964,1974-11-12,1974,CA 144223 A,1972-06-08,US 15473171 A,1971-06-21,APPARATUS REDUCING THE POWER FOR SCANNED DISPLAY DEVICES,,BURROUGHS CORP,EISENBERG MARK F;;HARMON WILLIAM J JR,,https://lens.org/128-784-880-082-964,Granted Patent,no,0,0,10,10,0,H01J17/494;;H04N3/125;;G09G3/285;;H04N3/125;;H01J17/494;;G09G3/285,G09G3/29;;H01J17/49;;H04N3/12,340-174,0,0,,,,EXPIRED
79,AU,A,AU 1982/081197 A,156-308-554-741-125,1982-09-30,1982,AU 1982/081197 A,1982-03-09,US 24808581 A,1981-03-27,HARVESTING OF HYDROPONIC PLANTS,,WHITTAKER CORP,MILHELM ROBERT;;EISENBERG STEVEN K;;HANCOCK MARK W,,https://lens.org/156-308-554-741-125,Patent Application,no,0,0,6,6,0,A01G31/045;;A01G9/088;;A01G9/143;;Y02A40/25;;Y02P60/21;;A01G31/045;;A01G9/143;;A01G9/088;;Y02A40/25;;Y02P60/21,A01D34/00;;A01G31/04,,0,0,,,,DISCONTINUED
80,US,A,US 4327538 A,027-518-961-202-653,1982-05-04,1982,US 24808581 A,1981-03-27,US 24808581 A,1981-03-27,Harvester,"Am improved harvester is provided for hydroponically grown produce borne in spaced cups extending down through a flexible elongated strip along the length thereof. The harvester comprises a frame having at least one and preferably a number of guideways each having a pair of elongated spaced parallel rails secured in the frame and adapted to guide the flexible strip bearing the produce-containing cups. A strip guide roll and separation means are also secured to the frame for separating the produce-bearing portions of the growing cups from the flexible strip during its passage through the frame. A strip take-up reel and means for powering the same are in or adjacent to the frame. In one embodiment, the guide roll is adapted to fully eject the cups from the strip and slide means are provided for passage of said cups to a recovery area. In another embodiment, the guide roll raises the cups while the cups are still retained in the strip and blade means sever the raised portions of the cups. In a further embodiment a holder defining an elongated guideway for the strip is positioned in the frame upstream of the guide roll and includes blade means for severing that portion of each of the cups which depends below the strip. Such blade means may comprise a removable blade with its edge angled across the path of the strip and positioned below the strip. It effectively separates and recovers both the strip and the produce contained in the cups.",WHITTAKER CORP,MILHEM ROBERT;;EISENBERG STEVEN K;;HANCOCK MARK W,WHITTAKER CORPORATION A CORP. OF CA (1981-03-26);;GROWING INDUSTRIES INC. A CORP. OF (1985-10-31),https://lens.org/027-518-961-202-653,Granted Patent,yes,13,15,6,6,0,A01G31/045;;A01G9/088;;A01G9/143;;Y02A40/25;;Y02P60/21;;A01G31/045;;A01G9/143;;A01G9/088;;Y02A40/25;;Y02P60/21,A01G31/04;;A01D34/00,56/1,1,0,,,"Anon. ""Danes Try Conveyor Belt Cropping"", The Grower, Aug. 31, 1978, pp. 395 and 396.",EXPIRED
81,EP,A1,EP 0061841 A1,041-287-689-491-629,1982-10-06,1982,EP 82301075 A,1982-03-03,US 24808581 A,1981-03-27,Harvester for hydroponically grown produce.,"A harvester (10) is provided for hydroponically grown produce (40) borne in spaced cups (36) extending down through a flexible elongated strip (32) along the length thereof. The harvester comprises a frame (12) having at least one and preferably a number of guideways (28) each having a pair of elongated spaced parallel rails (30) secured in the frame and adapted to guide the flexible strip bearing the produce-containing cups (36). A strip guide roll (56) and separation means are also secured to the frame (12) for separating the produce-bearing portions of the growing cups (36) from the flexible strip (32) during its passage through the frame. A strip take-up reel (60) and means (62) for powering the same are in or adjacent to the frame. In one embodiment, the guide roll (56) is adapted to fully eject the cups from the strip and slide means (66) are provided for passage of said cups to a recovery area. In another embodiment, the guide roll raises the cups while the cups are still retained in the strip and blade means sever the raised portions of the cups. In a further embodiment a holder defining an elongated guideway for the strip is positioned in the frame upstream of the guide roll and includes blade means for severing that portion of each of the cups which depends below the strip. Such blade means may comprise a removable blade with its edge angled across the path of the strip and positioned below the strip.",WHITTAKER CORP,MILHELM ROBERT;;EISENBERG STEVEN K;;HANCOCK MARK W,,https://lens.org/041-287-689-491-629,Patent Application,yes,3,6,6,6,0,A01G31/045;;A01G9/088;;A01G9/143;;Y02A40/25;;Y02P60/21;;A01G31/045;;A01G9/143;;A01G9/088;;Y02A40/25;;Y02P60/21,A01D34/00;;A01G31/04,,0,0,,,,DISCONTINUED
82,DE,C3,DE 2110805 C3,033-627-528-092-430,1979-07-05,1979,DE 2110805 A,1971-03-06,US 2175670 A;;US 4765070 A,1970-03-23,DE 2110805 C3,,"BURROUGHS CORP., DETROIT, MICH. (V.ST.A.)","EISENBERG, MARK FREDERICK, NORTH PLAINFIELD;;HARMON JUN., WILLIAM JOSEPH, MIDDLESEX",,https://lens.org/033-627-528-092-430,Granted Patent,no,0,0,13,14,0,G09G3/29;;G09G3/285,G09G3/29,,0,0,,,,EXPIRED
83,DE,B2,DE 2110805 B2,004-756-515-711-756,1978-11-09,1978,DE 2110805 A,1971-03-06,US 2175670 A;;US 4765070 A,1970-03-23,DE 2110805 B2,,"BURROUGHS CORP., DETROIT, MICH. (V.ST.A.)","EISENBERG, MARK FREDERICK, NORTH PLAINFIELD;;HARMON JUN., WILLIAM JOSEPH, MIDDLESEX",,https://lens.org/004-756-515-711-756,Patent Application,no,0,0,13,14,0,G09G3/29;;G09G3/285,G09G3/29,,0,0,,,,EXPIRED
84,DE,C2,DE 2229054 C2,096-037-687-765-669,1986-01-30,1986,DE 2229054 A,1972-06-14,US 15472971 A,1971-06-21,DE 2229054 C2,,"BURROUGHS CORP., DETROIT, MICH., US","EISENBERG, MARK FREDERICK;;HOLZ, GEORGE ERNEST, NORTH PLAINFIELD, N.J., US",,https://lens.org/096-037-687-765-669,Granted Patent,no,0,0,13,13,0,G09G3/285;;G09G3/285;;H04N3/125;;H04N3/125;;H01J17/494;;H01J17/494,G06F3/147;;G09G3/282;;G09G3/29;;H01J17/49;;H04N3/12,,0,0,,,,EXPIRED
85,BR,B1,BR 122013013915 B1,124-147-463-718-08X,2018-09-11,2018,BR 122013013915 A,2001-01-05,US 0100482 W;;US 48437000 A;;BR 0107554 A,2000-01-14,"leitora de identificação de freqüência de rádio (rfid) portátil, e, método de uso da mesma","A user interface for a radio frequency identification interrogation system is disclosed, which interface may include graphics, sounds, lights, or combinations of the foregoing that provide information to a user in regard to the materials being interrogated.",3M INNOVATIVE PROPERTIES CO,DAVID TIMOTHY BERQUIST;;MITCHELL BENJAMIN GRUNES;;PETER MARK EISENBERG;;ROBERT JOHN SCHILLING,,https://lens.org/124-147-463-718-08X,Granted Patent,no,0,0,23,23,0,G06K7/10079;;G06K7/10881;;G06K17/00;;G06K7/00;;G06K7/10079;;G06K7/10881;;G06K17/00,G06K17/00;;G06K7/00;;G06K7/10;;G06V30/00,,0,0,,,,EXPIRED
86,BR,B1,BR 0107554 B1,164-012-342-994-11X,2014-09-23,2014,BR 0107554 A,2001-01-05,US 48437000 A;;US 0100482 W,2000-01-14,LEITORA DE IDENTIFICAÇÃO DE FREQUÊNCIA DE RÁDIO ( RFID ) PORTÁTIL PARA ESTIMATIVA DE LOCALIZAÇÃO DE ITENS E MÉTODO INCORPORADO À MESMA.,"A user interface for a radio frequency identification interrogation system is disclosed, which interface may include graphics, sounds, lights, or combinations of the foregoing that provide information to a user in regard to the materials being interrogated.",3M INNOVATIVE PROPERTIES CO,BERQUIST DAVID TIMOTHY;;EISENBERG PETER MARK;;GRUNES MITCHELL BENJAMIN;;SCHILLING ROBERT JOHN,,https://lens.org/164-012-342-994-11X,Granted Patent,no,0,0,23,23,0,G06K7/10079;;G06K7/10881;;G06K17/00;;G06K7/00;;G06K7/10079;;G06K7/10881;;G06K17/00,G06K17/00;;G06K7/00;;G06K7/10;;G06V30/00,,0,0,,,,EXPIRED
87,BR,A,BR 0107554 A,019-440-614-878-15X,2002-10-08,2002,BR 0107554 A,2001-01-05,US 48437000 A;;US 0100482 W,2000-01-14,"Leitora de identificação de frequência de rádio ( rfid ) portátil, e, método de uso da mesma.","A user interface for a radio frequency identification interrogation system is disclosed, which interface may include graphics, sounds, lights, or combinations of the foregoing that provide information to a user in regard to the materials being interrogated.",3M INNOVATIVE PROPERIES COMPAN,BERQUIST DAVID TIMOTHY;;EISENBERG PETER MARK;;GRUNES MITCHELL BENJAMIN;;SCHILLING ROBERT JOHN,,https://lens.org/019-440-614-878-15X,Patent Application,no,0,0,23,23,0,G06K7/10079;;G06K7/10881;;G06K17/00;;G06K7/00;;G06K7/10079;;G06K7/10881;;G06K17/00,G06K17/00;;G06K7/00;;G06K7/10;;G06V30/00,,0,0,,,,EXPIRED
88,AR,A1,AR 037099 A1,160-947-996-555-771,2004-10-20,2004,AR P020103786 A,2002-10-08,US 97432101 A,2001-10-10,"UN METODO PARA REGISTRAR LA CANTIDAD DE TIEMPO UTILIZADA POR UNA PERSONA O UN PROVEEDOR DE SERVICIOS EN UN PROYECTO, UN PROGRAMA DE COMPUTACION ASOCIADO A DICHO METODO, UN SISTEMA COMPUTARIZADO DE REGISTRO DE TIEMPO, Y UNA FACTURA POR LA CANTIDAD DE TIEMPO UTILIZADA EN DICHO PROYECTO.","Se provee un método mejorado para llevar un registro del tiempo, y específicamente, un método para registrar la cantidad de tiempo utilizado por una persona o un proveedor de servicios en un proyecto. La persona o el proveedor de servicios escanea una etiqueta de identificación por radiofrecuencia (RFID) asociada con un archivo utilizando un lector RFID, y un programa de computación comienza con el conteo del tiempo y lo asocia con el asunto con el que se relaciona el archivo. Cuando la persona o el proveedor de servicios escanea la etiqueta (RFID) nuevamente, el conteo se detiene, y el tiempo transcurrido es facturado a un cliente respecto del asunto asociado con el archivo. También se divulgan un programa de computación asociado al método, un sistema computarizado de registro de tiempo y una factura por la cantidad de tiempo utilizada en el proyecto.",3M INNOVATIVE PROPERTIES CO,EISENBERG PETER MARK;;KAREL GERALD LOUIS;;GRUNES MITCHELL BENJAMIN;;KRUSE JOHN MICHAEL,,https://lens.org/160-947-996-555-771,Patent Application,no,0,0,12,12,0,G06Q10/06;;G06Q10/10;;G06Q10/10;;G06K17/00;;G06Q10/1091;;G06Q10/1091,G07C1/00;;G06K17/00;;G06Q10/10;;H04B1/59;;H04B5/02,,0,0,,,,DISCONTINUED
89,DE,C2,DE 2229053 C2,076-299-911-535-396,1985-12-05,1985,DE 2229053 A,1972-06-14,US 15473171 A,1971-06-21,DE 2229053 C2,,"BURROUGHS CORP., DETROIT, MICH., US","EISENBERG, MARK FREDERICK, PLAINFIELD, N.J., US;;HARMON JUN., WILLIAM JOSEPH, MIDDLESEX, N.J., US",,https://lens.org/076-299-911-535-396,Granted Patent,no,0,0,10,10,0,H01J17/494;;H04N3/125;;G09G3/285;;H04N3/125;;H01J17/494;;G09G3/285,G09G3/29;;H01J17/49;;H04N3/12,,0,0,,,,EXPIRED
90,NZ,A,NZ 529981 A,175-064-829-380-13X,2005-07-29,2005,NZ 52998101 A,2001-06-05,NZ 52998101 A;;US 0118157 W,2001-06-05,Methods of managing the transfer and use of data by a RFID reader,A method of transferring and using information comprises: (a) obtaining information related to a plurality of items from an existing database; (b) reformatting the information in a desired manner to facilitate the use of the information by an RFID reader; (c) exporting the information to a database stored on a data storage device and (d) using the information on the data storage device with an RFID reader in conjunction with the interrogation of RFID tags associated with the items. The existing database includes information correlating the items to item identifiers which can be barcodes or can be characters or handwriting.,3M INNOVATIVE PROPERTIES CO,EISENBERG PETER MARK;;MOREL DIANE EDITH;;MCINTYRE DANIEL KEITH;;SEVCIK PAUL ANTHONY;;GRUNES MITCHELL BENJAMIN,,https://lens.org/175-064-829-380-13X,Patent Application,no,0,0,1,1,0,,,,0,0,,,,PENDING
91,TW,B,TW I250457 B,041-404-230-042-707,2006-03-01,2006,TW 91111967 A,2002-06-04,US 87474901 A;;US 15312402 A,2001-06-05,Radio frequency identification in document management,"Various systems and methods of handling items such as files are disclosed, including systems and methods for polling RFID-tagged items while they are stored in storage areas. A method for interrogating a storage area that includes a number of items each bearing an RFID tag, the method comprising the steps of (a) providing at least one antenna system positioned on at lease one shelf in storage area; (b) providing a polling schedule for at least one antenna to poll the RFID tags; and (c) preempting the polling schedule to poll a designated portion of the storage area, prior to the at lease one antenna polling the RFID tags according to the polling schedule.",3M INNOVATIVE PROPERTIES CO,EISENBERG PETER MARK;;ERICKSON DAVID PAUL;;GOFF EDWARD DAVID;;GRUNES MITCHELL BENJAMIN;;HICKOK GENE JAMES,,https://lens.org/041-404-230-042-707,Granted Patent,no,0,6,19,31,0,G06K17/00;;G06K19/07796,G06K17/00;;G06K19/00;;B65G1/137;;G06K19/07;;G06K7/00;;H04Q5/22,,0,0,,,,EXPIRED
92,BG,B1,BG 66037 B1,068-157-514-961-101,2010-11-30,2010,BG 10757203 A,2003-02-19,US 22002100 P;;US 0123104 W,2000-07-21,PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME,"Изобретението се отнася до нов метод за селектиране на пролекарства на фосфонат нуклеотидни аналози и за получаване на пролекарства с антивирусна или антитуморна активност, селективно насочващи се към желани тъкани. По метода се получават нови смесени естер-емидати на РМРА за ретровирусна или хепадна вирусна терапия. Съединенията съгласно изобретението имат структурна формула@@в която значенията на заместителите са посочени в описанието. Изобретението се отнася и до състави на тези съединения с фармацевтично приемливи инертни носители, до използването им за профилактика и лечение, както и до подобрен метод за използване на магнезиев алкоксид за получаване на изходните материали и съединения съгласно изобретението.",GILEAD SCIENCES,BECKER MARK;;CHAPMAN HARLAN;;CIHLAR TOMAS;;EISENBERG EUGENE;;HE GONG-XIN;;KERNAN MICHAEL;;LEE WILLIAM;;PRISBE ERNEST;;ROHLOFF JOHN;;SPARACINO MARK,,https://lens.org/068-157-514-961-101,Granted Patent,no,3,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07F9/6561;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,EXPIRED
93,ES,T3,ES 2627903 T3,064-015-034-738-69X,2017-08-01,2017,ES 13164300 T,2001-07-20,US 22002100 P,2000-07-21,Profármacos de análogos de nucleótidos de fosfonato y métodos para seleccionar y preparar los mismos,"Un método para la fabricación de 9-[2-(fosfonometoxi)propil]adenina (PMPA) o 9-[2-(fosfonometoxi)etil] adenina (PMEA) que comprende hacer reaccionar 9-(2-hidroxipropil)adenina (HPA) o 9-(2-hidroxietil)adenina (HEA),, alcóxido de magnesio, y p-toluenosulfonoloxometilfosfonato protegido.",GILEAD SCIENCES INC,BECKER MARK;;CHAPMAN HARLAN;;CIHLAR TOMAS;;EISENBERG EUGENE;;HE GONG-XIN;;KERNAN MICHAEL;;LEE WILLIAM;;PRISBE ERNEST;;ROHLOFF JOHN;;SPARACINO MARK,,https://lens.org/064-015-034-738-69X,Granted Patent,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07F9/6561;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,EXPIRED
94,ES,T5,ES 2536972 T5,166-968-040-612-138,2022-04-06,2022,ES 01961695 T,2001-07-20,US 22002100 P;;US 0123104 W,2000-07-21,Profármacos de análogos de nucleótidos de fosfonato y métodos para seleccionar y preparar los mismos,,GILEAD SCIENCES INC,LEE WILLIAM;;BECKER MARK;;CHAPMAN HARLAN;;CIHLAR TOMAS;;EISENBERG EUGENE;;HE GONG-XIN;;KERNAN MICHAEL;;PRISBE ERNEST;;ROHLOFF JOHN;;SPARACINO MARK,,https://lens.org/166-968-040-612-138,Amended Patent,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07F9/6561;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,EXPIRED
95,OA,A,OA 12393 A,172-986-199-923-241,2006-04-18,2006,OA 1200300003 A,2001-07-20,US 22002100 P,2000-07-21,Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same.,,GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/172-986-199-923-241,Granted Patent,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,EXPIRED
96,AP,A,AP 1466 A,187-206-571-029-057,2005-09-22,2005,AP 2003002724 A,2001-07-20,US 22002100 P;;US 0123104 W,2000-07-21,Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same.,"A novel method is provided for screening prodrugs of methoxyphosphonate nucleotide analogues to identify prodrugs selectively targeting desired tissues with antiviral or antitumor activity. This method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided. Also provided is an improved method for the use of magnesium alkoxide for the preparation of starting materials and compounds for use herein.",GILEAD SCIENCES INC,BECKER MARK;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/187-206-571-029-057,Granted Patent,no,2,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,EXPIRED
97,EP,A1,EP 3235823 A1,024-316-309-182-896,2017-10-25,2017,EP 17160970 A,2001-07-20,US 22002100 P;;EP 13164300 A;;EP 01961695 A,2000-07-21,PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME,"A novel method is provided for screening prodrugs of methoxyphosphonate nucleotide analogues to identify prodrugs selectively targeting desired tissues with antiviral or antitumor activity. This method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided. Also provided is an improved method for the use of magnesium alkoxide for the preparation of starting materials and compounds for use herein.",GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/024-316-309-182-896,Patent Application,yes,26,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07F9/6561;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,17,7,060-516-842-835-850;;058-117-624-049-237;;077-295-491-167-117;;068-575-200-141-698;;061-123-661-112-505;;095-226-048-285-585;;087-104-081-149-221,10571273;;10.1023/a:1018945713623;;10.1021/jm00186a001;;7005447;;10.1002/0471220574;;10.1021/op980019a;;10.1177/095632029700800610;;1568310;;10.1093/clinchem/38.4.480;;6331228;;10.1016/0003-2697(84)90386-5,"OLIYAI ET AL., PHARMACEUTICAL RESEARCH, vol. 16, no. 11, 1999, pages 1687 - 1693;;STELLA ET AL., J. MED. CHEM., vol. 23, no. 12, 1980, pages 1275 - 1282;;AARONS, L.; BODDY, A.; PETRAK, K.: ""Novel Drug Delivery and Its Therapeutic Application"", 1989, pages: 121 - 126;;BUNDGAARD, H.: ""Design of Prodrugs"", 1985, pages: 70 - 74,79-92;;BANERJEE, P. K.; AMIDON, G. L.: ""Design of Prodrugs"", 1985, pages: 118 - 121;;NOTARI, R. E.: ""Design of Prodrugs"", 1985, pages: 135 - 156;;STELLA, V. J.; HIMMELSTEIN, K. J.: ""Design of Prodrugs"", 1985, pages: 177 - 198;;JONES, G.: ""Design of Prodrugs"", 1985, pages: 199 - 241;;CONNORS, T. A.: ""Design of Prodrugs"", 1985, pages: 291 - 316;;GREENE ET AL., PROTECTIVE GROUPS IN ORGANIC SYNTHESIS;;STRUBE ET AL., ORGANIC PROCESS RESEARCH AND DEVELOPMENT, vol. 2, 1998, pages 305 - 319;;ARIMILLI, MN ET AL.: ""Synthesis, in vitro biological evaluation and oral bioavailability of 9-[2-(phosphonomethoxy)propyl] adenine (PMPA) prodrugs"", ANTIVIRAL CHEMISTRY AND CHEMOTHERAPY, vol. 8, no. 6, 1997, pages 557 - 564, XP055254163;;A. POMPON ET AL, ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, vol. 5, 1994, pages 91 - 98;;""Guide for the Care and Use of Laboratory Animals"", NATIONAL INSTITUTES OF HEALTH PUBLICATION 86-23;;B. L. ROBINS ET AL, ANTIMICROB. AGENTS CHEMOTHER., vol. 42, 1998, pages 612;;L. NAESENS ET AL, CLIN. CHEM., vol. 38, 1992, pages 480;;K. TANAKA ET AL, ANAL. BIOCHEM., vol. 139, 1984, pages 35",DISCONTINUED
98,US,A1,US 2002/0119443 A1,032-539-328-741-022,2002-08-29,2002,US 90956001 A,2001-07-20,US 90956001 A;;US 22002100 P,2000-07-21,Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same,"
    A novel method is provided for screening prodrugs of methoxyphosphonate nucleotide analogues to identify prodrugs selectively targeting desired tissues with antiviral or antitumor activity. This method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5 a ) 

   having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided. Also provided is an improved method for the use of magnesium alkoxide for the preparation of starting materials and compounds for use herein. 
",GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,GILEAD SCIENCES INC (2001-08-21),https://lens.org/032-539-328-741-022,Patent Application,yes,0,93,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,435/5,0,0,,,,DISCONTINUED
99,US,A1,US 2008/0227754 A1,064-683-250-734-283,2008-09-18,2008,US 11082908 A,2008-04-28,US 11082908 A;;US 79869204 A;;US 35420703 A;;US 90956001 A;;US 22002100 P,2000-07-21,PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES,"A novel method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided.",BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,GILEAD SCIENCES INC (2001-08-21),https://lens.org/064-683-250-734-283,Patent Application,yes,28,3,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,A61K31/675;;A61K31/664;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,514/81,0,0,,,,EXPIRED
100,NO,L,NO 20150909 L,066-973-501-476-599,2003-03-20,2003,NO 20150909 A,2015-07-10,US 22002100 P;;US 0123104 W,2000-07-21,"Prodroger av fosfonatnukleotidanaloger, og fremgangsmåter for utvelgelse og fremstilling av disse","En ny fremgangsmåte er tilveiebrakt for screening av prodroger av metoksyfosfonatnukleotidanaloger for å identifisere prodroger som selektivt er målrettet mot ønskede vev, med antiviral eller antitumoraktivitet. Denne fremgangsmåten har ført til identifisering av nye blandede esteramidater av PMPA for retroviral eller hepadnaviral behandling, omfattende forbindelser ifølge struktur (5a) som har substituentgrupper som er definert heri. Preparater av disse nye forbindelsene i farmasøytisk akseptable eksipienser og deres anvendelse i terapi og profylakse er tilveiebrakt. Tilveiebrakt er også en forbedret fremgangsmåte for anvendelse av magnesiumalkoksid for fremstilling av startmaterialer og forbindelser for anvendelse heri.",GILEAD SCIENCES INC,PRISBE ERNEST J;;BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/066-973-501-476-599,Abstract,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07F9/6561;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,DISCONTINUED
101,CZ,B6,CZ 304734 B6,088-268-180-584-47X,2014-09-10,2014,CZ 2013310 A,2001-07-20,US 22002100 P,2000-07-21,Process for preparing 9-[2-(phosphonomethoxy)propyl]adenine and 9-[2-(phosphonomethoxy)ethyl]adenine,"In the present invention, there is described an improved process for preparing 9-[2-(phosphonomethoxy)propyl]adenine and 9-[2-(phosphonomethoxy)ethyl]adenine by making use of magnesium alkoxide.",GILEAD SCIENCES,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/088-268-180-584-47X,Granted Patent,no,2,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07F9/6561;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,EXPIRED
102,US,A1,US 2005/0124585 A1,094-427-402-828-269,2005-06-09,2005,US 3125205 A,2005-01-06,US 3125205 A;;US 79869204 A;;US 35420703 A;;US 90956001 A;;US 22002100 P,2000-07-21,Prodrugs of phosphonate nucleotide analogues,"A novel method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided.",BECKER MARK W.;;CHAPMAN HARLAN H.;;CIHLAR TOMAS;;EISENBERG EUGENE J.;;HE GONG-XIN;;KERNAN MICHAEL R.;;LEE WILLIAM A.;;PRISBE ERNEST J.;;ROHLOFF JOHN C.;;SPARACINO MARK L.,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/094-427-402-828-269,Patent Application,yes,0,2,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,514/81;;544/244,0,0,,,,DISCONTINUED
103,CA,C,CA 2725819 C,106-080-170-223-052,2015-09-22,2015,CA 2725819 A,2001-07-20,US 22002100 P;;CA 2416757 A,2000-07-21,PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME,"A novel method is provided for screening prodrugs of methoxyphosphonate nucleotide analogues to identify prodrugs selectively targeting desired tissues with antiviral or antitumor activity. This method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided. Also provided is an improved method for the use of magnesium alkoxide for the preparation of starting materials and compounds for use herein.",GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/106-080-170-223-052,Granted Patent,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07F9/6561;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/00;;C12Q1/18;;C12Q1/70;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,EXPIRED
104,PL,A1,PL 360490 A1,192-505-289-226-971,2004-09-06,2004,PL 36049001 A,2001-07-20,US 22002100 P,2000-07-21,PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME,,GILEAD SCIENCES,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/192-505-289-226-971,Patent Application,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,EXPIRED
105,HR,A8,HR P20160074 A8,019-033-477-034-541,2016-07-29,2016,HR P20160074 A,2016-01-25,US 22002100 P;;US 0123104 W,2000-07-21,PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME,"Prikazana je nova metoda za probiranje prolijekova metoksifosfonatnih analoga nukleotida za identifikaciju prolijekova koji selektivno ciljaju željena tkiva, a imaju antivirusnu ili antitumornu aktivnost. Metoda je vodila identifikaciji novih miješanih ester-amidata PMPA za retrovirusnu ili hepadnavirusnu terapiju, uključujući spojeve strukture (5a) koji imaju supstituente koji su ovdje definirani. Prikazani su pripravci tih novih spojeva u farmacetuski prihvatljivim ekscipijensima i njihova upotreba u terapiji ili profilaksi. Također je prikazana poboljšana metoda za upotrebu magenzijevog alkoksida za pripravu polaznih materijala i spojeva za ovdašnju upotrebu.",GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/019-033-477-034-541,Amended Application,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07F9/6561;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,EXPIRED
106,IS,B,IS 2985 B,008-207-828-456-77X,2017-09-15,2017,IS 6689 A,2003-01-17,US 0123104 W;;US 22002100 P,2000-07-21,Forlyf af fosfónat-kirna hliðstæðum og aðferð til að velja og búa þær til,,GILEAD SCIENCES INC,MARK W BECKER;;HARLAN H CHAPMAN;;TOMAS CIHLAR;;EUGENE J EISENBERG;;GONG-XIN HE;;MICHAEL R KERNAN;;WILLIAM A LEE;;ERNEST J PRISBE;;JOHN C ROHLOFF;;MARK L SPARACINO,,https://lens.org/008-207-828-456-77X,Granted Patent,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07F9/6561;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,EXPIRED
107,NZ,A,NZ 523438 A,051-724-035-929-674,2005-02-25,2005,NZ 52343801 A,2001-07-20,US 22002100 P;;US 0123104 W,2000-07-21,Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same,A compound of general formula (1) where Ra is H or methyl; a composition comprising the compound and a pharmaceutically effective excipient; and the use of the compound in the preparation of a medicament for antiviral therapy or prophylaxis in a subject in need of such therapy or prophylaxis.,GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/051-724-035-929-674,Patent Application,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,DISCONTINUED
108,HR,B1,HR P20160074 B1,021-803-037-091-956,2021-09-03,2021,HR P20160074 A,2016-01-25,US 22002100 P;;US 0123104 W,2000-07-21,PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME,"Prikazana je nova metoda za probiranje prolijekova metoksifosfonatnih analoga nukleotida za identifikaciju prolijekova koji selektivno ciljaju željena tkiva, a imaju antivirusnu ili antitumornu aktivnost. Metoda je vodila identifikaciji novih miješanih ester-amidata PMPA za retrovirusnu ili hepadnavirusnu terapiju, uključujući spojeve strukture (5a) koji imaju supstituente koji su ovdje definirani. Prikazani su pripravci tih novih spojeva u farmacetuski prihvatljivim ekscipijensima i njihova upotreba u terapiji ili profilaksi. Također je prikazana poboljšana metoda za upotrebu magenzijevog alkoksida za pripravu polaznih materijala i spojeva za ovdašnju upotrebu. <BR/><IMAGE NAME=""20160074_01"" TYPE=""JPG"" CENTER=TRUE/>A novel method is provided for screening prodrugs of methoxyphosphonate nucleotide analogues to identify prodrugs selectively targeting desired tissues with antiviral or antitumor activity. This method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided. Also provided is an improved method for the use of magnesium alkoxide for the preparation of starting materials and compounds for use herein.",GILEAD SCIENCES INC,ROHLOFF JOHN C;;BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;SPARACINO MARK L,,https://lens.org/021-803-037-091-956,Granted Patent,no,2,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07F9/6561;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,2,2,051-337-710-931-250;;038-484-273-520-697,10.1002/(sici)1099-0682(200005)2000:5<987::aid-ejic987>3.0.co;2-s;;10.1021/ol990246c,"BARREIRA TERESA ET AL, ""Standard molar enthalpies of formation of Mg and Ca alkoxides"", EUROPEAN JOURNAL OF INORGANIC CHEMISTRY, WILEY-VCH VERLAG, WEINHEIM, DE, (01.01.2000.), ISSN 1434-1948, 987 – 991 str.;;MASCARENHAS C M ET AL, ""Simple metal alkoxides as effective catalysts for the Hetero-Aldol-Tishchenko reaction"", ORGANIC LETTERS, AMERICAN CHEMICAL SOCIETY, US, (01.01.1999.), vol. 1, no. 9, ISSN 1523-7060, 1427 – 1429 str.",EXPIRED
109,PT,T,PT 2682397 T,053-975-556-283-644,2017-05-31,2017,PT 13164300 T,2001-07-20,US 22002100 P,2000-07-21,PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME,,GILEAD SCIENCES INC,MARK W BECKER;;HARLAN H CHAPMAN;;TOMAS CIHLAR;;EUGENE J EISENBERG;;GONG-XIN HE;;MICHAEL R KERNAN;;WILLIAM A LEE;;ERNEST J PRISBE;;JOHN C ROHLOFF;;MARK L SPARACINO,,https://lens.org/053-975-556-283-644,Patent Application,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07F9/6561;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,PENDING
110,CZ,B6,CZ 304886 B6,036-603-610-203-374,2015-01-07,2015,CZ 2003413 A,2001-07-20,US 22002100 P,2000-07-21,"Medicament precursors based on phosphonate nucleotide analogs, processes of their selection and preparation","A novel method is provided for screening prodrugs based on methoxyphosphonate nucleotide analogues to identify prodrugs selectively targeting desired tissues with antiviral or antitumor activity. This method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided",GILEAD SCIENCES,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/036-603-610-203-374,Granted Patent,no,5,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07H21/00;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,EXPIRED
111,JP,A,JP 2011140506 A,140-630-096-953-888,2011-07-21,2011,JP 2011050854 A,2011-03-08,US 22002100 P,2000-07-21,PRODRUG OF PHOSPHONATE NUCLEOTIDE ANALOG AND METHOD FOR SELECTING AND PRODUCING THE SAME,"<P>PROBLEM TO BE SOLVED: To provide a new method for screening the prodrugs of methoxyphosphonate nucleotide analogs for identifying the prodrugs selectively targeting desired tissues with antiviral activity or antitumor activity. <P>SOLUTION: This method for selecting and producing the prodrugs is provided by inducing identification of the new mixed ester amidates of PMPA ä9-[2-(phosphonomethoxy)propyl]adenine} for treating retrovirus or hepadnavirus, and the ester amidates of the PMPA contain a compound of a structure (5a) having substituent groups prescribed in this specification. The composition of these new compounds in a pharmaceutically acceptable excipient and use of them in treatment and prophylaxis are provided. Further, the improved method for using a magnesium alkoxide for preparing a starting material and the compounds for the uses described in the specification is provided. <P>COPYRIGHT: (C)2011,JPO&INPIT",GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/140-630-096-953-888,Patent Application,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07F9/6561;;A61K31/664;;A61K31/675;;A61P1/16;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C07B61/00;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,DISCONTINUED
112,US,A1,US 2004/0018150 A1,182-413-941-685-474,2004-01-29,2004,US 33310703 A,2003-01-14,US 33310703 A;;US 0123104 W;;US 22002100 P,2000-07-21,Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same,"
    A novel method is provided for screening prodrugs of methoxyphosphonate nucleotide analogues to identify prodrugs selectively targeting desired tissues with antiviral or antitumor activity. This method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5 a ) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided. Also provided is an improved method for the use of magnesium alkoxide for the preparation of starting materials and compounds for use herein. 
",BECKER MARK W.;;CHAPMAN HARLAN H.;;CIHLAR TOMAS;;EISENBERG EUGENE J.;;HE GONG-XI;;KERNAN MICHAEL R.;;LEE WILLIAM A.;;PRISBE ERNEST J.;;ROHLOFF JOHN C.;;SPARACINO MARK L.,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XI;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/182-413-941-685-474,Patent Application,yes,0,10,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,424/9.1;;435/5;;514/45;;514/49,0,0,,,,DISCONTINUED
113,HR,A2,HR P20160074 A2,020-069-968-084-009,2016-03-11,2016,HR P20160074 A,2016-01-25,US 22002100 P;;US 0123104 W,2000-07-21,PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME,"Prikazana je nova metoda za probiranje prolijekova metoksifosfonatnih analoga nukleotida za identifikaciju prolijekova koji selektivno ciljaju željena tkiva, a imaju antivirusnu ili antitumornu aktivnost. Metoda je vodila identifikaciji novih miješanih ester-amidata PMPA za retrovirusnu ili hepadnavirusnu terapiju, uključujući spojeve strukture (5a) koji imaju supstituente koji su ovdje definirani. Prikazani su pripravci tih novih spojeva u farmacetuski prihvatljivim ekscipijensima i njihova upotreba u terapiji ili profilaksi. Također je prikazana poboljšana metoda za upotrebu magenzijevog alkoksida za pripravu polaznih materijala i spojeva za ovdašnju upotrebu.",GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/020-069-968-084-009,Patent Application,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07F9/6561;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,EXPIRED
114,CZ,A3,CZ 2003413 A3,087-250-502-904-738,2003-12-17,2003,CZ 2003413 A,2001-07-20,US 22002100 P,2000-07-21,"Medicament precursors based on phosphonate nucleotide analogs, processes of their selection and preparation",,GILEAD SCIENCES,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/087-250-502-904-738,Patent Application,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,EXPIRED
115,HU,B1,HU 230960 B1,127-613-989-530-940,2019-06-28,2019,HU P0301307 A,2001-07-20,US 22002100 P;;US 0123104 W,2000-07-21,Prodrugs of phosphonate nucleotide analogues and compositions thereof,,GILEAD SCIENCES,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST JOSEPH;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/127-613-989-530-940,Granted Patent,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07F9/6561;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,ACTIVE
116,SI,T1,SI 2682397 T1,127-528-864-126-083,2017-08-31,2017,SI 200131061 T,2001-07-20,US 22002100 P;;EP 13164300 A,2000-07-21,Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same,,GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/127-528-864-126-083,Granted Patent,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07F9/00;;A61K31/00;;A61K31/664;;A61K31/675;;A61P31/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P35/00;;C07F9/6561;;C07H19/00;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/00;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,EXPIRED
117,US,B2,US 7803788 B2,159-673-940-029-608,2010-09-28,2010,US 11082908 A,2008-04-28,US 11082908 A;;US 79869204 A;;US 35420703 A;;US 90956001 A;;US 22002100 P,2000-07-21,Prodrugs of phosphonate nucoleotide analogues,"A novel method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided.",GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,GILEAD SCIENCES INC (2001-08-21),https://lens.org/159-673-940-029-608,Granted Patent,yes,39,73,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,A61K31/675;;A61K31/664;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,514/81;;514/7;;514/85;;435/4;;435/9.1,36,26,178-454-029-156-829;;044-043-608-046-952;;111-581-607-830-645;;046-005-969-838-205;;044-156-633-677-511;;032-783-350-997-408;;135-968-084-585-464;;145-860-815-730-097;;067-062-912-650-351;;077-636-046-622-946;;150-408-841-838-288;;049-518-278-714-572;;007-958-707-068-237;;004-388-994-921-489;;100-773-165-636-796;;016-644-697-707-318;;076-745-635-479-005;;025-829-844-592-125;;008-811-925-472-828;;060-516-842-835-850;;000-333-154-695-235;;118-639-478-179-932;;121-013-526-975-25X;;058-117-624-049-237;;068-575-200-141-698;;040-895-920-632-600,10.1135/cccc19942127;;10.1016/s0149-2918(98)80031-3;;9522101;;11674802;;10.1021/jo990205u;;7606391;;10.1016/0968-0896(95)00022-9;;11563079;;10.1081/ncn-100002338;;16979654;;10.1016/j.jmb.2006.07.073;;10931658;;10.1016/s1359-6446(00)01540-3;;10.1177/095632029800900402;;10.1046/j.1469-0691.2003.00570.x;;12667250;;10.1097/00001432-200202000-00002;;11964899;;10.2174/1381612033453668;;14529543;;10.1007/bf02443422;;10.1016/0169-409x(95)00111-j;;pmc105777;;10.1128/aac.42.5.1200;;9593150;;10.1021/jo990085q;;10.1016/s0960-894x(00)80395-9;;10.1016/0166-3542(92)90026-2;;1642482;;10.1016/0014-5793(94)00776-4;;8076677;;8478904;;10.1021/jm00060a013;;10571273;;10.1023/a:1018945713623;;pmc105507;;9517941;;10.1128/aac.42.3.612;;10514282;;10.1021/jm9807104;;10.1021/jm00038a015;;8021925;;10.1021/jm00186a001;;7005447;;10.1021/op980019a;;11153141;;10.1007/s004320000165,"Aarons et al., ""Pharmacokinetic Evaluation of Site-Specific Drug Delivery Systems"", 12:121-126, Novel Drug Delivery and Its TherapeuticApplication (John Wiley & Sons), 1989.;;Alexander et al. (1994) ""Prodrugs of Analogs of Nucleic acid components,"" Collect Czech Chem Comm. 59:2127-2165.;;Banerjee et al., ""Design of Prodrugs Based on Enzyme-Substrate Specificity"", Chapter 2, pp. 118-121, Design of Prodrugs, 1985.;;Beach et al. (1998) ""Chemotherapeutic agents for human immuodeficiency virus infection: Mechanism of action, pharmacokinetics, metabolism, and adverse reactions,"" Clinical Thereapeutics 20(1):2-25.;;Brunel et al., ""A Practical Method for the Large-Scale Synthesis of Diastereomerically Pure (2R,5S)-3-Phenyl-2-(8-quinolinoxy)-1,3-diaza-2-phosphabicycIo-[3.3.0]-oct- ane Ligand (Quiphos)"", 64:8940-8942, J Org Chem, 1999.;;Bundgaard (1991) ""Novel Chemical Approaches in Prodrug Design,"" Drugs of the Future 16(5):443-458.;;Bundgaard, H., ""Design of Prodrugs: Bioreversible Derivatives for Various Functional Groups and Chemical Entities"", Chapter 1, pp. 70-92, Design of Prodrugs, 1985.;;Camp, N.P. et al. (1995) ""Synthesis of Peptide Analogues Containing Phosphonamidate Methyl Ester Functionality: HIV-1 Proteinase Inhibitors Possessing Unique Cell Uptake Properties,"".;;Chapman et al., ""Practical Synthesis, Separation, and Stereochemical Assignment of the PMPA Pro-Drug GS-7340"", 20(4-7):621-628, Nucleosides, Nucleotides & Nucleic Acids, 2001.;;Cihlar et al. (2006) ""Suppression of HIV-1 Protease Inhibitor Resistance by Phosphonate-mediated solvent anchoring,"" Journal of Molecular Biology 363(3):635-647.;;Connors, T.A., ""Prodrugs in Cancer Chemotherapy"", Chapter 9, pp. 291-316, Design of Prodrugs, 1985.;;Eddershaw et al. (2000) ""ADME/PK as part of a retional approach to drug discovery"" Drug Discovery Today 5(9):409-414.;;Franchetti, P., et al. (1998) ""Potent and Selective Inhibitors of Human Immunodeficiency Virus Protease Structurally Related to L-94,746,"" Antiviral Chemistry & Chemotherapy 9(4):303-309.;;Gulick (2003) ""New Antiviral Drugs,"" Clinical Microbiology amd Infectious Diseases 9:186-193.;;Hoggard et al. (2002) ""Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transporter molecules,"" Current Opinion in Infectious Diseases 15(1):3-8.;;Holy (2003) ""Phosphonomethoxyalkyl analogs of Nucleotides,"" Current Pharmaceutical Design 9:2567-2592.;;Jones, Geraint, ""Decreased Toxicity and Adverse Reactions via Prodrugs"", Chapter 6:pp. 199-241, Design of Prodrugs, 1985.;;Kiso et al. (1999) ""Design of smalll peptidominetic HIV-1 Protease Inhibitors and Prodrug Forms,:"" 6(5/6):275-281.;;Krise et al. (1996) ""Prodrugs of Phosphates, Phosphanates, and Phosphinates,"" Advanced Drug Delivery Reviews 19(2):287-310.;;Kubota et al. (1998) ""Novel inhibitory effects of gamma-glutamyicysteine ethyl ester against human immunodeficiency virus type 1 production and propagation,"" Antimicrobial Agents and Chemotherapy 42(5):1200-1206.;;Kumar et al., ""Heterocalixarenes. 1. Calix[2]uracil[2]arene: Synthesis, X-ray Structure, Conformational Analysis, and Binding Character"", 64:7717-7726, J Org Chem, 1999.;;Lee et al.(2002) 'In Vivo and In Vitro Characterization of GS 7340, and isopropylalaninyl phnyl ester prodrug of Tenofovir: selective intracellular activation of GS 7340 leads to preferential distribution in lymphatic tissues. 9th Conference of Retroviruses and Opporunistic infections, Abstract No. 384T.;;McGuigan et al., ""Aryl Phosphate Derivatives of AZT Inhibit HIV Replication in Cells Where the Nucleoside is Poorly Active"", 2(7):701-704, Bioorg Med Chem Lett, 1992.;;McGuigan et al., ""Aryl phosphate derivatives of AZT retain activity against HIV1 in cell lines which are resistant to the action of AZT"", 17:311-321, Antiviral Res, 1992.;;McGuigan et al., ""Certain phosphoramidate derivatives of dideoxy uridine (ddU) are active against HIV and successfully by-pass thymidine kinase"", 351:11-14, FEBS, 1994.;;McGuigan et al., ""Intracellular Delivery of Bioactive AZT Nucleotides by Aryl Phosphate Derivatives of AZT"", 36:1048-1052, J Med Chem, 1993.;;McGuigan et al., ""Phosphoramidates as potent prodrugs of anti-HIV nucleotides: studies in the amino region"", 7(1):31-36, Antiviral Chem & Chemo, 1996.;;Notari, Robert E., ""Pharmacokinetic Aspects of Prodrug Design and Evaluation"", Chapter 3, pp. 135-156, Design of Prodrugs, 1985.;;Oliyai et al., ""Aryl Ester Prodrugs of Cyclic HPMPC. I: Physicochemical Characterization and In Vitro Biological Stability"", 16(11):1687-1693, Pharm Res, 1999.;;Robbins et al. (1998) ""Anti-Human Immunodeficiency Virus Activity and Cellular Metabolism of a Potential Prodrug of the Acyclic Nucleoside Phosphonate 9-R-(2-Phosphonomethoxypropyl) Adenine (PMPA), Bis (Isopropyloxymethylcarbonyl) PMPA"" Antimicrobial Agents and Chemotherapy 42(3):612-617.;;Siddiqui et al., ""Design and Synthesis of Lipophillic Phosphoramidate d4T-MP Prodrugs Expressing High Potency Against HIV in Cell Culture: Structural Determinants for in Vitro Activity and QSAR"", 42:4122-4128, Pharm Res, 1999.;;Starrett et al., ""Synthesis, Oral Bioavailability Determination, and in Vitro Evaluation of Prodrugs of the Antiviral Agent 9-[2-(Phosphonomethoxy)ethyl]adenine (PMEA)"", 37:1857-1864, J Med Chem, 1994.;;Stella et al., ""Site-Specific Drug Delivery via Prodrugs"", Chapter 5, pp. 177-198, Design of Prodrugs, 1985.;;Stella, Valentino J., ""Prodrugs and Site-Specific Drug Delivery"", 23(12):1275-1282, J Med Chem, Dec. 1980.;;Strube et al., ""Comparison of Batch Elution and Continuous Simulated Moving Bed Chromatography"", 2:305-319, Organic Process Research & Development, 1998.;;Zimra et al. (2000) ""Uptake of pivaloyloxymethyl butyrate into leukemic esterase-catalyzed hydrolysis,"" Journal of Cancer Research and Clinical Oncology 126(12):693-698.",EXPIRED
118,NO,D0,NO 20030270 D0,196-523-888-883-37X,2003-01-20,2003,NO 20030270 A,2003-01-20,US 22002100 P;;US 0123104 W,2000-07-21,"Prodroger av fosfonatnukleotidanaloger, og fremgangsmåter for utvelgelse ogfremstilling av disse",,GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/196-523-888-883-37X,Patent Application,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,EXPIRED
119,CA,C,CA 2416757 C,053-062-431-413-875,2011-02-15,2011,CA 2416757 A,2001-07-20,US 22002100 P;;US 0123104 W,2000-07-21,PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME,"A novel method is provided for screening prodrugs of methoxyphosphonate nucleotide analogues to identify prodrugs selectively targeting desired tissues with antiviral or antitumor activity. This method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided. Also provided is an improved method for the use of magnesium alkoxide for the preparation of starting materials and compounds for use herein.",GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/053-062-431-413-875,Granted Patent,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07F9/6561;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/02;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,EXPIRED
120,US,A1,US 2006/0024659 A1,094-671-828-436-224,2006-02-02,2006,US 78549704 A,2004-02-24,US 78549704 A;;US 90956001 A;;US 22002100 P,2000-07-21,Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same,"A novel method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided.",GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/094-671-828-436-224,Patent Application,yes,25,5,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C12Q1/00;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;C12Q1/70;;G01N33/15;;G01N33/50;;G01N33/53,435/4;;435/5,0,0,,,,DISCONTINUED
121,IS,A,IS 6689 A,110-585-935-522-002,2003-01-17,2003,IS 6689 A,2003-01-17,US 0123104 W;;US 22002100 P,2000-07-21,Forlyf af fosfónat-kirna hliðstæðum og aðferð tilað velja og búa þær til,,GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/110-585-935-522-002,Patent Application,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,EXPIRED
122,AU,A1,AU 2005/225039 A1,083-369-077-465-262,2005-11-10,2005,AU 2005/225039 A,2005-10-18,US 0123104 W;;US 22002100 P;;AU 2001/282941 A;;AU 2005/225039 A,2000-07-21,Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same,,GILEAD SCIENCES INC,KERNAN MICHAEL R;;ROHLOFF JOHN C;;CHAPMAN HARLAN H;;LEE WILLIAM A;;SPARACINO MARK L;;HE GONG-XIN;;BECKER MARK W;;PRISBE ERNEST J;;EISENBERG EUGENE J;;CIHLAR TOMAS,,https://lens.org/083-369-077-465-262,Patent Application,no,0,1,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,EXPIRED
123,US,A1,US 2005/0124584 A1,145-918-791-798-52X,2005-06-09,2005,US 3125105 A,2005-01-06,US 3125105 A;;US 79869204 A;;US 35420703 A;;US 90956001 A;;US 22002100 P,2000-07-21,Prodrugs of phosphonate nucleotide analogues,"A novel method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided.",BECKER MARK W.;;CHAPMAN HARLAN H.;;CIHLAR TOMAS;;EISENBERG EUGENE J.;;HE GONG-XIN;;KERNAN MICHAEL R.;;LEE WILLIAM A.;;PRISBE ERNEST J.;;ROHLOFF JOHN C.;;SPARACINO MARK L.,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/145-918-791-798-52X,Patent Application,yes,0,2,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,514/81;;544/244,0,0,,,,DISCONTINUED
124,BR,B8,BR PI0112646 B8,155-319-363-817-649,2021-05-25,2021,BR 0112646 A,2001-07-20,US 22002100 P;;US 0123104 W,2000-07-21,pró-fármacos de análogos de nucleotídeo de fosfonato e composições que as compreende,"""pró-drogas de análogos de nucleotídeo de fosfonato e métodos para selecionar e preparar as mesmas"". a presente invenção refere-se a método que é fornecido para avaliar pró-drogas de análogos de nucleotídeo de metoxifosfonato para identificar pró-drogas seletivamente alvejando tecidos desejados com atividade antiviral ou antitumor. este método tem induzido à identificação de novos éster-amidatos misturados de pmpa para terapia retroviral ou hepadnaviral, incluindo compostos de estrutura (5a) tendo grupos substituintes como aqui definido. composições destes compostos em excipientes farmaceuticamente aceitáveis e seu uso em terapia e profilaxia são fornecidas. também fornecido é um método para o uso de alcóxido de magnésio para a preparação de materiais de partida e compostos para uso aqui.",GILEAD SCIENCES INC,ERNEST J PRISBE;;EUGENE J EISENBERG;;GONG-XIN HE;;HARLAN H CHAPMAN;;JOHN C ROHLOFF;;MARK L SPARACINO;;MARK W BECKER;;MICHAEL R KERNAN;;TOMAS CIHLAR;;WILLIAM A LEE,,https://lens.org/155-319-363-817-649,Amended Patent,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07H21/00;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,EXPIRED
125,BR,B1,BR PI0112646 B1,167-607-025-786-159,2017-10-17,2017,BR 0112646 A,2001-07-20,US 22002100 P;;US 0123104 W,2000-07-21,pró-fármacos de análogos de nucleotídeo de fosfonato e composições que as compreende,"""pró-drogas de análogos de nucleotídeo de fosfonato e métodos para selecionar e preparar as mesmas"". a presente invenção refere-se a método que é fornecido para avaliar pró-drogas de análogos de nucleotídeo de metoxifosfonato para identificar pró-drogas seletivamente alvejando tecidos desejados com atividade antiviral ou antitumor. este método tem induzido à identificação de novos éster-amidatos misturados de pmpa para terapia retroviral ou hepadnaviral, incluindo compostos de estrutura (5a) tendo grupos substituintes como aqui definido. composições destes compostos em excipientes farmaceuticamente aceitáveis e seu uso em terapia e profilaxia são fornecidas. também fornecido é um método para o uso de alcóxido de magnésio para a preparação de materiais de partida e compostos para uso aqui.",GILEAD SCIENCES INC,ERNEST J PRISBE;;EUGENE J EISENBERG;;GONG-XIN HE;;HARLAN H CHAPMAN;;JOHN C ROHLOFF;;MARK L SPARACINO;;MARK W BECKER;;MICHAEL R KERNAN;;TOMAS CIHLAR;;WILLIAM A LEE,,https://lens.org/167-607-025-786-159,Granted Patent,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07H21/00;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,EXPIRED
126,TR,T2,TR 200300055 T2,016-185-629-557-979,2004-12-21,2004,TR 200300055 T,2001-07-20,US 22002100 P,2000-07-21,"Fosfonat nükleotid analoglarının ön ilaçları, bunların seçimi-yapımı için yöntemler","Antiviral ya da antitümör etkinin istendigi dokulari selektif olarak hedef alan ön ilaçlarin belirlenmesi için metoksifosfonat nükleotit analoglarinin ön ilaçlarinin taranmasindan olusan yeni bir yöntem sunulmaktadir. Bu yöntem, burada tanimlanan ikame gruplarini tasiyan formül yapisina (5a) sahip bilesikler de dahil olmak üzere, retroviral ya da hepadnaviral tedavi için yeni PMPA ester-amidat karisiminin tanimlanmasini saglamistir. Farmakolojik olarak kabul edilebilir katki maddeleri içindeki bu yeni bilesiklerin bilesimleri ve bunlarin tedavide ve profilakside kullanimi sunulmaktadir. Bunun yani sira, baslangiç maddelerinin ve burada kullanilmak üzere bilesiklerin hazirlanmasinda magnezyum alkoksit kullanimi için gelismis bir yöntem sunulmaktadir.Formül (5a)",GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/016-185-629-557-979,Patent Application,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,PENDING
127,CA,A1,CA 2725819 A1,070-424-315-371-120,2002-01-31,2002,CA 2725819 A,2001-07-20,US 22002100 P;;CA 2416757 A,2000-07-21,PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME,,GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/070-424-315-371-120,Patent Application,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C12Q1/02;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;C12Q1/70;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,EXPIRED
128,CA,A1,CA 2416757 A1,063-190-056-742-00X,2002-01-31,2002,CA 2416757 A,2001-07-20,US 22002100 P;;US 0123104 W,2000-07-21,PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME,"A novel method is provided for screening prodrugs of methoxyphosphonate nucleotide analogues to identify prodrugs selectively targeting desired tissues with antiviral or antitumor activity. This method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substitue nt groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided. Also provided is an improved method for the use of magnesium alkoxide for the preparation of starting materials and compounds f or use herein.",GILEAD SCIENCES INC,PRISBE ERNEST J;;LEE WILLIAM A;;KERNAN MICHAEL R;;EISENBERG EUGENE J;;CIHLAR TOMAS;;BECKER MARK W;;HE GONG-XIN;;ROHLOFF JOHN C;;SPARACINO MARK L;;CHAPMAN HARLAN H,,https://lens.org/063-190-056-742-00X,Patent Application,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,EXPIRED
129,ES,T3,ES 2536972 T3,086-548-511-323-367,2015-06-01,2015,ES 01961695 T,2001-07-20,US 22002100 P;;US 0123104 W,2000-07-21,Profármacos de análogos de nucleótidos de fosfonato y métodos para seleccionar y preparar los mismos,Un compuesto de estructura (6):**Fórmula** o sus sales y solvatos.,GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/086-548-511-323-367,Granted Patent,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07F9/6561;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,EXPIRED
130,AU,B2,AU 2001/282941 B2,112-808-733-272-63X,2006-04-27,2006,AU 2001/282941 A,2001-07-20,US 22002100 P;;US 0123104 W,2000-07-21,Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same,,GILEAD SCIENCES INC,SPARACINO MARK L;;HE GONG-XIN;;PRISBE ERNEST J;;CIHLAR TOMAS;;CHAPMAN HARLAN H;;ROHLOFF JOHN C;;EISENBERG EUGENE J;;KERNAN MICHAEL R;;BECKER MARK W;;LEE WILLIAM A,,https://lens.org/112-808-733-272-63X,Granted Patent,no,2,1,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07H21/00;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,ACTIVE
131,WO,A3,WO 2002/008241 A3,158-594-320-164-639,2002-08-29,2002,US 0123104 W,2001-07-20,US 22002100 P,2000-07-21,PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME,"A novel method is provided for screening prodrugs of methoxyphosphonate nucleotide analogues to identify prodrugs selectively targeting desired tissues with antiviral or antitumor activity. This method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided. Also provided is an improved method for the use of magnesium alkoxide for the preparation of starting materials and compounds for use herein.",GILEAD SCIENCES INC;;BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/158-594-320-164-639,Search Report,yes,3,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,2,2,118-639-478-179-932;;044-156-633-677-511,10514282;;10.1021/jm9807104;;11563079;;10.1081/ncn-100002338,"SIDDIQUI A Q ET AL: ""DESIGN AND SYNTHESIS OF LIPOPHILIC PHOSPHORAMIDATE D4T-MP PRODRUGS EXPRESSING HIGH POTENCY AGAINST HIV IN CELL CULTRURE: STRUCTURAL DETERMINANTS FOR IN VITRO ACTIVITY AND QSAR"", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 42, no. 20, 1999, pages 4122 - 4128, XP000999173, ISSN: 0022-2623;;H. CHAPMAN ET AL.: ""Practical synthesis, separation, and stereochemical assignment of the PMPA pro-drug GS-7340"", NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS, vol. 20, 2001, pages 621 - 628, XP002202043",PATENTED
132,JP,A,JP 2009062383 A,176-837-398-526-261,2009-03-26,2009,JP 2008267991 A,2008-10-16,US 22002100 P,2000-07-21,PRODRUG OF PHOSPHONATE NUCLEOTIDE ANALOGUE AND METHOD FOR SELECTING AND PREPARING THE SAME,"<P>PROBLEM TO BE SOLVED: To provide a new method for screening prodrugs of methoxyphosphonate nucleotide analogues to identify prodrugs selectively targeting desired tissues having antiviral activity or antitumor activity. <P>SOLUTION: The method has led to the identification of new mixed ester-amidates of PMPA for retroviral therapy or hepadnaviral therapy, and the ester-amidates of PMPA includes compounds of a structure (5a) having substituent groups as defined herein. Compositions of the new compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided. Also provided is an improved method for the use of magnesium alkoxide for the preparation of starting materials and compounds for use herein. <P>COPYRIGHT: (C)2009,JPO&INPIT",GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/176-837-398-526-261,Patent Application,no,2,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;C07B53/00;;C07B61/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,INACTIVE
133,ZA,B,ZA 200210271 B,014-877-619-638-024,2003-12-31,2003,ZA 200210271 A,2002-12-19,US 22002100 P;;US 0123104 W,2000-07-21,PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME,,GILEAD SCIENCES INC,MARK L SPARACINO;;JOHN C ROHLOFF;;ERNEST J PRISBE;;EUGENE J EISENBERG;;HARLAN H CHAPMAN;;WILLIAM A LEE;;MICHAEL R KERNAN;;GONG XIN HE;;TOMAS CIHLAR;;MARK W BECKER,,https://lens.org/014-877-619-638-024,Granted Patent,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,EXPIRED
134,US,A1,US 2003/0219727 A1,063-853-099-466-812,2003-11-27,2003,US 35420703 A,2003-01-28,US 35420703 A;;US 90956001 A;;US 22002100 P,2000-07-21,Prodrugs of phosphonate nucleotide analogues,"
    A novel method is provided for screening prodrugs of methoxyphosphonate nucleotide analogues to identify prodrugs selectively targeting desired tissues with antiviral or antitumor activity. This method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) 

   having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided. Also provided is an improved method for the use of magnesium alkoxide for the preparation of starting materials and compounds for use herein. 
",BECKER MARK W.;;CHAPMAN HARLAN H.;;CIHLAR TOMAS;;EISENBERG EUGENE J.;;HE GONG-XIN;;KERNAN MICHAEL R.;;LEE WILLIAM A.;;PRISBE ERNEST J.;;ROHLOFF JOHN C.;;SPARACINO MARK L.,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/063-853-099-466-812,Patent Application,yes,0,17,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,435/5;;435/6,0,0,,,,DISCONTINUED
135,NO,L,NO 20131717 L,066-283-898-718-526,2003-03-20,2003,NO 20131717 A,2013-12-20,US 22002100 P;;US 0123104 W,2000-07-21,"Prodroger av fosfonatnukleotidanaloger, og fremgangsmåter for utvelgelse og fremstilling av disse","En ny fremgangsmåte er tilveiebrakt for screening av prodroger av metoksyfosfonatnukleotidanaloger for å identifisere prodroger som selektivt er målrettet mot ønskede vev, med antiviral eller antitumoraktivitet. Denne fremgangsmåten har ført til identifisering av nye blandede esteramidater av PMPA for retroviral eller hepadnaviral behandling, omfattende forbindelser ifølge struktur (5a) som har substituentgrupper som er definert heri. Preparater av disse nye forbindelsene i farmasøytisk akseptable eksipienser og deres anvendelse i terapi og profylakse er tilveiebrakt. Tilveiebrakt er også en forbedret fremgangsmåte for anvendelse av magnesiumalkoksid for fremstilling av startmaterialer og forbindelser for anvendelse heri.",GILEAD SCIENCES INC,PRISBE ERNEST J;;BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/066-283-898-718-526,Abstract,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07H19/10;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,PENDING
136,AU,A,AU 2001/082941 A,127-054-512-425-694,2002-02-05,2002,AU 2001/082941 A,2001-07-20,US 22002100 P;;US 0123104 W,2000-07-21,Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same,,GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/127-054-512-425-694,Patent Application,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,PENDING
137,PT,E,PT 1301519 E,136-239-238-805-826,2015-06-11,2015,PT 01961695 T,2001-07-20,US 22002100 P,2000-07-21,PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME,,GILEAD SCIENCES INC,PRISBE ERNEST J;;ROHLOFF JOHN C;;HE GONG-XIN;;LEE WILLIAM A;;BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;KERNAN MICHAEL R;;SPARACINO MARK L,,https://lens.org/136-239-238-805-826,Granted Patent,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,A61K31/664;;C07F9/6561;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,EXPIRED
138,US,A1,US 2005/0009043 A1,051-166-274-127-878,2005-01-13,2005,US 79869204 A,2004-03-11,US 79869204 A;;US 35420703 A;;US 90956001 A;;US 22002100 P,2000-07-21,Prodrugs of phosphonate nucleotide analogues,"A novel method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided.",GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,GILEAD SCIENCES INC (2001-08-21),https://lens.org/051-166-274-127-878,Patent Application,yes,23,15,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,435/6;;X5303;;544/243;;544/244;;514/7;;514/81,0,0,,,,EXPIRED
139,CA,A1,CA 2893174 A1,059-300-412-728-977,2002-01-31,2002,CA 2893174 A,2001-07-20,US 22002100 P;;CA 2725819 A,2000-07-21,PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME,,GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/059-300-412-728-977,Patent Application,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C12Q1/00;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;C12Q1/70;;C40B30/06;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,DISCONTINUED
140,NO,L,NO 20120466 L,074-510-092-351-144,2003-03-20,2003,NO 20120466 A,2012-04-23,US 22002100 P;;US 0123104 W,2000-07-21,"Prodroger av fosfonatnukleotidanaloger, og fremgangsmater for utvelgelse og fremstilling av disse","En ny fremgangsmåte er tilveiebrakt for screening av prodroger av metoksyfosfonatnukleotidanalogerfor å identifisere prodroger som selektivt er målrettet mot ønskede vev, med antiviral eller antitumoraktivitet. Denne fremgangsmåten har ført til identifisering av nye blandede esteramidater av PMPA for retroviral eller hepadnaviral behandling, omfattende forbindelser ifølge struktur (5a) som har substituentgrupper som er definert heri. Preparater av disse nye forbindelsene i farmasøytisk akseptable eksipienser og deres anvendelse i terapi og profylakse er tilveiebrakt. Tilveiebrakt er også en forbedret fremgangsmåte for anvendelse av magnesiumalkoksid for fremstilling av startmaterialer og forbindelser for anvendelse heri.",GILEAD SCIENCES INC,PRISBE ERNEST J;;BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/074-510-092-351-144,Abstract,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C12Q1/18;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,DISCONTINUED
141,NO,B1,NO 336718 B1,072-976-608-964-980,2015-10-26,2015,NO 20030270 A,2003-01-20,US 22002100 P;;US 0123104 W,2000-07-21,"Prodroger av fosfonatnukleotidanaloger, preparat derav og dets anvendelse til terapeutisk og profylaktisk behandling av virusinfeksjoner",,GILEAD SCIENCES INC,PRISBE ERNEST J;;BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/072-976-608-964-980,Granted Patent,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07F9/24;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,EXPIRED
142,BR,A,BR 0112646 A,105-299-438-253-536,2003-06-24,2003,BR 0112646 A,2001-07-20,US 22002100 P;;US 0123104 W,2000-07-21,Pró-drogas de análogos de nucleotìdeo de fosfonato e métodos para selecionar e preparar as mesmas,"""PRó-DROGAS DE ANáLOGOS DE NUCLEOTìDEO DE FOSFONATO E MéTODOS PARA SELECIONAR E PREPARAR AS MESMAS"". A presente invenção refere-se a método que é fornecido para avaliar pró-drogas de análogos de nucleotídeo de metoxifosfonato para identificar pró-drogas seletivamente alvejando tecidos desejados com atividade antiviral ou antitumor. Este método tem induzido à identificação de novos éster-amidatos misturados de PMPA para terapia retroviral ou hepadnaviral, incluindo compostos de estrutura (5a) tendo grupos substituintes como aqui definido. Composições destes compostos em excipientes farmaceuticamente aceitáveis e seu uso em terapia e profilaxia são fornecidas. Também fornecido é um método para o uso de alcóxido de magnésio para a preparação de materiais de partida e compostos para uso aqui.",GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/105-299-438-253-536,Patent Application,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,EXPIRED
143,HR,B1,HR P20030047 B1,163-970-988-109-389,2016-02-26,2016,HR P20030047 A,2003-01-24,US 22002100 P;;US 0123104 W,2000-07-21,PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME,"Prikazana je nova metoda za probiranje prolijekova metoksifosfonatnih analoga nukleotida za identifikaciju prolijekova koji selektivno ciljaju željena tkiva, a imaju antivirusnu ili antitumornu aktivnost. Metoda je vodila identifikaciji novih miješanih ester-amidata PMPA za retrovirusnu ili hepadnavirusnu terapiju, uključujući spojeve strukture (5a) koji imaju supstituente koji su ovdje definirani. Prikazani su pripravci tih novih spojeva u farmaceutski prihvatljivim ekscipijensima i njihova upotreba u terapiji ili profilaksi. Također je prikazana poboljšana metoda za upotrebu magnezijevog alkoksida za pripravu polaznih materijala i spojeva za ovdašnju upotrebu.",GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,"GILEAD SCIENCES, INC., US (2016-09-19)",https://lens.org/163-970-988-109-389,Granted Patent,no,3,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07F9/6561;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,2,2,044-156-633-677-511;;118-639-478-179-932,11563079;;10.1081/ncn-100002338;;10514282;;10.1021/jm9807104,"CHAPMAN H, ET AL: ""Practical synthesis, separation, and stereochemical assignment of the PMPA pro-drug GS-7340"", NUCLEOSIDES, NUCLEOTIDES AND NUCLEIC ACIDS., TAYLOR & FRANCIS, US, vol. 20, no. 4-7, 1 January 2001 (2001-01-01), US, pages 621 - 628, XP002202043, ISSN: 1525-7770, DOI: 10.1081/NCN-100002338;;SIDDIQUI A Q, ET AL.: ""DESIGN AND SYNTHESIS OF LIPOPHILIC PHOSPHORAMIDATE D4T-MP PRODRUGS EXPRESSING HIGH POTENCY AGAINST HIV IN CELL CULTRURE: STRUCTURAL DETERMINANTS FOR IN VITRO ACTIVITY AND QSAR"", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 42, no. 20, 1 January 1999 (1999-01-01), US, pages 4122 - 4128, XP000999173, ISSN: 0022-2623, DOI: 10.1021/jm9807104",EXPIRED
144,AU,B2,AU 2005/225039 B2,031-800-676-622-417,2008-09-25,2008,AU 2005/225039 A,2005-10-18,US 0123104 W;;US 22002100 P;;AU 2001/282941 A;;AU 2005/225039 A,2000-07-21,Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same,,GILEAD SCIENCES INC,KERNAN MICHAEL R;;ROHLOFF JOHN C;;CHAPMAN HARLAN H;;LEE WILLIAM A;;SPARACINO MARK L;;HE GONG-XIN;;BECKER MARK W;;PRISBE ERNEST J;;EISENBERG EUGENE J;;CIHLAR TOMAS,,https://lens.org/031-800-676-622-417,Granted Patent,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07H21/00;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,EXPIRED
145,DK,T3,DK 2682397 T3,080-800-738-737-285,2017-06-19,2017,DK 13164300 T,2001-07-20,US 22002100 P;;EP 01961695 A,2000-07-21,Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same,,GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/080-800-738-737-285,Granted Patent,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07F9/6561;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,EXPIRED
146,DK,T4,DK 1301519 T4,156-056-203-244-217,2021-12-20,2021,DK 01961695 T,2001-07-20,US 22002100 P;;US 0123104 W,2000-07-21,PRODRUGS AF PHOSPHONATNUKLEOTIDANALOGER OG FREMGANGSMÅDER TIL UDVÆLGELSE OG FREMSTILLING HERAF,,GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/156-056-203-244-217,Amended Patent,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07F9/6561;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,EXPIRED
147,AU,C1,AU 2001/282941 C1,169-791-475-016-069,2016-12-22,2016,AU 2001/282941 A,2001-07-20,US 22002100 P;;US 0123104 W,2000-07-21,Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same,,GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/169-791-475-016-069,Amended Patent,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,ACTIVE
148,US,B2,US 7390791 B2,015-151-233-082-848,2008-06-24,2008,US 79869204 A,2004-03-11,US 79869204 A;;US 35420703 A;;US 90956001 A;;US 22002100 P,2000-07-21,Prodrugs of phosphonate nucleotide analogues,"A novel method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided.",GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,GILEAD SCIENCES INC (2001-08-21),https://lens.org/015-151-233-082-848,Granted Patent,yes,34,133,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,A01N43/48;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6512;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,514/44;;514/7;;514/81,20,12,111-581-607-830-645;;044-156-633-677-511;;100-773-165-636-796;;076-745-635-479-005;;016-644-697-707-318;;025-829-844-592-125;;008-811-925-472-828;;060-516-842-835-850;;118-639-478-179-932;;121-013-526-975-25X;;058-117-624-049-237;;068-575-200-141-698,11674802;;10.1021/jo990205u;;11563079;;10.1081/ncn-100002338;;10.1021/jo990085q;;10.1016/0166-3542(92)90026-2;;1642482;;10.1016/s0960-894x(00)80395-9;;10.1016/0014-5793(94)00776-4;;8076677;;8478904;;10.1021/jm00060a013;;10571273;;10.1023/a:1018945713623;;10514282;;10.1021/jm9807104;;10.1021/jm00038a015;;8021925;;10.1021/jm00186a001;;7005447;;10.1021/op980019a,"Aarons et al., ""Pharmacokinetic Evaluation of Site-Specific Drug Delivery Systems"", 12:121-126, Novel Drug Delivery and Its Therapeutic Application (John Wiley & Sons), 1989.;;Banerjee et al., ""Design of Prodrugs Based on Enzyme-Substrate Specificity"", Chapter 2, pp. 118-121, Design of Prodrugs, 1985.;;Brunel et al., ""A Practical Method for the Large-Scale Synthesis of Diastereomerically Pure (2R,5S)-3-Phenyl-2-(8-quinolinoxy)-1,3-diaza-2-phosphabicyclo-[3.3.0]-octane Ligand (QUIPHOS)"", 64:8940-8942, J Org Chem, 1999.;;Bundgaard, H., ""Design of Prodrugs: Bioreversible Derivatives for Various Functional Groups and Chemical Entities"", Chapter 1, pp. 70-92, Design of Prodrugs, 1985.;;Chapman et al., ""Practical Synthesis, Separation, and Stereochemical Assignment of the PMPA Pro-Drug GS-7340"", 20(4-7):621-628, Nucleosides, Nucleotides & Nucleic Acids, 2001.;;Connors, T.A., ""Prodrugs in Cancer Chemotherapy"", Chapter 9, pp. 291-316, Design of Prodrugs, 1985.;;Jones, Geraint, ""Decreased Toxicity and Adverse Reactions via Prodrugs"", Chapter 6:pp. 199-241, Design of Prodrugs, 1985.;;Kumar et al., ""Heterocalixarenes. 1. Calix[2]uracil[2]arene: Synthesis, X-ray Structure, Conformational Analysis, and Binding Character"", 64:7717-7726, J Org Chem, 1999.;;McGuigan et al., ""Aryl phosphate derivatives of AZT retain activity against HIV1 in cell lines which are resistant to the action of AZT"", 17:311-321, Antiviral Res, 1992.;;McGuigan et al., ""Aryl Phosphate Derivatives of AZT Inhibit HIV Replication in Cells Where the Nucleoside is Poorly Active"", 2(7):701-704, Bioorg Med Chem Lett, 1992.;;McGuigan et al., ""Certain phosphoramidate derivatives of dideoxy uridine (ddU) are active against HIV and successfully by-pass thymidine kinase"", 351:11-14, FEBS, 1994.;;McGuigan et al., ""Intracellular Delivery of Bioactive AZT Nucleotides by Aryl Phosphate Derivatives of AZT"", 36:1048-1052, J Med Chem, 1993.;;McGuigan et al., ""Phosphoramidates as potent prodrugs of anti-HIV nucleotides: studies in the amino region"", 7(1):31-36, Antiviral Chem & Chemo, 1996.;;Notari, Robert E., ""Pharmacokinetic Aspects of Prodrug Design and Evaluation"", Chapter 3, pp. 135-156, Design of Prodrugs, 1985.;;Oliyai et al., ""Aryl Ester Prodrugs of Cyclic HPMPC. I: Physicochemical Characterization and In Vitro Biological Stability"", 16(11):1687-1693, Pharm Res, 1999.;;Siddiqui et al., ""Design and Synthesis of Lipophillic Phosphoramidate d4T-MP Prodrugs Expressing High Potency Against HIV in Cell Culture: Structural Determinants for in Vitro Activity and QSAR"", 42:4122-4128, Pharm Res, 1999.;;Starrett et al., ""Synthesis, Oral Bioavailability Determination, and in Vitro Evaluation of Prodrugs of the Antiviral Agent 9-[2-(Phosphonomethoxy)ethyl]adenine (PMEA)"", 37:1857-1864, J Med Chem, 1994.;;Stella et al., ""Site-Specific Drug Delivery via Prodrugs"", Chapter 5, pp. 177-198, Design of Prodrugs, 1985.;;Stella, Valentino J., ""Prodrugs and Site-Specific Drug Delivery"", 23(12):1275-1282, J Med Chem, Dec. 1980.;;Strube et al., ""Comparison of Batch Elution and Continuous Simulated Moving Bed Chromatography"", 2:305-319, Organic Process Research & Development, 1998.",EXPIRED
149,CY,T1,CY 1116523 T1,082-711-941-106-727,2016-12-14,2016,CY 151100413 T,2015-05-11,EP 01961695 A;;US 22002100 A,2000-07-21,ΠΡΟΦΑΡΜΑΚΑ ΑΝΑΛΟΓΩΝ ΦΩΣΦΟΝΙΚΟΥ ΝΟΥΚΛΕΟΤΙΔΙΟΥ ΚΑΙ ΜΕΘΟΔΟΙ ΓΙΑ ΕΠΙΛΟΓΗ ΚΑΙ ΚΑΤΑΣΚΕΥΗ ΑΥΤΩΝ,"Παρέχεται νέα μέθοδος για συστηματική εξέταση προφαρμάκων αναλόγων μεθοξυφωσφονικού νουκλεοτιδίου για να πιστοποιούνται προφάρμακα που στοχεύουν εκλεκτικώς επιθυμητούς ιστούς με αντι-ιική ή κατά του όγκου δραστικότητα. Η μέθοδος αυτή έχει οδηγήσει στην πιστοποίηση νέων δεικτών εστέρα-αμιδικών του ΡΜΡΑ για ρετροϊική ή ηπατοτροφικής-dna μόλυνσης θεραπεία, συμπεριλαμβανομένων ενώσεων της σύνταξης (5a) που έχουν ομάδες υποκαταστάτη όπως ορίζεται στο παρόν. Παρέχονται συνθέσεις αυτών των νέων ενώσεων σε φαρμακευτικώς αποδεκτά έκδοχα και χρήση αυτών στην θεραπεία και προφύλαξη. Επίσης, παρέχεται βελτιωμένη μέθοδος για την χρήση αλκοξειδίου μαγνησίου για την παρασκευή υλικών έναρξης και ενώσεων για χρήση στο παρόν.",GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/082-711-941-106-727,Granted Patent,no,0,0,1,1,0,,C07F9/6561;;A61K31/675;;A61P31/12;;A61P35/00;;C07H19/20;;G01N33/53,,0,0,,,,ACTIVE
150,US,A1,US 2005/0159392 A1,084-018-852-696-160,2005-07-21,2005,US 3122805 A,2005-01-06,US 3122805 A;;US 79869204 A;;US 35420703 A;;US 90956001 A;;US 22002100 P,2000-07-21,Prodrugs of phosphonate nucleotide analogues,"A novel method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5 a ) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided.",BECKER MARK W.;;CHAPMAN HARLAN H.;;CIHLAR TOMAS;;EISENBERG EUGENE J.;;HE GONG-XIN;;KERNAN MICHAEL R.;;LEE WILLIAM A.;;PRISBE ERNEST J.;;ROHLOFF JOHN C.;;SPARACINO MARK L.,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/084-018-852-696-160,Patent Application,yes,0,1,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,514/81,0,0,,,,DISCONTINUED
151,HR,A2,HR P20030047 A2,086-641-641-671-147,2007-08-31,2007,HR P20030047 A,2003-01-24,US 22002100 P;;US 0123104 W,2000-07-21,PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME,"Prikazana je nova metoda za probiranje prolijekova metoksifosfonatnih analoga nukleotida za identifikaciju prolijekova koji selektivno ciljaju željena tkiva, a imaju antivirusnu ili antitumornu aktivnost. Metoda je vodila identifikaciji novih miješanih ester-amidata PMPA za retrovirusnu ili hepadnavirusnu terapiju, uključujući spojeve strukture (5a) koji imaju supstituente koji su ovdje definirani. Prikazani su pripravci tih novih spojeva u farmaceutski prihvatljivim ekscipijensima i njihova upotreba u terapiji ili profilaksi. Također je prikazana poboljšana metoda za upotrebu magnezijevog alkoksida za pripravu polaznih materijala i spojeva za ovdašnju upotrebu.",GILEAD SCIENCES,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,"GILEAD SCIENCES, INC., US (2016-09-19)",https://lens.org/086-641-641-671-147,Patent Application,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07F9/6561;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,EXPIRED
152,WO,A2,WO 2002/008241 A2,128-221-767-658-539,2002-01-31,2002,US 0123104 W,2001-07-20,US 22002100 P,2000-07-21,PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME,"A novel method is provided for screening prodrugs of methoxyphosphonate nucleotide analogues to identify prodrugs selectively targeting desired tissues with antiviral or antitumor activity. This method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided. Also provided is an improved method for the use of magnesium alkoxide for the preparation of starting materials and compounds for use herein.",GILEAD SCIENCES INC;;BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/128-221-767-658-539,Patent Application,yes,7,147,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,10,2,060-516-842-835-850;;058-117-624-049-237,10571273;;10.1023/a:1018945713623;;10.1021/jm00186a001;;7005447,"OLIYAI ET AL., PHARMACEUTICAL RESEARCH, vol. 16, no. 11, 1999, pages 1687 - 1693;;STELLA ET AL., J. MED. CHEM., vol. 23, no. 12, 1980, pages 1275 - 1282;;AARONS, L.; BODDY, A.; PETRAK, K.: ""Novel Drug Delivery and Its Therapeutic Application"", 1989, pages: 121 - 126;;BUNDGAARD, H.: ""Design of Prodrugs"", 1985, pages: 70 - 74,79-92;;BANERJEE, P. K.; AMIDON, G. L.: ""Design of Prodrugs"", 1985, pages: 118 - 121;;NOTARI, R. E.: ""Design of Prodrugs"", 1985, pages: 135 - 156;;STELLA, V. J.; HIMMELSTEIN, K. J: ""Design of Prodrugs"", 1985, pages: 177 - 198;;JONES, G.: ""Design of Prodrugs"", 1985, pages: 199 - 241;;CONNORS, T. A.: ""Design of Prodrugs"", 1985, pages: 291 - 316;;See also references of EP 1301519A2",PATENTED
153,EP,B1,EP 2682397 B1,140-955-786-584-480,2017-04-19,2017,EP 13164300 A,2001-07-20,US 22002100 P;;EP 01961695 A,2000-07-21,Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same,,GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/140-955-786-584-480,Granted Patent,yes,11,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07F9/6561;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,16,12,051-337-710-931-250;;038-484-273-520-697;;000-562-046-059-417;;113-949-496-938-519;;041-881-484-662-318;;051-337-710-931-250;;113-949-496-938-519;;041-881-484-662-318;;000-562-046-059-417;;020-130-805-761-693;;020-130-805-761-693;;141-449-591-982-571,10.1002/(sici)1099-0682(200005)2000:5<987::aid-ejic987>3.0.co;2-s;;10.1021/ol990246c;;10.1021/op980067v;;10.1139/v99-018;;10.1016/0040-4039(96)01046-5;;10.1002/(sici)1099-0682(200005)2000:5<987::aid-ejic987>3.0.co;2-s;;10.1139/v99-018;;10.1016/0040-4039(96)01046-5;;10.1021/op980067v;;10.1016/s0040-4039(98)00131-2;;10.1016/s0040-4039(98)00131-2;;10.1021/acs.oprd.5b00364,"BARREIRA TERESA ET AL.: ""Standard molar enthalpies of formation of Mg and Ca alkoxides"", EUROPEAN JOURNAL OF INORGANIC CHEMISTRY, 1 January 2000 (2000-01-01), WEINHEIM, DE, pages 987 - 991, XP003029300, ISSN: 1434-1948;;MASCARENHAS C M ET AL.: ""Simple metal alkoxides as effective catalysts for the Hetero-Aidol-Tishchenko reaction"", ORGANIC LETTERS, vol. 1, no. 9, 1 January 1999 (1999-01-01), pages 1427 - 1429, XP003029301, ISSN: 1523-7060;;YU R. ET AL.: ""Process Optimization in the Synthesis of 9-[2- (Diethylphosphonomethoxy)ethyl]adenine: Replacement of Sodium Hydride with Sodium tert-Butoxide as the Base for Oxygen Alkylation"", ORG PROC RES DEV, vol. 3, no. 1, 1999, pages 53 - 55, XP001097187;;NISHIYAMA T. ET AL.: ""Ether Synthesis Using Trifluoromethanesulfonic Anhydride or Triflates Under Mild Reaction Conditions"", CANADIAN JOURNAL OF CHEMISTRY, vol. 77, 1999, pages 258 - 262, XP003035268;;LIN J. M. ET AL.: ""Synthesis of Benzyl/Allyl Alkyl Ethers from Corresponding Magnesium Alkoxides"", TETRAHEDRON LETTERS, vol. 37, no. 29, 15 July 1996 (1996-07-15), pages 5159 - 5160, XP004029615;;JOHN MCMURRY: ""Organic Chemistry, Second Edition"", 1988, BROOKS/COLE PUBLISHING COMPANY, article ""18.4 The Williamson Ether Synthesis"", pages: 623 - 624, XP055455730;;BARREIRA TERESA ET AL.: ""Standard molar enthalpies of formation of Mg and Ca alkoxides"", EUR. J. INORG. CHEM., 2000, pages 987 - 991, XP003029300;;MASADA ET AL.: ""A New Heterogeneous Williamson Synthesis of Ethers Using t-Alkyl Substrates"", J. CHEM. SOC. JAP., no. 3, 1996, pages 275 - 282, XP055456185;;TOMIHIRO NISHIYAMA ET AL.: ""Ether synthesis using trifluoromethanesulfonic anhydride or triflates under mild reaction conditions"", CAN. J. CHEM., vol. 77, 1999, pages 258 - 262, XP003035268;;JI-MAO LIN ET AL.: ""Synthesis of Benzyl/Allyl Alkyl Ethers from Corresponding Magnesium Alkoxides"", TETRAHEDRON LETTERS, vol. 37, no. 29, 1996, pages 5159 - 5160, XP004029615;;""Collier's Encyclopedia"", vol. 9, 1966, pages: 35 - 40, XP055456188;;RICHARD H. YU ET AL.: ""PROCESS OPTIMIZATION IN THE SYNTHESIS OF 9- not 2-(DIETHYLPHOSPHONOMETHOXY)ETHYL 3/4 ADENINE: REPLACEMENT OF SODIUM HYDRIDE WITH SODIUM TERT-BUTOXIDE AS THE BASE FOR OXYGEN ALKYLATION"", ORGANIC PROCESS RESEARCH & DEVELOPMENT, vol. 3, no. 1, 1999, pages 53 - 55, XP001097187;;SCHULTZE ET AL.: ""Practical Synthesis of the anti-HIV Drug, PMPA"", TETRAHEDRON LETTERS, vol. 39, 1998, pages 1853 - 1856, XP004109567;;L. M. SCHULTZE ET AL.: ""Practical Synthesis of the anti-HIV Drug, PMPA"", TETRAHEDRON LETTERS, vol. 39, 2 April 1998 (1998-04-02), pages 1853 - 1856, XP004109567;;HIROMITSU MASADA; DOI Y ET AL: ""A New Heterogeneous Williamson Synthesis of Ethers Using t-Alkyl Substrates"", J. CHEM. SOC. JAP., no. 3, 1996, pages 275 - 282, XP055456185;;D. L. RILEY ET AL.: ""An Improved Process for the Preparation of Tenofovir Disoproxil Fumarate"", ORG PROCESS RES DEV, vol. 20, 2016, pages 742 - 750, XP055596964",EXPIRED
154,SI,T1,SI 1301519 T1,158-231-773-708-472,2015-07-31,2015,SI 200131040 T,2001-07-20,US 22002100 P;;US 0123104 W;;EP 01961695 A,2000-07-21,PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME,,GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/158-231-773-708-472,Granted Patent,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07F9/00;;A61K31/00;;A61K31/664;;A61K31/675;;A61P31/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P35/00;;C07F9/6561;;C07H19/00;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/00;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,EXPIRED
155,EP,B2,EP 1301519 B2,185-270-512-131-151,2021-11-10,2021,EP 01961695 A,2001-07-20,US 0123104 W;;US 22002100 P,2000-07-21,PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME,,GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/185-270-512-131-151,Granted Patent,yes,4,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07F9/6561;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,51,35,000-333-154-695-235;;014-084-520-425-942;;056-366-576-702-848;;075-788-273-419-040;;136-295-566-407-698;;026-123-461-710-181;;040-083-543-251-875;;030-422-205-031-491;;044-156-633-677-511;;090-595-392-204-029;;059-314-340-792-650;;021-390-957-807-627;;006-356-668-723-66X;;008-811-925-472-828;;031-704-501-374-730;;046-645-962-151-756;;055-842-602-682-034;;022-999-059-503-898;;029-525-919-227-097;;056-515-861-490-983;;075-572-122-453-855;;094-091-182-369-024;;114-563-268-962-124;;049-693-008-165-540;;099-476-445-962-006;;160-926-691-035-692;;184-464-436-827-374;;014-196-997-879-542;;036-353-184-311-559;;046-516-420-168-00X;;057-578-217-015-123;;009-362-566-462-163;;110-610-499-145-432;;007-958-707-068-237;;024-738-665-446-19X,pmc105507;;9517941;;10.1128/aac.42.3.612;;8452366;;pmc187663;;10.1128/aac.37.2.332;;10.1177/095632029600700402;;11058891;;10.1002/1098-1128(200011)20:6<417::aid-med1>3.0.co;2-z;;10.1177/095632029400500304;;10.1021/jm981096z;;10229629;;9873653;;10.1016/s0960-894x(98)00530-7;;11562963;;10.1081/ncn-100002496;;11563079;;10.1081/ncn-100002338;;10.1177/095632029600700106;;10.1177/095632029800900202;;9875382;;10.1021/jm00047a011;;7523675;;10.1016/0166-3542(95)00011-a;;7486948;;8478904;;10.1021/jm00060a013;;8692986;;pmc38977;;10.1073/pnas.93.14.7295;;10.1021/jm950605j;;8648614;;10496951;;10.1016/s0166-3542(97)00029-6;;9298759;;10.1021/jm9803931;;9986709;;9453075;;10.1023/a:1012108719462;;8642557;;10.1021/jm9507338;;9865385;;10.1177/095632029800900603;;11563034;;10.1081/ncn-100002567;;10.1177/009286159703100303;;10.1177/095632029300400204;;10.1016/0960-894x(96)00195-3;;10.14217/9781848599215-9-en;;10.1016/j.antiviral.2015.11.009;;26640223;;10.1021/ja00397a024;;10.1016/s0960-894x(00)00061-5;;10762044;;10.1016/j.antiviral.2007.01.080;;10.1128/aac.49.5.1898-1906.2005;;15855512;;pmc1087627;;pmc3457391;;10.1128/aac.01089-12;;22850510;;10.1016/0169-409x(95)00111-j;;10.1021/jm00003a012;;7853342,"ROBBINS ET AL, ANTIMICROB. AGENTS AND CHEMOTHER., vol. 42, 1998, pages 612 - 617;;BALZARINI ET AL, ANTIMICRAB. AGENTS CHEMOTHER., vol. 37, no. 2, 1993, pages 332 - 338;;VAN DER GOOT, TRENDS IN DRUG RESEARCH II, 1998, pages 105 - 116;;DE CLERCQ, ADVANCES IN ANTIVIRAL DRUG DESIGN, vol. 3, 1999, pages 69 - 91;;Gilead press release 27 April 2000;;FREEMAN ET AL, PROGRESS IN MEDICINAL CHEMISTRY. CHAPTER 3, vol. 34, 1997;;MCGUIGAN ET AL, ANTIVIRAL CHEM. CHEMOTHER., vol. 7, no. 4, 1996, pages 184 - 188;;Guidance for Industry Stereochemical Issues in Chiral Drug Development, 2000;;MEIER, SYNLETT, 1998, pages 233 - 241;;WAGNER ET AL, MED RES REV, vol. 20, no. 6, 2000, pages 417 - 451;;MCGUIGAN ET AL, ANTIVIRAL CHEM. CHEMOTHER., vol. 1, no. 2, 1990, pages 107 - 113;;MCGUIGAN ET AL, ANTIVIRAL CHEM. CHEMOTHER., vol. 5, no. 3, 1994, pages 162 - 168;;MEIER ET AL, J. MED. CHEM., vol. 42, 1999, pages 1604 - 1614;;VYLE, ORGANOPHOSPHORUS CHEMISTRY, CHAPTER 5, 2000, pages 135 - 145;;BURGER'S MEDICINAL CHEMISTRY AND DRUG DISCOVERY, vol. 1, 1995, pages 168-171, 264 - 265, 543-544;;FOYE'S PRINCIPLES OF MEDICINAL CHEMISTRY, 5TH ED., 2002, pages 49-54, 221,255 - 25;;MCGUIGAN ET AL, BIOORGANIC & MEDICINAL CHEM LETT, vol. 8, no. 21, 1998, pages 2949 - 2954;;EISENBERG ET AL, NUCLEOSIDES, NUCLEOTIDES AND NUCLEIC ACIDS, vol. 20, no. 4-7, 2001, pages 1091 - 1098;;CHAPMAN ET AL, NUCLEOSIDES, NUCLEOTIDES AND NUCLEIC ACIDS, vol. 20, no. 4-7, 2001, pages 621 - 628, 1085-1090;;MCGUIGAN ET AL, ANTIVIRAL CHEM. CHEMOTHER., vol. 7, no. 1, 1996, pages 31 - 36;;MCGUIGAN ET AL, ANTIVIRAL CHEM. CHEMOTHER., vol. 9, 1998, pages 109 - 115;;FRANCHETTI ET AL, J. MED. CHEM., vol. 37, 1994, pages 3534 - 3541;;JONES ET AL, ANTIVIRAL RESEARCH, vol. 27, 1995, pages 1 - 17;;MCGUIGAN ET AL, J. MED. CHEM., vol. 36, 1993, pages 1048 - 1052;;BALZARINI ET AL, PNAS, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 93, 1996, pages 7295 - 7299;;MCGUIGAN ET AL, J. MED. CHEM., vol. 39, 1996, pages 1748 - 1753;;SABOULARD ET AL, MOL. PHARMACOL., vol. 56, 1999, pages 693 - 704;;MCGUIGAN ET AL, ANTIVIRAL RESEARCH, vol. 35, 1997, pages 195 - 204;;SIDDIQUI ET AL, J. MED. CHEM., vol. 42, 1999, pages 393 - 399;;SHAW ET AL, PHARM RES., vol. 14, 1997, pages 1824 - 1829;;ARMILLI ET AL, ANTIVIRAL CHEM. CHEMOTHER., vol. 8, no. 6, 1997, pages 557 - 564;;VALETTE ET AL, J. MED. CHEM., vol. 39, 1996, pages 1981 - 1990;;MCGUIGAN ET AL, ANTIVIRAL CHEM. CHEMOTHER., vol. 9, 1998, pages 473 - 479;;Gilead press release 12 June 2000;;LYNCH ET AL, NUCLEOSIDES, NUCLEOTIDES AND NUCLEIC ACIDS, vol. 20, no. 4-7, 2001, pages 1415 - 1419;;DANIELS ET AL, DRUG INFORMATION JOURNAL, vol. 31, 1997, pages 639 - 646;;MCGUIGAN ET AL, ANTIVIRAL CHEM. CHEMOTHER., vol. 4, no. 2, 1993, pages 97 - 101;;MCGUIGAN ET AL, BIOORGANIC & MEDICINAL CHEM LETT, vol. 6, no. 10, 1996, pages 1183 - 1186;;Summary of Product Characteristics (SmPC) for Genvoya(R);;Gilead press release 25 April 2016;;Gilead press release 27 June 2016;;RAY ET AL, ANTIVIRAL RESEARCH, vol. 125, 2016, pages 63 - 70;;RAHIL ET AL, JACS, vol. 103, 1981, pages 1723 - 1734;;MCGUIGAN ET AL, BIOORGANIC & MEDICINAL CHEM LETT, vol. 10, 2000, pages 645 - 647;;BIRKUS ET AL, MOLECULAR PHARMACOLOGY, vol. 74, no. 1, 2008, pages 92 - 100;;LEE ET AL, ANTIMICROB. AGENTS AND CHEMOTHER., vol. 49, no. 5, 2005, pages 1898 - 1906;;SZABO: ""The Problem and Solution Approach in the European Patent Office, IIC"", INT. REV. INDUST. PROPERTY & COPYRIGHT, vol. 26, 1995, pages 457 - 487;;CRANDALL (ED.): ""The evolution of HIV"", 1999, JOSH HOPKINS UNIVERSITY PRESS, pages: 288 - 293;;LEPIST, ANTIMICROB. AGENTS AND CHEMOTHER., vol. 56, no. 1, 2012, pages 5409 - 5413;;KRISE, ADV DRUG DELIV. REV., vol. 19, 1996, pages 287 - 310;;FARQUHAR, J. MED. CHEM., vol. 38, no. 3, 1995, pages 488 - 495",EXPIRED
156,LT,T,LT 2682397 T,001-197-631-072-165,2017-06-12,2017,LT 13164300 T,2001-07-20,US 22002100 P,2000-07-21,Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same,,GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/001-197-631-072-165,Unknown,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07F9/6561;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,PENDING
157,BG,A,BG 107572 A,023-455-780-637-438,2003-11-28,2003,BG 10757203 A,2003-02-19,US 22002100 P;;US 0123104 W,2000-07-21,PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME,"A novel method for screening prodrugs of methoxyphosphonate nucleotide analogues to identify prodrugs selectively targeting desired tissues with antiviral or antitumor activity. This method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including components of structure having substituent groups as defined in the description. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided. Also provided is an improved method for the use of magnesium alkoxide for the preparation of starting materials and compounds for use herein. 33 claims",GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/023-455-780-637-438,Patent Application,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,EXPIRED
158,DK,T3,DK 1301519 T3,070-687-272-717-367,2015-05-26,2015,DK 01961695 T,2001-07-20,US 22002100 P;;US 0123104 W,2000-07-21,PRODRUGS AF PHOSPHONATNUKLEOTIDANALOGER OG FREMGANGSMÅDER TIL UDVÆLGELSE OG FREMSTILLING HERAF,,GILEAD SCIENCES INC,CHAPMAN HARLAN H;;SPARACINO MARK L;;KERNAN MICHAEL R;;ROHLOFF JOHN C;;BECKER MARK W;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;LEE WILLIAM A;;PRISBE ERNEST J,,https://lens.org/070-687-272-717-367,Granted Patent,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07F9/6561;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,EXPIRED
159,CY,T1,CY 1119411 T1,076-645-276-756-681,2018-03-07,2018,CY 171100687 T,2017-06-28,US 22002100 P;;EP 01961695 A,2000-07-21,ΠΡΟΦΑΡΜΑΚΑ ΑΝΑΛΟΓΩΝ ΦΩΣΦΟΝΙΚΟΥ ΝΟΥΚΛΕΟΤΙΔΙΟΥ ΚΑΙ ΜΕΘΟΔΟΙ ΓΙΑ ΕΠΙΛΟΓΗ ΚΑΙ ΚΑΤΑΣΚΕΥΗ ΑΥΤΩΝ,"Παρέχεται νέα μέθοδος για συστηματική εξέταση προφαρμάκων αναλόγων μεθοξυφωσφονικού νουκλεοτιδίου για να πιστοποιούνται προφάρμακα που στοχεύουν εκλεκτικώς επιθυμητούς ιστούς με αντι-ιική ή κατά του όγκου δραστικότητα. Η μέθοδος αυτή έχει οδηγήσει στην πιστοποίηση νέων μεικτών εστέρα-αμιδικών του ΡΜΡΑ για ρετροϊική ή hepadna-ιική θεραπεία, συμπεριλαμβανομένων ενώσεων της σύνταξης (5a) που έχουν ομάδες υποκατάστατη όπως ορίζεται στο παρόν. Παρέχονται συνθέσεις αυτών των νέων ενώσεων σε φαρμακευτικώς αποδεκτά έκδοχα και χρήση αυτών στην θεραπεία και προφύλαξη. Επίσης, παρέχεται βελτιωμένη μέθοδος για την χρήση αλκοξειδίου μαγνησίου για την παρασκευή υλικών έναρξης και ενώσεων για χρήση στο παρόν.",GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/076-645-276-756-681,Granted Patent,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07F9/6561;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,ACTIVE
160,HK,A1,HK 1243711 A1,103-622-505-633-868,2018-07-20,2018,HK 18103347 A,2018-03-09,US 22002100 P,2000-07-21,PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME,,GILEAD SCIENCES INC,MARK W BECKER;;HARLAN H CHAPMAN;;TOMAS CIHLAR;;EUGENE J EISENBERG;;GONG-XIN HE;;MICHAEL R KERNAN;;WILLIAM A LEE;;ERNEST J PRISBE;;JOHN C ROHLOFF;;MARK L SPARACINO,,https://lens.org/103-622-505-633-868,Patent Application,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07F/;;A61K/;;A61K31/664;;A61K31/675;;A61P/;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N/;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,PENDING
161,JP,A,JP 2010174033 A,164-204-070-911-785,2010-08-12,2010,JP 2010095542 A,2010-04-16,US 22002100 P,2000-07-21,PRODRUG OF PHOSPHONATE NUCLEOTIDE ANALOGUE AND METHOD FOR SCREENING AND PRODUCING THE SAME,"<P>PROBLEM TO BE SOLVED: To provide a new method for screening prodrugs of methoxyphosphonate nucleotide analogues to identify prodrugs selectively targeting desired tissues with antiviral or antitumor activity. <P>SOLUTION: The method leads to the identification of new mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, and the ester-amidates of PMPA includes compounds of structure (5a) having specified substituent groups. Compositions of these new compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided. An improved method for the use of magnesium alkoxide for the preparation of starting materials and compounds for specific use is also provided. <P>COPYRIGHT: (C)2010,JPO&INPIT",GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/164-204-070-911-785,Patent Application,no,2,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;A61P43/00;;C07F3/02;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,1,0,,,"JPN6012049858; Ｃａｒｌｏ ＢＡＬＬＡＴＯＲＥ ｅｔ ａｌ．: Ｂｉｏｏｒｇａｎｉｃ ＆ Ｍｅｄｉｃｉｎａｌ Ｃｈｅｍｉｓｔｒｙ Ｌｅｔｔｅｒｓ １１（８）, 2001, ｐｐ．１０５３-１０５６",ACTIVE
162,HU,A2,HU P0301307 A2,185-871-600-271-721,2003-09-29,2003,HU P0301307 A,2001-07-20,US 22002100 P;;US 0123104 W,2000-07-21,PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME,"A találmány metoxifoszfonát nukleotid analógok előgyógyszereinekszűrésére alkalmas új eljárásra vonatkozik olyan előgyógyszerekazonosítására, amelyek a kívánt szövetekben szelektíven biztosítják avírusellenes vagy daganatellenes hatást. Ez az eljárás vezetett a PMPAúj, retrovírusos vagy hepadnavírusos terápiában használható vegyesészteramidátjaihoz, többek között az (5a) általános képletű vegyületekazonosításához, a képletben R5 jelentése metilcsoport vagyhidrogénatom; R6 jelentése hidrogénatom vagy adott esetbenhelyettesített alkil-, alkenil-, alkinil-, aril- vagyarilalkilcsoport; R7 jelentése aminosav-oldallánc; R11 jelentéseamino-, alkilamino-, oxo- vagy dialkilaminocsoport; és R12 jelentéseaminocsoport vagy hidrogénatom. A találmány ezen új vegyületeketgyógyászatilag elfogadható segédanyagokban tartalmazó készítményekre,azok terápiában vagy megelőzésben való alkalmazására vonatkozik. Atalálmány kiterjed magnézium-alkoxid alkalmazására is a kiindulásianyagok javított eljárással való előállítására. Ó",GILEAD SCIENCES,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHEAL R;;LEE WILLIAM A;;PRISBE ERNEST JOSEPH;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/185-871-600-271-721,Patent Application,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,ACTIVE
163,EP,A1,EP 2682397 A1,030-675-912-198-608,2014-01-08,2014,EP 13164300 A,2001-07-20,US 22002100 P;;EP 01961695 A,2000-07-21,Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same,"An improved method for the use of magnesium alkoxide for the preparation of starting materials and compounds for use herein is provided. The method is useful for preparing compounds of structure (5a)
  
having substituent groups as defined herein which compounds can be used in antiviral therapy and prophylaxis.",GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/030-675-912-198-608,Patent Application,yes,27,5,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07F9/6561;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,20,12,051-337-710-931-250;;038-484-273-520-697;;060-516-842-835-850;;058-117-624-049-237;;077-295-491-167-117;;068-575-200-141-698;;061-123-661-112-505;;137-456-464-372-982;;000-333-154-695-235;;095-226-048-285-585;;087-104-081-149-221;;113-949-496-938-519,10.1002/(sici)1099-0682(200005)2000:5<987::aid-ejic987>3.0.co;2-s;;10.1021/ol990246c;;10571273;;10.1023/a:1018945713623;;10.1021/jm00186a001;;7005447;;10.1002/0471220574;;10.1021/op980019a;;10.1177/095632029700800610;;10.1177/095632029400500205;;pmc105507;;9517941;;10.1128/aac.42.3.612;;1568310;;10.1093/clinchem/38.4.480;;6331228;;10.1016/0003-2697(84)90386-5;;10.1139/v99-018,"BARREIRA TERESA ET AL: ""Standard molar enthalpies of formation of Mg and Ca alkoxides"", EUROPEAN JOURNAL OF INORGANIC CHEMISTRY, WILEY-VCH VERLAG, WEINHEIM, DE, 1 January 2000 (2000-01-01), pages 987 - 991, XP003029300, ISSN: 1434-1948;;MASCARENHAS C M ET AL: ""Simple metal alkoxides as effective catalysts for the Hetero-Aldol-Tishchenko reaction"", ORGANIC LETTERS, AMERICAN CHEMICAL SOCIETY, US, vol. 1, no. 9, 1 January 1999 (1999-01-01), pages 1427 - 1429, XP003029301, ISSN: 1523-7060;;OLIYAI ET AL., PHARMACEUTICAL RESEARCH, vol. 16, no. 11, 1999, pages 1687 - 1693;;STELLA ET AL., J. MED. CHEM., vol. 23, no. 12, 1980, pages 1275 - 1282;;AARONS, L.; BODDY, A.; PETRAK, K.: ""Novel Drug Delivery and Its Therapeutic Application"", 1989, pages: 121 - 126;;BUNDGAARD, H.: ""Design of Prodrugs"", 1985, pages: 70-74 - 79-92;;BANERJEE, P. K.; AMIDON, G. L.: ""Design of Prodrugs"", 1985, pages: 118 - 121;;NOTARI, R. E.: ""Design of Prodrugs"", 1985, pages: 135 - 156;;STELLA, V. J.; HIMMELSTEIN, K. J.: ""Design of Prodrugs"", 1985, pages: 177 - 198;;JONES, G.: ""Design of Prodrugs"", 1985, pages: 199 - 241;;CONNORS, T. A.: ""Design of Prodrugs"", 1985, pages: 291 - 316;;GREENE ET AL., PROTECTIVE GROUPS IN ORGANIC SYNTHESIS;;STRUBE ET AL., ORGANIC PROCESS RESEARCH AND DEVELOPMENT, vol. 2, 1998, pages 305 - 319;;ARIMILLI, MN ET AL.: ""Synthesis, in vitro biological evaluation and oral bioavailability of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) prodrugs"", ANTIVIRAL CHEMISTRY AND CHEMOTHERAPY, vol. 8, no. 6, 1997, pages 557 - 564, XP055254163;;A. POMPON; I. LEFEBVRE; J.-L. IMBACH; S. KAHN; D. FARQUHAR, ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, vol. 5, 1994, pages 91 - 98;;""Guide for the Care and Use of Laboratory Animals"", NATIONAL INSTITUTES OF HEALTH PUBLICATION 86-23;;B. L. ROBINS; R.V. SRINIVAS; C. KIM; N. BISCHOFBERGER; A. FRIDLAND, ANTIMICROB. AGENTS CHEMOTHER., vol. 42, 1998, pages 612;;L. NAESENS; J. BALZARINI; E. DE CLERCQ, CLIN. CHEM., vol. 38, 1992, pages 480;;K. TANAKA; A. YOSHIOKA; S. TANAKA; Y. WATAYA, ANAL. BIOCHEM., vol. 139, 1984, pages 35;;NISHIYAMA T. ET AL.: ""ETHER SYNTHESIS USING TRIFLUOROMETHANESULFONIC ANHYDRIDE OR TRIFLATES UNDER MILD REACTION CONDITIONS"", CANADIAN JOURNAL OF CHEMISTRY, vol. 77, 1999, pages 258 - 262, XP003035268",EXPIRED
164,EP,A2,EP 1301519 A2,106-918-040-895-682,2003-04-16,2003,EP 01961695 A,2001-07-20,US 0123104 W;;US 22002100 P,2000-07-21,PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME,,GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/106-918-040-895-682,Patent Application,yes,6,1,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,5,4,051-337-710-931-250;;038-484-273-520-697;;020-130-805-761-693;;000-562-046-059-417,10.1002/(sici)1099-0682(200005)2000:5<987::aid-ejic987>3.0.co;2-s;;10.1021/ol990246c;;10.1016/s0040-4039(98)00131-2;;10.1021/op980067v,"BARREIRA T. ET AL: ""Standard molar enthalpies of formation of Mg and Ca alkoxides."", EUR. J. INORG. CHEM., 2000, pages 987 - 991, XP003029300;;MASCARENHAS C.M. ET AL: ""Simple metal alkoxides as effective catalysts for the Hetero-Aldol-Tishchenko reaction."", ORGANIC LETTERS, vol. 1, no. 9, 1999, pages 1427 - 1429, XP003029301;;SCHULTZE L.M. ET AL: ""Practical synthesis of the anti-HIV drug, PMPA."", TETRAHEDRON LETTERS, vol. 39, 1998, pages 1853 - 1856, XP004109567;;YU R.H. ET AL: ""PROCESS OPTIMIZATION IN THE SYNTHESIS OF 9-[2-(DIETHYLPHOSPHONOMETHOXY)ETHYL]ADENINE: REPLACEMENT OF SODIUM HYDRIDE WITH SODIUM TERT-BUTOXIDE AS THE BASE FOR OXYGEN ALKYLATION."", ORGANIC PROCESS RESEARCH AND DEVELOPMENT, vol. 3, 1999, pages 53 - 55, XP001097187;;See also references of WO 0208241A2",EXPIRED
165,EE,B1,EE 05366 B1,174-467-554-597-507,2010-12-15,2010,EE P200300029 A,2001-07-20,US 22002100 P;;US 0123104 W,2000-07-21,Fosfonaatnukleotiidanaloogide eelravimid ja skriinimise meetodid nende identifitseerimiseks,,GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/174-467-554-597-507,Granted Patent,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,A61K31/675;;A61K31/664;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,ACTIVE
166,NO,L,NO 20030270 L,025-585-209-242-267,2003-03-20,2003,NO 20030270 A,2003-01-20,US 22002100 P;;US 0123104 W,2000-07-21,"Prodroger av fosfonatnukleotidanaloger, og fremgangsmåter for utvelgelse ogfremstilling av disse",,GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/025-585-209-242-267,Abstract,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,EXPIRED
167,PL,B1,PL 213214 B1,131-099-134-168-283,2013-01-31,2013,PL 36049001 A,2001-07-20,US 22002100 P,2000-07-21,PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME,,GILEAD SCIENCES,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/131-099-134-168-283,Granted Patent,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07H19/20;;A61K31/664;;A61K31/675;;A61K31/7052;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,EXPIRED
168,EP,B1,EP 1301519 B1,128-059-035-416-179,2015-02-25,2015,EP 01961695 A,2001-07-20,US 0123104 W;;US 22002100 P,2000-07-21,PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME,,GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/128-059-035-416-179,Granted Patent,yes,3,2,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07F9/6561;;A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,2,0,,,"SIDDIQUI A Q ET AL: ""DESIGN AND SYNTHESIS OF LIPOPHILIC PHOSPHORAMIDATE D4T-MP PRODRUGS EXPRESSING HIGH POTENCY AGAINST HIV IN CELL CULTRURE: STRUCTURAL DETERMINANTS FOR IN VITRO ACTIVITY AND QSAR"" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 42, no. 20, 1999, pages 4122-4128, XP000999173 ISSN: 0022-2623;;H. CHAPMAN ET AL.: ""Practical synthesis, separation, and stereochemical assignment of the PMPA pro-drug GS-7340"" NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS, vol. 20, 2001, pages 621-628, XP002202043",EXPIRED
169,KR,A,KR 20060105807 A,148-424-729-636-246,2006-10-11,2006,KR 20067020061 A,2006-09-27,US 22002100 P;;US 0123104 W,2000-07-21,METHODS FOR MAKING PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES,"A novel method is provided for screening prodrugs of methoxyphosphonate nucleotide analogues to identify prodrugs selectively targeting desired tissues with antiviral or antitumor activity. This method has led to the identification of novel mixed ester- amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided. Also provided is an improved method for the use of magnesium alkoxide for the preparation of starting materials and compounds for use herein.",GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/148-424-729-636-246,Patent Application,no,0,3,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,A61K31/336;;A61K31/664;;A61K31/675;;A61K33/06;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,EXPIRED
170,EE,A,EE 200300029 A,187-579-054-080-26X,2004-10-15,2004,EE P200300029 A,2001-07-20,US 22002100 P;;US 0123104 W,2000-07-21,Fosfonaatnukleotiidanaloogide eelravimid ning meetodid nende valimiseks ning valmistamiseks,,GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/187-579-054-080-26X,Patent Application,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,A61K31/664;;A61K31/675;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,ACTIVE
171,HK,A1,HK 1054238 A1,000-868-194-345-29X,2003-11-21,2003,HK 03105871 A,2003-08-15,US 0123104 W;;US 22002100 P,2000-07-21,PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME,,GILEAD SCIENCES INC,BECKER MARK W;;CHAPMAN G HARLAN H;;CIHLAR TOMAS;;EISENBERG EUGENE J;;HE GONG-XIN;;KERNAN MICHAEL R;;LEE WILLIAM A;;PRISBE ERNEST J;;ROHLOFF JOHN C;;SPARACINO MARK L,,https://lens.org/000-868-194-345-29X,Patent Application,no,0,0,112,112,0,C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N33/5011;;C07F9/65616;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/20;;A61P35/00;;A61P43/00;;C12Q1/70;;C07H19/10;;C12Q1/18;;C07H19/20;;C07H21/00;;G01N33/5011;;C07F9/65616,C07F/;;A61K/;;A61K31/664;;A61K31/675;;A61P/;;A61P31/12;;A61P31/18;;A61P35/00;;C07F9/6561;;C07H/;;C07H19/10;;C07H19/20;;C07H21/00;;C12Q1/18;;G01N/;;G01N33/15;;G01N33/50;;G01N33/53,,0,0,,,,DISCONTINUED
172,WO,A1,WO 2005/064008 A1,056-017-891-446-113,2005-07-14,2005,US 2004/0042991 W,2004-12-22,US 74069403 A,2003-12-22,METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS,Methods are provided for identifying anti-HIV therapeutic compounds substituted with carboxyl ester or phosphonate ester groups. Libraries of such compounds are screened optionally using the novel enzyme GS-7340 Ester Hydrolase. Compositions and methods relating to GS-7340 Ester Hydrolase also are provided.,GILEAD SCIENCES INC;;ARIMILLI MURTY N;;BECKER MARK M;;BIRKUS GABRIEL;;BRYANT CLIFFORD;;CHEN JAMES M;;CHEN XIAOWU;;CIHLAR TOMAS;;DASTGAH AZAR;;EISENBERG EUGENE J;;FARDIS MARIA,ARIMILLI MURTY N;;BECKER MARK M;;BIRKUS GABRIEL;;BRYANT CLIFFORD;;CHEN JAMES M;;CHEN XIAOWU;;CIHLAR TOMAS;;DASTGAH AZAR;;EISENBERG EUGENE J;;FARDIS MARIA,,https://lens.org/056-017-891-446-113,Patent Application,yes,1,11,7,7,0,A61K31/66;;A61K31/66;;A61K31/675;;A61K31/675;;A61P31/18;;A61P43/00;;C07D213/75;;C07D213/75;;C07D213/85;;C07D213/85;;C07D231/12;;C07D231/12;;C07D231/20;;C07D231/20;;C07D233/42;;C07D233/42;;C07D239/49;;C07D239/49;;C07D239/80;;C07D239/80;;C07D243/04;;C07D243/04;;C07D265/18;;C07D265/18;;C07D307/68;;C07D307/68;;C07D401/06;;C07D401/06;;C07D403/06;;C07D403/06;;C07D471/14;;C07D471/14;;C07D491/04;;C07D491/04;;C07F9/4006;;C07F9/4006;;C07F9/58;;C07F9/58;;C07F9/645;;C07F9/645;;C07F9/6506;;C07F9/6506;;C07F9/650905;;C07F9/650905;;C07F9/650947;;C07F9/650947;;C07F9/6512;;C07F9/6512;;C07F9/65128;;C07F9/65128;;C07F9/65335;;C07F9/65335;;C07F9/65515;;C07F9/65515;;C07F9/65583;;C07F9/65583;;C07F9/6561;;C07F9/6561;;C12N9/16;;C12N9/16;;C12Q1/18;;C12Q1/18;;C12Q1/37;;C12Q1/37;;C12Q1/44;;C12Q1/44;;C40B40/04;;C40B40/04;;G01N33/5038;;G01N33/5038;;G01N2333/16;;G01N2333/16;;G01N2500/04;;G01N2500/04;;G01N2500/20;;G01N2500/20,C12N9/99;;A61K31/4155;;A61K31/66;;A61K31/665;;A61K31/675;;A61P31/18;;A61P43/00;;C07D213/75;;C07D213/85;;C07D231/12;;C07D231/20;;C07D233/42;;C07D239/48;;C07D239/80;;C07D243/04;;C07D265/18;;C07D307/68;;C07D401/06;;C07D403/06;;C07D471/14;;C07D491/04;;C07F/;;C07F9/02;;C07F9/38;;C07F9/40;;C07F9/44;;C07F9/58;;C07F9/62;;C07F9/645;;C07F9/6506;;C07F9/6509;;C07F9/6512;;C07F9/653;;C07F9/6533;;C07F9/655;;C07F9/6558;;C07F9/6561;;C07F9/6584;;C12N9/16;;C12Q1/18;;C12Q1/37;;C12Q1/44;;C12Q1/70;;G01N33/04;;G01N33/50,,0,0,,,,PENDING
173,US,A1,US 2022/0009323 A1,155-758-350-366-812,2022-01-13,2022,US 202117369303 A,2021-07-07,US 202117369303 A;;US 202063049438 P;;US 202063049374 P;;US 202063049377 P;;US 202063049444 P;;US 202063049456 P;;US 202063049446 P,2020-07-08,DOOR ASSEMBLY FOR DELIVERY VEHICLE,"A vehicle includes a chassis, a body, and a door assembly. The body is supported by the chassis, and defines a driver compartment and a cargo compartment. The driver compartment has a cab opening and the cargo compartment has a cargo opening. The door assembly is coupled to the body and provides selective access into the driver compartment and into the cargo compartment through the cab opening and cargo opening, respectively. The door assembly includes a first door and a second door. The first door is movable between a first position extending across the cab opening and a second position extending across a portion of the cab opening. The second door is movable between a third position extending across the cargo opening and a fourth position extending across a portion of the cab opening.",OSHKOSH CORP,SCHMIDT PAUL;;WOLFRATH MITCHELL;;KAUNISTO RONALD;;KRAMER JAMES;;ERVIN MARK;;BARRON TY;;EISENBERG DREW;;ANDREWS BEN;;MINGER ROBERT;;HOLLIDAY WES;;MCGRAW DAVE;;DRACH ANDREW;;QUIGLEY THOMAS,OSHKOSH CORPORATION (2021-11-06),https://lens.org/155-758-350-366-812,Patent Application,yes,0,0,22,22,0,B60J5/06;;B60J5/0477;;B62D33/04;;B62D33/06;;B62D25/082;;E05B83/40;;E05C3/042;;B60N2/06;;B60N2/065;;B60N2/005;;B60N2/015;;E05B79/04;;E05B29/00;;B60N2/01508;;B60N2/06;;B60R7/08;;B60P3/007;;B60N2/688;;B60J5/04;;B60J10/70;;B60J1/10;;B60J1/12;;B60J1/08;;B60J5/0401;;B60N2/00;;B62D1/16;;B62D21/02;;B62D25/04;;B62D25/082;;B62D25/10;;B62D33/06;;B60P7/0815;;B60P7/15;;E05B79/04,B60J5/04,,0,0,,,,ACTIVE
174,CA,A1,CA 3124142 A1,028-258-100-045-64X,2022-01-08,2022,CA 3124142 A,2021-07-07,US 202063049374 P;;US 202063049377 P;;US 202063049438 P;;US 202063049444 P;;US 202063049446 P;;US 202063049456 P,2020-07-08,DOOR ASSEMBLY FOR DELIVERY VEHICLE,"A vehicle includes a chassis, a body, and a door assembly. The body is supported by the chassis, and defines a driver compai _______________________________________________ tment and a cargo compai tment. The driver compailment has a cab opening and the cargo compailment has a cargo opening. The door assembly is coupled to the body and provides selective access into the driver compai _________________ tment and into the cargo compm intent through the cab opening and cargo opening, respectively. The door assembly includes a first door and a second door. The first door is movable between a first position extending across the cab opening and a second position extending across a portion of the cab opening. The second door is movable between a third position extending across the cargo opening and a fourth position extending across a portion of the cab opening.",OSHKOSH CORP,SCHMIDT PAUL;;WOLFRATH MITCHELL;;KAUNISTO RONALD;;KRAMER JAMES;;ERVIN MARK;;BARRON TY;;EISENBERG DREW;;ANDREWS BEN;;MINGER ROBERT;;HOLLIDAY WES;;MCGRAW DAVE;;DRACH ANDREW;;QUIGLEY THOMAS,,https://lens.org/028-258-100-045-64X,Patent Application,no,0,0,22,22,0,B60J5/06;;B60J5/0477;;B62D33/04;;B62D33/06;;B62D25/082;;E05B83/40;;E05C3/042;;B60N2/06;;B60N2/065;;B60N2/005;;B60N2/015;;E05B79/04;;E05B29/00;;B60N2/01508;;B60N2/06;;B60R7/08;;B60P3/007;;B60N2/688;;B60J5/04;;B60J10/70;;B60J1/10;;B60J1/12;;B60J1/08;;B60J5/0401;;B60N2/00;;B62D1/16;;B62D21/02;;B62D25/04;;B62D25/082;;B62D25/10;;B62D33/06;;B60P7/0815;;B60P7/15;;E05B79/04,B60J5/06,,0,0,,,,PENDING
175,US,B2,US 11807134 B2,069-284-851-365-296,2023-11-07,2023,US 202117369303 A,2021-07-07,US 202117369303 A;;US 202063049438 P;;US 202063049374 P;;US 202063049377 P;;US 202063049444 P;;US 202063049456 P;;US 202063049446 P,2020-07-08,Door assembly for delivery vehicle,"A vehicle includes a chassis, a body, and a door assembly. The body is supported by the chassis, and defines a driver compartment and a cargo compartment. The driver compartment has a cab opening and the cargo compartment has a cargo opening. The door assembly is coupled to the body and provides selective access into the driver compartment and into the cargo compartment through the cab opening and cargo opening, respectively. The door assembly includes a first door and a second door. The first door is movable between a first position extending across the cab opening and a second position extending across a portion of the cab opening. The second door is movable between a third position extending across the cargo opening and a fourth position extending across a portion of the cab opening.",OSHKOSH CORP,SCHMIDT PAUL;;WOLFRATH MITCHELL;;KAUNISTO RONALD;;KRAMER JAMES;;ERVIN MARK A;;BARRON TY;;EISENBERG DREW;;ANDREWS BENJAMIN;;MINGER ROBERT;;HOLLIDAY ROBERT WESLEY;;MCGRAW DAVID C;;DRACH ANDREW;;QUIGLEY THOMAS,OSHKOSH CORPORATION (2021-11-06),https://lens.org/069-284-851-365-296,Granted Patent,yes,102,0,22,22,0,B60J5/06;;B60J5/0477;;B62D33/04;;B62D33/06;;B62D25/082;;E05B83/40;;E05C3/042;;B60N2/06;;B60N2/065;;B60N2/005;;B60N2/015;;E05B79/04;;E05B29/00;;B60N2/01508;;B60N2/06;;B60R7/08;;B60P3/007;;B60N2/688;;B60J5/04;;B60J10/70;;B60J1/10;;B60J1/12;;B60J1/08;;B60J5/0401;;B60N2/00;;B62D1/16;;B62D21/02;;B62D25/04;;B62D25/082;;B62D25/10;;B62D33/06;;B60P7/0815;;B60P7/15;;E05B79/04,B60J5/04;;B60J1/08;;B60J1/10;;B60J1/12;;B60J10/70;;B60N2/00;;B60N2/015;;B60N2/06;;B60N2/68;;B60P3/00;;B60P7/08;;B60P7/15;;B60R7/08;;B62D1/16;;B62D21/02;;B62D25/04;;B62D25/08;;B62D25/10;;B62D33/06;;E05B79/04,,2,0,,,"Canadian Office Action issued in connection with CA Appl. Ser. No. 3124181 dated Oct. 7, 2022.;;Canadian Office Action issued in connection with CA Appl. Ser. No. 3124175 dated Oct. 25, 2022.",ACTIVE
176,US,A1,US 2023/0406159 A1,072-433-097-308-146,2023-12-21,2023,US 202318240144 A,2023-08-30,US 202318240144 A;;US 202117369303 A;;US 202063049446 P;;US 202063049374 P;;US 202063049456 P;;US 202063049444 P;;US 202063049438 P;;US 202063049377 P,2020-07-08,DOOR ASSEMBLY FOR DELIVERY VEHICLE,"A vehicle includes a chassis, a body, and a door assembly. The body is supported by the chassis, and defines a driver compartment and a cargo compartment. The driver compartment has a cab opening and the cargo compartment has a cargo opening. The door assembly is coupled to the body and provides selective access into the driver compartment and into the cargo compartment through the cab opening and cargo opening, respectively. The door assembly includes a first door and a second door. The first door is movable between a first position extending across the cab opening and a second position extending at least partially across a portion of the cab opening. The second door is movable between a third position extending across the cargo opening and a fourth position extending at least partially across a portion of the cab opening.",OSHKOSH CORP,SCHMIDT PAUL;;WOLFRATH MITCHELL;;KAUNISTO RONALD;;KRAMER JAMES;;ERVIN MARK A;;BARRON TY;;EISENBERG DREW;;ANDREWS BENJAMIN;;MINGER ROBERT;;HOLLIDAY ROBERT WESLEY;;MCGRAW DAVID C;;DRACH ANDREW;;QUIGLEY THOMAS,KNOWBE4 INC (2023-08-15),https://lens.org/072-433-097-308-146,Patent Application,yes,0,0,22,22,0,B60J5/06;;B60J5/0477;;B62D33/04;;B62D33/06;;B62D25/082;;E05B83/40;;E05C3/042;;B60N2/06;;B60N2/065;;B60N2/005;;B60N2/015;;E05B79/04;;E05B29/00;;B60N2/01508;;B60N2/06;;B60R7/08;;B60P3/007;;B60N2/688;;B60J5/04;;B60J10/70;;B60J1/10;;B60J1/12;;B60J1/08;;B60J5/0401;;B60N2/00;;B62D1/16;;B62D21/02;;B62D25/04;;B62D25/082;;B62D25/10;;B62D33/06;;B60P7/0815;;B60P7/15;;E05B79/04,B60N2/015;;B60N2/06;;B60P3/00;;B60R7/08;;E05B81/14;;E05B83/40,,0,0,,,,PENDING
177,BR,A,BR 0210166 A,036-047-662-895-814,2004-08-24,2004,BR 0210166 A,2002-06-03,US 87474901 A;;US 15312402 A;;US 0217637 W,2001-06-05,"Métodos para minimizar interações entre etiquetas de rfid, para interrogar uma área de armazenamento, para eleger itens etiquetados de rfid e etiquetas de rfid, para usar um sistema de interrogação de rfid, para associar itens, para usar um leitor de rfid, para verificar itens, para transferir um grupo de arquivos, para prover notificação que um item etiquetado de rfid foi interrogado e para operar um computador, guia para posicionar etiquetas de rfid, pasta de arquivo, sistemas de eleição de rfid, de rastreamento, de administração de itens, de identificação por radiofrequência e de recipiente, programa de software, software e instalação médica ou legal","Various systems and methods of handling items such as files are disclosed, including systems and methods for polling RFID-tagged items while they are stored in storage areas.",3M INNOVATIVE PROPERTIES CO,EISENBERG PETER MARK;;ERICKSON DAVID PAUL;;GOLF EDWARD DAVID;;GRUNES MITCHELL BENJAMIN;;HICKOK GENE JAMES;;KELLER JANET THERESSIE;;KELLIHER WILLIAM JOSEPH JR;;KIRSCHHOFFER JON ARTHUR;;KRUSE JOHN MICHAEL;;MOREL DIANE EDITH;;PEARSON SCOTT DAVID;;PIOTROWSKI CHESTER;;RING EDMUND JOHN;;SAINATI ROBERT ARTHUR;;WALDNER MICHELE ANN,,https://lens.org/036-047-662-895-814,Patent Application,no,0,0,19,31,0,G06K17/00;;G06K19/07796,B65G1/137;;G06K17/00;;G06K19/00;;G06K19/07,,0,0,,,,DISCONTINUED
178,EP,A1,EP 1711617 A1,049-791-520-452-273,2006-10-18,2006,EP 04817046 A,2004-12-22,US 2004/0042991 W;;US 74069403 A,2003-12-22,METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTICS COMPOUNDS,,GILEAD SCIENCES INC,ARIMILLI MURTY N;;BECKER MARK M;;BIRKUS GABRIEL;;BRYANT CLIFFORD;;CHEN JAMES M;;CHEN XIAOWU;;CIHLAR TOMAS;;DASTGAH AZAR;;EISENBERG EUGENE J;;FARDIS MARIA;;HATADA MARCOS;;HE GONG-XIN;;JIN HAOLUN;;KIM CHOUNG U;;LEE WILLIAM A;;LEE CHRISTOPHER P;;LIN KUEI-YING;;LIU HONGTAO;;MACKMAN RICHARD L;;MITCHELL MICHAEL L,,https://lens.org/049-791-520-452-273,Patent Application,yes,0,0,7,7,0,A61K31/66;;A61K31/66;;A61K31/675;;A61K31/675;;A61P31/18;;A61P43/00;;C07D213/75;;C07D213/75;;C07D213/85;;C07D213/85;;C07D231/12;;C07D231/12;;C07D231/20;;C07D231/20;;C07D233/42;;C07D233/42;;C07D239/49;;C07D239/49;;C07D239/80;;C07D239/80;;C07D243/04;;C07D243/04;;C07D265/18;;C07D265/18;;C07D307/68;;C07D307/68;;C07D401/06;;C07D401/06;;C07D403/06;;C07D403/06;;C07D471/14;;C07D471/14;;C07D491/04;;C07D491/04;;C07F9/4006;;C07F9/4006;;C07F9/58;;C07F9/58;;C07F9/645;;C07F9/645;;C07F9/6506;;C07F9/6506;;C07F9/650905;;C07F9/650905;;C07F9/650947;;C07F9/650947;;C07F9/6512;;C07F9/6512;;C07F9/65128;;C07F9/65128;;C07F9/65335;;C07F9/65335;;C07F9/65515;;C07F9/65515;;C07F9/65583;;C07F9/65583;;C07F9/6561;;C07F9/6561;;C12N9/16;;C12N9/16;;C12Q1/18;;C12Q1/18;;C12Q1/37;;C12Q1/37;;C12Q1/44;;C12Q1/44;;C40B40/04;;C40B40/04;;G01N33/5038;;G01N33/5038;;G01N2333/16;;G01N2333/16;;G01N2500/04;;G01N2500/04;;G01N2500/20;;G01N2500/20,C12N9/99;;C12Q1/44;;A61K31/4155;;A61K31/66;;A61K31/665;;A61K31/675;;A61P31/18;;A61P43/00;;C07D213/75;;C07D213/85;;C07D231/12;;C07D231/20;;C07D233/42;;C07D239/48;;C07D239/80;;C07D243/04;;C07D265/18;;C07D307/68;;C07D401/06;;C07D403/06;;C07D471/14;;C07D491/04;;C07F/;;C07F9/02;;C07F9/38;;C07F9/40;;C07F9/44;;C07F9/58;;C07F9/62;;C07F9/645;;C07F9/6506;;C07F9/6509;;C07F9/6512;;C07F9/653;;C07F9/6533;;C07F9/655;;C07F9/6558;;C07F9/6561;;C07F9/6584;;C12N9/16;;C12Q1/18;;C12Q1/37;;C12Q1/70;;G01N33/04;;G01N33/50,,1,0,,,See references of WO 2005064008A1,DISCONTINUED
179,US,A1,US 2005/0239054 A1,062-615-171-800-599,2005-10-27,2005,US 74069403 A,2003-12-22,US 74069403 A;;US 42418603 A;;US 42349603 A;;US 42413003 A;;US 0312901 W;;US 0312926 W;;US 0312943 W;;US 37562202 P;;US 37583402 P;;US 37566502 P;;US 37577902 P;;US 46581003 P;;US 46572103 P;;US 46582403 P,2002-04-26,Method and compositions for identifying anti-HIV therapeutic compounds,Methods are provided for identifying anti-HIV therapeutic compounds substituted with carboxyl ester or phosphonate ester groups. Libraries of such compounds are screened optionally using the novel enzyme GS-7340 Ester Hydrolase. Compositions and methods relating to GS-7340 Ester Hydrolase also are provided.,ARIMILLI MURTY N;;BECKER MARK M;;BIRKUS GABRIEL;;BRYANT CLIFFORD;;CHEN JAMES M;;CHEN XIAOWU;;CIHLAR TOMAS;;DASTGAH AZAR;;EISENBERG EUGENE J;;FARDIS MARIA;;HATADA MARCOS;;HE GONG-XIN;;JIN HAOLUN;;KIM CHOUNG U;;LEE WILLIAM A;;LEE CHRISTOPHER P;;LIN KUEI-YING;;LIU HONGTAO;;MACKMAN RICHARD L;;MCDERMOTT MARTIN J;;MITCHELL MICHAEL L;;NELSON PETER H;;PYUN HYUNG-JUNG;;ROWE TANISHA D;;SPARACINO MARK;;SWAMINATHAN SUNDARAMOORTHI;;TARIO JAMES D;;WANG JIANYING;;WILLIAMS MATTHEW A;;XU LIANHONG;;YANG ZHENG-YU;;YU RICHARD H;;ZHANG JIANCUN;;ZHANG LIJUN,ARIMILLI MURTY N;;BECKER MARK M;;BIRKUS GABRIEL;;BRYANT CLIFFORD;;CHEN JAMES M;;CHEN XIAOWU;;CIHLAR TOMAS;;DASTGAH AZAR;;EISENBERG EUGENE J;;FARDIS MARIA;;HATADA MARCOS;;HE GONG-XIN;;JIN HAOLUN;;KIM CHOUNG U;;LEE WILLIAM A;;LEE CHRISTOPHER P;;LIN KUEI-YING;;LIU HONGTAO;;MACKMAN RICHARD L;;MCDERMOTT MARTIN J;;MITCHELL MICHAEL L;;NELSON PETER H;;PYUN HYUNG-JUNG;;ROWE TANISHA D;;SPARACINO MARK;;SWAMINATHAN SUNDARAMOORTHI;;TARIO JAMES D;;WANG JIANYING;;WILLIAMS MATTHEW A;;XU LIANHONG;;YANG ZHENG-YU;;YU RICHARD H;;ZHANG JIANCUN;;ZHANG LIJUN,GILEAD SCIENCES. INC (2004-07-20),https://lens.org/062-615-171-800-599,Patent Application,yes,14,20,7,7,0,A61K31/66;;A61K31/66;;A61K31/675;;A61K31/675;;A61P31/18;;A61P43/00;;C07D213/75;;C07D213/75;;C07D213/85;;C07D213/85;;C07D231/12;;C07D231/12;;C07D231/20;;C07D231/20;;C07D233/42;;C07D233/42;;C07D239/49;;C07D239/49;;C07D239/80;;C07D239/80;;C07D243/04;;C07D243/04;;C07D265/18;;C07D265/18;;C07D307/68;;C07D307/68;;C07D401/06;;C07D401/06;;C07D403/06;;C07D403/06;;C07D471/14;;C07D471/14;;C07D491/04;;C07D491/04;;C07F9/4006;;C07F9/4006;;C07F9/58;;C07F9/58;;C07F9/645;;C07F9/645;;C07F9/6506;;C07F9/6506;;C07F9/650905;;C07F9/650905;;C07F9/650947;;C07F9/650947;;C07F9/6512;;C07F9/6512;;C07F9/65128;;C07F9/65128;;C07F9/65335;;C07F9/65335;;C07F9/65515;;C07F9/65515;;C07F9/65583;;C07F9/65583;;C07F9/6561;;C07F9/6561;;C12N9/16;;C12N9/16;;C12Q1/18;;C12Q1/18;;C12Q1/37;;C12Q1/37;;C12Q1/44;;C12Q1/44;;C40B40/04;;C40B40/04;;G01N33/5038;;G01N33/5038;;G01N2333/16;;G01N2333/16;;G01N2500/04;;G01N2500/04;;G01N2500/20;;G01N2500/20,C12N9/99;;A61K31/4155;;A61K31/66;;A61K31/665;;A61K31/675;;A61P31/18;;A61P43/00;;C07D213/75;;C07D213/85;;C07D231/12;;C07D231/20;;C07D233/42;;C07D239/48;;C07D239/80;;C07D243/04;;C07D265/18;;C07D307/68;;C07D401/06;;C07D403/06;;C07D471/14;;C07D491/04;;C07F/;;C07F9/02;;C07F9/38;;C07F9/40;;C07F9/44;;C07F9/58;;C07F9/62;;C07F9/645;;C07F9/6506;;C07F9/6509;;C07F9/6512;;C07F9/653;;C07F9/6533;;C07F9/655;;C07F9/6558;;C07F9/6561;;C07F9/6584;;C12N9/16;;C12Q1/18;;C12Q1/37;;C12Q1/44;;C12Q1/70;;G01N33/04;;G01N33/50,435/5;;514/114;;514/80,0,0,,,,DISCONTINUED
180,CA,A1,CA 2550730 A1,072-704-456-151-569,2005-07-14,2005,CA 2550730 A,2004-12-22,US 74069403 A;;US 2004/0042991 W,2003-12-22,METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTICCOMPOUNDS,Methods are provided for identifying anti-HIV therapeutic compounds substituted with carboxyl ester or phosphonate ester groups. Libraries of su ch compounds are screened optionally using the novel enzyme GS-7340 Ester Hydrolase. Compositions and methods relating to GS-7340 Ester Hydrolase also are provided.,GILEAD SCIENCES INC,BECKER MARK M;;ARIMILLI MURTY N;;LEE CHRISTOPHER P;;KIM CHOUNG U;;WANG JIANYING;;HE GONG-XIN;;ZHANG LIJUN;;LIU HONGTAO;;JIN HAOLUN;;BRYANT CLIFFORD;;WILLIAMS MATTHEW A;;CHEN JAMES M;;FARDIS MARIA;;MACKMAN RICHARD L;;ZHANG JIANCUN;;LEE WILLIAM A;;HATADA MARCOS;;XU LIANHONG;;YANG ZHENG-YU;;YU RICHARD H;;BIRKUS GABRIEL;;MCDERMOTT MARTIN J;;PYUN HYUNG-JUNG;;CHEN XIAOWU;;MITCHELL MICHAEL L;;NELSON PETER H;;SWAMINATHAN SUNDARAMOORTHI;;CIHLAR TOMAS;;SPARACINO MARK;;DASTGAH AZAR;;ROWE TANISHA D;;EISENBERG EUGENE J;;TARIO JAMES D;;LIN KUEI-YING,,https://lens.org/072-704-456-151-569,Patent Application,no,0,0,7,7,0,A61K31/66;;A61K31/66;;A61K31/675;;A61K31/675;;A61P31/18;;A61P43/00;;C07D213/75;;C07D213/75;;C07D213/85;;C07D213/85;;C07D231/12;;C07D231/12;;C07D231/20;;C07D231/20;;C07D233/42;;C07D233/42;;C07D239/49;;C07D239/49;;C07D239/80;;C07D239/80;;C07D243/04;;C07D243/04;;C07D265/18;;C07D265/18;;C07D307/68;;C07D307/68;;C07D401/06;;C07D401/06;;C07D403/06;;C07D403/06;;C07D471/14;;C07D471/14;;C07D491/04;;C07D491/04;;C07F9/4006;;C07F9/4006;;C07F9/58;;C07F9/58;;C07F9/645;;C07F9/645;;C07F9/6506;;C07F9/6506;;C07F9/650905;;C07F9/650905;;C07F9/650947;;C07F9/650947;;C07F9/6512;;C07F9/6512;;C07F9/65128;;C07F9/65128;;C07F9/65335;;C07F9/65335;;C07F9/65515;;C07F9/65515;;C07F9/65583;;C07F9/65583;;C07F9/6561;;C07F9/6561;;C12N9/16;;C12N9/16;;C12Q1/18;;C12Q1/18;;C12Q1/37;;C12Q1/37;;C12Q1/44;;C12Q1/44;;C40B40/04;;C40B40/04;;G01N33/5038;;G01N33/5038;;G01N2333/16;;G01N2333/16;;G01N2500/04;;G01N2500/04;;G01N2500/20;;G01N2500/20,C12N9/99;;C12Q1/44;;A61K31/4155;;A61K31/66;;A61K31/665;;A61K31/675;;A61P31/18;;A61P43/00;;C07D213/75;;C07D213/85;;C07D231/12;;C07D231/20;;C07D233/42;;C07D239/48;;C07D239/80;;C07D243/04;;C07D265/18;;C07D307/68;;C07D401/06;;C07D403/06;;C07D471/14;;C07D491/04;;C07F/;;C07F9/02;;C07F9/38;;C07F9/40;;C07F9/44;;C07F9/58;;C07F9/62;;C07F9/645;;C07F9/6506;;C07F9/6509;;C07F9/6512;;C07F9/653;;C07F9/6533;;C07F9/655;;C07F9/6558;;C07F9/6561;;C07F9/6584;;C12N9/16;;C12Q1/18;;C12Q1/37;;C12Q1/70;;G01N33/04;;G01N33/50,,0,0,,,,DISCONTINUED
181,AU,A1,AU 2004/309379 A1,189-461-072-951-013,2005-07-14,2005,AU 2004/309379 A,2004-12-22,US 74069403 A;;US 2004/0042991 W,2003-12-22,Method and compositions for identifying anti-HIV therapeutic compounds,,GILEAD SCIENCES INC,ARIMILLI MURTY N;;LIU HONGTAO;;WANG JIANYING;;DASTGAH AZAR;;MITCHELL MICHAEL L;;YANG ZHENG-YU;;SWAMINATHAN SUNDARAMOORTHI;;EISENBERG EUGENE J;;XU LIANHONG;;JIN HAOLUN;;PYUN HYUNG-JUNG;;FARDIS MARIA;;LEE CHRISTOPHER P;;WILLIAMS MATTHEW A;;BECKER MARK M;;ROWE TANISHA D;;CIHLAR TOMAS;;YU RICHARD H;;LEE WILLIAM A;;ZHANG JIANCUN;;HE GONG-XIN;;BRYANT CLIFFORD;;SPARACINO MARK;;KIM CHOUNG U;;CHEN JAMES M;;NELSON PETER H;;LIN KUEI-YING;;BIRKUS GABRIEL;;CHEN XIAOWU;;MCDERMOTT MARTIN J;;TARIO JAMES D;;ZHANG LIJUN;;HATADA MARCOS;;MACKMAN RICHARD L,,https://lens.org/189-461-072-951-013,Patent Application,no,0,0,7,7,0,A61K31/66;;A61K31/66;;A61K31/675;;A61K31/675;;A61P31/18;;A61P43/00;;C07D213/75;;C07D213/75;;C07D213/85;;C07D213/85;;C07D231/12;;C07D231/12;;C07D231/20;;C07D231/20;;C07D233/42;;C07D233/42;;C07D239/49;;C07D239/49;;C07D239/80;;C07D239/80;;C07D243/04;;C07D243/04;;C07D265/18;;C07D265/18;;C07D307/68;;C07D307/68;;C07D401/06;;C07D401/06;;C07D403/06;;C07D403/06;;C07D471/14;;C07D471/14;;C07D491/04;;C07D491/04;;C07F9/4006;;C07F9/4006;;C07F9/58;;C07F9/58;;C07F9/645;;C07F9/645;;C07F9/6506;;C07F9/6506;;C07F9/650905;;C07F9/650905;;C07F9/650947;;C07F9/650947;;C07F9/6512;;C07F9/6512;;C07F9/65128;;C07F9/65128;;C07F9/65335;;C07F9/65335;;C07F9/65515;;C07F9/65515;;C07F9/65583;;C07F9/65583;;C07F9/6561;;C07F9/6561;;C12N9/16;;C12N9/16;;C12Q1/18;;C12Q1/18;;C12Q1/37;;C12Q1/37;;C12Q1/44;;C12Q1/44;;C40B40/04;;C40B40/04;;G01N33/5038;;G01N33/5038;;G01N2333/16;;G01N2333/16;;G01N2500/04;;G01N2500/04;;G01N2500/20;;G01N2500/20,C12N9/99;;C12Q1/44;;A61K31/4155;;A61K31/66;;A61K31/665;;A61K31/675;;A61P31/18;;A61P43/00;;C07D213/75;;C07D213/85;;C07D231/12;;C07D231/20;;C07D233/42;;C07D239/48;;C07D239/80;;C07D243/04;;C07D265/18;;C07D307/68;;C07D401/06;;C07D403/06;;C07D471/14;;C07D491/04;;C07F/;;C07F9/02;;C07F9/38;;C07F9/40;;C07F9/44;;C07F9/58;;C07F9/62;;C07F9/645;;C07F9/6506;;C07F9/6509;;C07F9/6512;;C07F9/653;;C07F9/6533;;C07F9/655;;C07F9/6558;;C07F9/6561;;C07F9/6584;;C12N9/16;;C12Q1/18;;C12Q1/37;;C12Q1/70;;G01N33/04;;G01N33/50,,0,0,,,,DISCONTINUED
182,WO,A9,WO 2005/064008 A9,139-396-104-637-706,2006-09-28,2006,US 2004/0042991 W,2004-12-22,US 74069403 A,2003-12-22,METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS,Methods are provided for identifying anti-HIV therapeutic compounds substituted with carboxyl ester or phosphonate ester groups. Libraries of such compounds are screened optionally using the novel enzyme GS-7340 Ester Hydrolase. Compositions and methods relating to GS-7340 Ester Hydrolase also are provided.,GILEAD SCIENCES INC;;ARIMILLI MURTY N;;BECKER MARK M;;BIRKUS GABRIEL;;BRYANT CLIFFORD;;CHEN JAMES M;;CHEN XIAOWU;;CIHLAR TOMAS;;DASTGAH AZAR;;EISENBERG EUGENE J;;FARDIS MARIA;;HATADA MARCOS;;HE GONG-XIN;;JIN HAOLUN;;KIM CHOUNG U;;LEE WILLIAM A;;LEE CHRISTOPHER P;;LIN KUEI-YING;;LIU HONGTAO;;MACKMAN RICHARD L;;MCDERMOTT MARTIN J;;MITCHELL MICHAEL L;;NELSON PETER H;;PYUN HYUNG-JUNG;;ROWE TANISHA D;;SPARACINO MARK;;SWAMINATHAN SUNDARAMOORTHI;;TARIO JAMES D;;WANG JIANYING;;WILLIAMS MATTHEW A;;XU LIANHONG;;YANG ZHENG-YU;;YU RICHARD H;;ZHANG JIANCUN;;ZHANG LIJUN,ARIMILLI MURTY N;;BECKER MARK M;;BIRKUS GABRIEL;;BRYANT CLIFFORD;;CHEN JAMES M;;CHEN XIAOWU;;CIHLAR TOMAS;;DASTGAH AZAR;;EISENBERG EUGENE J;;FARDIS MARIA;;HATADA MARCOS;;HE GONG-XIN;;JIN HAOLUN;;KIM CHOUNG U;;LEE WILLIAM A;;LEE CHRISTOPHER P;;LIN KUEI-YING;;LIU HONGTAO;;MACKMAN RICHARD L;;MCDERMOTT MARTIN J;;MITCHELL MICHAEL L;;NELSON PETER H;;PYUN HYUNG-JUNG;;ROWE TANISHA D;;SPARACINO MARK;;SWAMINATHAN SUNDARAMOORTHI;;TARIO JAMES D;;WANG JIANYING;;WILLIAMS MATTHEW A;;XU LIANHONG;;YANG ZHENG-YU;;YU RICHARD H;;ZHANG JIANCUN;;ZHANG LIJUN,,https://lens.org/139-396-104-637-706,Patent Application,no,0,0,7,7,0,A61K31/66;;A61K31/66;;A61K31/675;;A61K31/675;;A61P31/18;;A61P43/00;;C07D213/75;;C07D213/75;;C07D213/85;;C07D213/85;;C07D231/12;;C07D231/12;;C07D231/20;;C07D231/20;;C07D233/42;;C07D233/42;;C07D239/49;;C07D239/49;;C07D239/80;;C07D239/80;;C07D243/04;;C07D243/04;;C07D265/18;;C07D265/18;;C07D307/68;;C07D307/68;;C07D401/06;;C07D401/06;;C07D403/06;;C07D403/06;;C07D471/14;;C07D471/14;;C07D491/04;;C07D491/04;;C07F9/4006;;C07F9/4006;;C07F9/58;;C07F9/58;;C07F9/645;;C07F9/645;;C07F9/6506;;C07F9/6506;;C07F9/650905;;C07F9/650905;;C07F9/650947;;C07F9/650947;;C07F9/6512;;C07F9/6512;;C07F9/65128;;C07F9/65128;;C07F9/65335;;C07F9/65335;;C07F9/65515;;C07F9/65515;;C07F9/65583;;C07F9/65583;;C07F9/6561;;C07F9/6561;;C12N9/16;;C12N9/16;;C12Q1/18;;C12Q1/18;;C12Q1/37;;C12Q1/37;;C12Q1/44;;C12Q1/44;;C40B40/04;;C40B40/04;;G01N33/5038;;G01N33/5038;;G01N2333/16;;G01N2333/16;;G01N2500/04;;G01N2500/04;;G01N2500/20;;G01N2500/20,C12N9/99;;C12Q1/44;;A61K31/4155;;A61K31/66;;A61K31/665;;A61K31/675;;A61P31/18;;A61P43/00;;C07D213/75;;C07D213/85;;C07D231/12;;C07D231/20;;C07D233/42;;C07D239/48;;C07D239/80;;C07D243/04;;C07D265/18;;C07D307/68;;C07D401/06;;C07D403/06;;C07D471/14;;C07D491/04;;C07F/;;C07F9/02;;C07F9/38;;C07F9/40;;C07F9/44;;C07F9/58;;C07F9/62;;C07F9/645;;C07F9/6506;;C07F9/6509;;C07F9/6512;;C07F9/653;;C07F9/6533;;C07F9/655;;C07F9/6558;;C07F9/6561;;C07F9/6584;;C12N9/16;;C12Q1/18;;C12Q1/37;;C12Q1/70;;G01N33/04;;G01N33/50,,0,0,,,,PENDING
